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Summary 
 
 
 
 
 
Cancer is often the result of a multi-step 
process in which normal cells have acquired the 
ability to survive and proliferate limitlessly and can 
invade the surrounding tissue, which may lead to 
metastasis. In this study, we addressed the role that 
growth factor systems and cell-cell adhesion 
molecules may play in melanoma and breast cancer.  
Crucial in the process of carcinogenesis is 
the mutual cross-talk between the tumor and the 
micro-environment, an interaction which may be 
exerted by soluble factors. Based on the identification 
of two glycoproteins that were secreted by melanoma 
cells, we characterized two new growth factor systems 
in human melanoma.  Both of these may contribute to 
malignant progression. The use of mass spectrometry 
as a biochemical approach led to the identification of 
follistatin as a factor secreted by several melanoma 
cell lines. Since we found that follistatin can protect 
melanocytes against the growth-inhibitory and pro-
apoptotic effects of activin (a transforming growth 
factor-β-like ligand), its secretion may promote the 
survival of transformed melanocytic cells. Using a 
biological approach as a starting point, we found that 
a melanoma conditioned medium can induce 
activation of a 185kD protein in a test cell line. This 
activity was attributed to the presence of heregulin, an 
epidermal growth factor-like ligand for receptor 
tyrosine kinases. Subsequent evaluation of the 
heregulin-human epidermal growth factor receptor 
system in a panel of melanoma cell lines revealed the 
presence of multiple deregulations. These included 
both autocrine activation and ligand insensitivity 
owing to the absence of (functional) receptors. 
When heregulin was tested in an in vitro 
model of invasion and aggregation, using a breast 
cancer cell line with a functionally deficient cell-cell 
adhesion complex, we found that invasion is 
counteracted, whereas aggregation is promoted. 
Crucial for cell-cell contacts between epithelial cells 
are cadherins, calcium-dependent cell-cell adhesion 
molecules that are involved in the regulation of cell 
motility, growth, differentiation and survival. 
E(epithelial)-cadherin, the prototype member of this 
family, has a well-described invasion-suppressor 
function. Functional inactivation of E-cadherin may 
occur at the genomic, transcriptional, and post-
transcriptional level. An example of the latter is 
proteolytic cleavage of E-cadherin, resulting in 
release of its ectodomain, which we found to be 
capable of promoting invasion and counteracting 
aggregation. 
In contrast to E-cadherin, which has been 
extensively studied in cancer, little is known about the 
role of the highly related P-cadherin in cancer. We 
found that P-cadherin may either function as an 
invasion-suppressor or as an invasion promoter, 
depending on the context. Melanoma cells lose P-
cadherin expression during progression. 
Reconstituting this expression led to improved cell-
cell adhesion and counteraction of invasion. In breast 
cancer, in contrast, upregulation of P-cadherin 
correlates with estrogen receptor negativity and poor 
survival. We established a direct link between P-
cadherin expression and the lack of estrogen receptor 
signaling and found that P-cadherin, via its 
intracellular membrane-proximal domain, promotes 
invasion of breast cancer cells. 
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Samenvatting 
 
 
 
 
 
Kanker is vaak het resultaat van een 
meerstapsproces, waarbij normale cellen de 
eigenschap verworven hebben te overleven, 
ongebreideld te delen en naburig weefsel te invaderen, 
wat kan leiden tot metastase. In deze studie hebben 
we onderzocht welke rol groeifactor- systemen en cel-
celadhesiemoleculen kunnen spelen in melanoom en 
borstkanker. 
  Een cruciale factor in het proces van 
carcinogenese is de wederzijdse communicatie tussen 
de tumor en de micro-omgeving die tot stand kan 
worden gebracht door oplosbare factoren. Op basis 
van de identificatie van twee glycoproteïnes die 
vrijgesteld werden door melanoomcellen, 
karakteriseerden we twee nieuwe groeifactor- 
systemen in humaan melanoom die beide kunnen 
bijdragen tot  maligne progressie. Het gebruik van 
massaspectrometrie als een biochemische benadering 
leidde tot de identificatie van follistatine als een factor 
die werd vrijgesteld door verscheidene 
melanoomcellijnen. Vermits we zagen dat follistatine 
melanocyten kon beschermen tegen de 
groeiremmende en pro-apoptotische effecten van 
activine (een transformerende groeifactor-β-achtige 
ligand), kan secretie ervan mogelijk bijdragen tot het 
overleven van getransformeerde melanocytische 
cellen. Uitgaand van een biologische benadering 
vonden we dat een door melanoom geconditioneerd 
medium activering van een 185 kD proteïne kon 
induceren in een testcellijn. Deze activiteit kon 
toegeschreven worden aan de aanwezigheid van 
hereguline, een epidermale groeifactor-achtige ligand 
voor receptor tyrosine kinases. De daaropvolgende 
evaluatie van het hereguline-humaan epidermale 
groeifactor receptorsysteem in een set van 
melanoomcellijnen toonde de aanwezigheid van 
meerdere ontregelingen aan, gaande van autocriene 
activering tot ligandongevoeligheid te wijten aan de 
afwezigheid van (functionele) receptoren.  
 Wanneer hereguline getest werd in een in 
vitro model van invasie en aggregatie, gebruik 
makend van een borstkankercellijn met een 
functioneel deficiënt cel-celadhesiecomplex, vonden 
we dat invasie werd tegengegaan, terwijl aggregatie 
bevorderd werd. Cruciaal voor cel-celcontacten tussen 
epitheliale cellen zijn cadherines, calcium-
afhankelijke cel-celadhesie-moleculen die betrokken 
zijn in de regeling van de beweeglijkheid, groei, 
differentiatie en overleving van cellen. E(epitheliaal)-
cadherine, het prototype van deze familie, bezit een 
goed beschreven invasie-onderdrukkende functie. 
Functionele inactivering van E-cadherine kan ontstaan 
op zowel genomisch, transcriptioneel, als post-
transcriptioneel niveau. Een voorbeeld van dit laatste 
is de proteolytische klieving van E-cadherine, met een 
vrijstelling van zijn ectodomein als resultaat, waarbij 
we vaststelden dat dit ectodomein invasie bevorderde 
en aggregatie tegenwerkte. 
In tegenstelling tot E-cadherine, dat reeds 
intensief werd bestudeerd in kanker, is er slechts 
weinig gekend over de rol van het sterk verwante P-
cadherine in kanker. Wij stelden vast dat P-cadherine, 
afhankelijk van de context, zowel als een invasie-
onderdrukker als een invasie-promotor kan 
functioneren. Melanoomcellen verliezen P-cadherine 
tijdens progressie. Het herstel van deze expressie 
resulteerde in een verbeterde cel-celadhesie en een 
opheffing van hun invasief vermogen. In borstkanker 
daarentegen, correleert de opregulatie van P-cadherine 
met oestrogeenreceptor negativiteit en zwakke 
overleving. We legden een rechtstreekse link tussen 
P-cadherine expressie en het gebrek aan 
oestrogeenreceptorsignalering en vonden dat P-
cadherine, via zijn intracellulair membraan-proximaal 
domein, invasie bevorderde in borstkankercellen. 
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Résumé 
 
 
 
 
 
Le cancer est souvent le résultat d’un processus multi-
étapes dans lequel les cellules normales ont acquis la 
capacité de survivre, de proliférer de façon illimitée et 
d’envahir le tissu environnant, lequel peut conduire 
aux métastases. Dans cette étude, nous avons adressé 
le rôle que les systèmes de facteur de croissance et des 
molécules d’adhérence cellule-cellule peuvent jouer 
dans le mélanome et le cancer du sein. 
Le cross-talk mutuel entre la tumeur et 
l’environnement est crucial dans le processus de 
cancérologie, lequel peut être exercé par des facteurs 
solubles. Basé sur l’identification de 2 glycoprotéines 
qui sont sécrétées par les cellules du mélanome, nous 
avons caractérisé deux nouveaux systèmes de facteurs 
de croissance dans les mélanomes humains, lesquels 
peuvent contribuer à la progression maligne. 
L’utilisation de la spectrométrie de masse comme une 
approche biochimique a conduit à l’identification de 
la follistatine comme un facteur sécrété par de 
nombreuses lignées de cellules de mélanome. Depuis, 
nous avons trouvé que la follistatine pourrait protéger 
les mélanocytes contre les effets inhibiteurs de 
croissance et pro-apoptique de l’activine, un ligand de 
la famille TGF-β (‘transforming growth factor β’). 
Ainsi, la sécrétion de follistatine peut contribuer à la 
survie de cellules mélanocytes transformés. En 
utilisant une approche biologique comme point de 
départ, nous avons trouvé que un milieu conditionné 
de mélanome pouvait induire l’activation d’une 
protéine de 185 kDa dans une lignée de cellules 
expérimentale. Cette activité pourrait être attribué à la 
présence de l’héréguline, un ligand de la famille de 
l’EGF (‘epidermal growth factor’) pour les récepteurs 
à activité tyrosine kinase. Une évaluation ultérieure du 
système héréguline-EGFR dans un panel de lignées 
cellulaires de mélanome a révélé la présence de 
dérégulations multiples, allant de l’activation 
autocrine à l’insensibilité du ligand autorisée par 
l’absence de récepteurs fonctionnels.  
Quand l’héréguline était mis dans un modèle 
d’invasion et d’agrégation, utilisant des cellules de 
cancer du sein qui renferment un complexe E-
cadhérine fonctionnellement inactif,  l’agrégation 
améliorait et l’invasion était contre carré. Crucial pour 
les contacts entre des cellules épithéliales sont les 
cadhérines, des molécules d’adhésion cellule-cellule 
calcium dépendantes qui sont  impliquées dans la 
régulation de la motilité cellulaire, la croissance, la 
différenciation et la survie. La E(épithéliale)-
cadhérine, membre prototype de cette famille, possède 
une fonction suppresseur de tumeur très bien décrite. 
L’inactivation fonctionnelle de la E-cadhérine peut se 
produire à la fois au niveau génomique, 
transcriptionnel, ainsi qu’au niveau post-
transcriptionnel. Un exemple de cette dernière est le 
clivage protéolique de la E-cadhérine, conduisant à la 
libération de son ectodomaine, lequel nous avons 
trouvé d’être capable de promouvoir l’invasion et de 
contre carrer l’agrégation.  
Au contraire de la E-cadhérine, qui a été 
largement étudiée dans le cancer, peu de choses sont 
connues à propos du rôle de la P-cadhérine dans cette 
pathologie. Nous avons trouvé que la P-cadhérine 
peut, en fonction du contexte, fonctionner comme un 
suppresseur d’invasion ou comme un promoteur 
d’invasion. Les cellules de mélanome ont perdu 
l’expression de la P-cadhérine durant leur progression 
tumorale. La restauration de cette expression a 
conduit à améliorer l’adhérence cellule-cellule et à 
contrecarrer  l’invasion. Dans le cancer de sein, au 
contraire, l’augmentation de l’expression de la P-
cadhérine corrobore avec la négativité du récepteur de 
l’oestrogène et une pauvre survie. Nous avons établi 
un lien direct entre l’expression de la P-cadhérine et le 
manque de la signalisation du récepteur de 
l’oestrogène, et nous avons trouvé que la P-cadhérine, 
via son domaine intracellulaire membrane-proximale, 
promouvoit l’invasion des cellules de cancer du sein. 
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General Introduction and Objectives 
 
 
 
In this thesis we have combined the study of 
cell-cell adhesion molecules and growth factors in 
two different types of cancer, melanoma and breast 
cancer. Although, at first sight, the different themes 
that are presented may seem unrelated, they all result 
from a same starting point. One interesting 
observation that had been done long before I entered 
the laboratory was the phenotypical difference 
between two sub-lines of the MCF-7 mammary 
cancer cell line. This estrogen receptor positive cell 
line was isolated in 1970 from a pleural effusion of a 
mammary cancer patient by Dr. Soule, working at the 
Michigan Cancer Foundation (Soule et al., 1973). 
This cell line was distributed over the entire world 
and was used as a model for studying breast cancer by 
many thousands of researchers. However, different 
culture conditions and/or spontaneous alterations led 
to the generation of different variants of this cell line. 
Two such variants are the MCF-7/AZ (‘Academisch 
Ziekenhuis’) and MCF-7/6 cell line, obtained from Dr 
P. Briand from Copenhagen en Dr H. Rochefort from 
Paris, respectively. Although these cell lines share the 
same genetic background and have many common 
characteristics, they diverge in several biochemical 
and functional aspects. When tested in some in vitro 
aggregation and invasion assays, the MCF-7/6 cell 
line poorly aggregates and invades, in contrast to the 
non-invasive behavior and strong cell-cell adhesion of 
the MCF-7/AZ cell line in these assays (De Bruyne et 
al., 1988). Since exogenous factors may direct the 
behavior of one cell line to that of the other, this 
couple represents a useful in vitro system for studying 
compounds/conditions that influence cell-cell 
adhesion and invasion and the mechanism underlying 
these changes (Bracke et al., 1996). 
Among the many conditions that promoted 
cell-cell adhesion of MCF-7/6 cells and negatively 
influenced their invasive behavior in a chick heart 
invasion assay, was a medium that had been 
conditioned by a melanoma cell line (Bowes 
melanoma). However, the nature of the factor(s) that 
was (were) responsible for these effects remained 
unknown. Therefore, our study had two aims. The 
first one was to characterize the factors that are 
released by the melanoma cells and to analyze their 
potential effects on these cells themselves. Using 
biological (induction of phosphorylation) and 
biochemical (mass spectrometry) approaches, this led 
to the identification and characterization of two new 
growth factor systems in human melanoma. The 
second aim was to gain knowledge about conditions 
that may alter the aggregation and invasion status of 
cells, with special focus on the role of cell-cell 
adhesion molecules. 
Critical for cell-cell adhesion of MCF-7 cells 
is the functionality of the cadherin cell-cell adhesion 
molecules. In these cells, the transmembrane 
E(epithelial)-cadherin molecules form homophilic 
complexes between molecules on adjacent cells. 
Cancers have developed many ways to overcome the 
pro-aggregating and anti-invasive effects of these 
molecules. In this part of our work, new aspects of the 
role of these molecules were studied. Proteolytical 
cleavage of E-cadherin may result in the release of the 
extracellular domain, which, as such, turned out to be 
capable of promoting invasion and counteracting 
aggregation of cells in vitro. The second mechanism 
studied was based upon the observation that aberrant 
expression of another cadherin, P(placental)-cadherin, 
in breast cancer correlates with estrogen receptor 
negativity of the tumor and is a bad prognostic factor. 
Using MCF-7/AZ as a model system, we found that 
abrogation of estrogen receptor signaling results in 
decreased aggregation, increased invasion and 
increased P-cadherin expression. Ectopic expression 
of P-cadherin in these cells can mimic the effect of the 
anti-estrogen on invasion, providing evidence that 
aberrant expression of P-cadherin may provide cells 
with a pro-invasive signal, in the presence of their 
endogenous cadherin(s). However, P-cadherin 
expression is not always aberrant: in some cell types, 
like melanocytes, it is normally expressed but is lost 
during malignant progression. Ectopic expression of 
P-cadherin in melanoma cell lines confirmed a role 
for this protein in maintaining cell-cell contacts of 
melanoma cell lines, inhibiting invasion of these cells 
both in vitro and in vivo. 
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Part I. Identification of new growth factor systems in 
human melanoma 
 
 
 
I.1. Introduction 
I.1.1. Melanoma: general aspects
Human skin is a multi-layered, cohesive 
tissue with a unique functional architecture, providing 
the primary barrier to the outside environment. The 
pigment-producing cells of the skin are called 
melanocytes and their activity is the major 
determinant of the color of the hair and skin. 
Melanocytes originate in the neural crest and migrate 
to the basal layer of the epidermis and the hair 
matrices during embryogenesis (Dupin and Le 
Douarin, 2003). These neural crest-derived cells also 
populate the inner ear (cochlea, stria vascularis), uveal 
tract (choroid, retina, sclera), central nervous system 
(leptomeninges, substantia nigra, locus ceruleus, 
dorsal root ganglia, cranial ganglia) and mesentery. A 
failure of melanocytes to migrate to these locations 
explains several clinical features, such as white 
spotting of the skin (piebaldism), heterochromia of 
the iris and congenital deafness in Waardenburg 
syndrome. Within the epidermis, melanocytes reside 
in the basal layer, undergoing controlled self-
replication, resulting in a stable, life-long ratio with 
basal keratinocytes of approximately 1 melanocyte:5-
8 keratinocytes. Within its ‘epidermal melanin unit’, 
each melanocyte supplies via its dendrites pigment 
(melanin) to approximately 30 nearby keratinocytes, 
thus providing protection against the deleterious 
effects of ultraviolet light. 
 
Among the most common cancers are 
malignant neoplasms of the skin (Geller and Annas, 
2003; Hall et al., 2003). Whereas melanoma ranks as 
the third most common form of skin cancer, after 
basal and squamous cell carcinoma, it is far more 
notorious since it affects a relatively younger 
population and causes far more deaths because of its 
propensity to metastasize and its poor response to 
therapeutic treatment. Melanoma, a malignant tumor, 
derived from melanocytes is one of the fastest rising 
malignancies. In 2002, approximately 53.000 
individuals developed melanoma in the U.S. and more 
than 7000 died of the disease. For the moment, more 
than 1 of 70 Americans is expected to develop 
melanoma over his/her lifetime (Geller and Annas, 
2003). Despite worldwide efforts in prevention, 
diagnosis and treatment, melanoma incidence 
continues to rise at an alarming rate. Fortunately, the 
increasing incidence exceeds the mortality rate, 
apparently because of faster detection of biologically 
early primary melanomas which are curable through 
surgery. However, despite significant improvements 
in diagnosis and surgical, local and systemic therapy, 
reducing the mortality from melanoma metastases 
remains a major challenge. 
Although most melanomas arise in the skin, 
they may also arise from mucosal surfaces or at other 
sites to which neural crest cells migrate. Melanoma 
occurs predominantly in adults, and more than half of 
the cases arise in apparently normal areas of the skin. 
As main risk factors for melanoma are considered: the 
total number of nevi, number of dysplastic nevi, color 
of hair, skin, and eyes, and sun exposure during 
childhood. Clinical staging and prognosis are affected 
by clinical and histological factors and by anatomic 
location of the lesion. Among factors that affect the 
prognosis are: thickness and/or level of invasion of 
the melanoma, mitotic index, presence of tumor 
infiltrating lymphocytes, number of regional lymph 
nodes involved, and ulceration or bleeding at the 
primary site (Slominski et al., 1995; Tucker and 
Goldstein, 2003; Beddingfield III, 2003). 
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I.1.2. Molecular events in 
melanoma 
During melanoma development and 
progression, profound histological alterations take 
place: aberrant cell growth and migration lead to 
cluster formation, dermal invasion and, eventually, 
distant metastasis (Clark, 1991). This is typically a 
multi-step process, in which melanoma develops and 
progresses in a sequence of events (Meier et al., 
1998). However, as in any neoplastic system, 
individual melanomas can skip steps in their 
development or alternatively, may arise from 
malignant transformation of precursor cells.  
The progression from a melanocyte to a 
common acquired nevus is very common and does 
not appear to be dictated by major genetic changes. 
This is supported by the fact that nevus cells isolated 
from common acquired nevi 1) have a finite lifespan 
and 2) generally do not carry cytogenetic 
abnormalities. However, this view has recently been 
challenged by the high frequency of mutations in an 
oncogene, BRAF, in nevi (see below) (Pollock et al., 
2003). At that time, cells must receive a (second) 
genetic “hit” in order to progress, and then cytological 
and architectural atypia may follow. The nature of 
these changes is not fully clear, yet. Two models are 
currently proposed to explain the genesis of 
melanocytic dysplastic nevi (MDN) (Hussein and 
Wood, 2002). The first one considers that MDN arise 
by inactivation of one allele of melanoma suppressor 
genes, while subsequent loss of the second allele leads 
to malignant transformation of the MDN. The second 
model relies on the presence of at least two genes 
working independently. Therefore, alterations of one 
of these may cause dysplasia in melanocytes, while 
the other results in malignant transformation. Both 
models rely on the “two-hit” hypothesis, suggesting 
that at least two genetic events are required for 
inactivation of tumor suppressor genes. In familial 
forms of cancer, one mutation is believed to be 
germline and the other somatic, whereas in sporadic 
cancers, both mutations are somatic (Knudson, 1971). 
Whatever the mechanisms that may be involved, from 
here on the cells do not regress anymore, but persist. 
This persistence can last for years before they begin to 
proliferate to form radial growth phase (RGP) 
melanoma.  
Progression from dysplasia to in situ and invasive 
RGP melanoma is gradual and spontaneous, and may 
not require additional molecular changes. The 
transition from RGP to vertical growth phase (VGP) 
melanoma is a biologically and clinically critical 
step, likely accompanied by additional genetic 
changes. At this step, cells begin to proliferate more 
rapidly and stroma induction and angiogenesis occurs. 
Unlike RGP melanomas, VGP cells are metastasis-
competent and are easily adapted to growth in culture. 
They are less dependent on exogenous growth factors 
and have characteristics that are similar to metastatic 
cells, such as anchorage-independent growth and 
tumorigenesis in immunodeficient mice. VGP 
primary melanomas display numerous cytogenetic 
abnormalities, suggesting considerable genomic 
instability. They can rapidly adapt to selective 
pressure, allowing them to survive even under the 
most unfavorable circumstances. No major additional 
genetic changes may be required for further 
progression to metastatic dissemination, since most 
VGP melanomas can be readily adapted to a 
metastatic phenotype through selection in growth 
factor-free medium or induction of invasion through 
artificial basement membranes. This final step, 
metastasis, is dictated by endogenous oncogenes and 
tumor suppressor genes, and by exogenous 
interactions with the host, through micro-
environmental factors, such as cell-matrix and cell-
cell signaling (Meier et al., 1998; Bogenrieder and 
Herlyn, 2003). 
 
Growth autonomy appears as the result of 
multiple mechanisms by which growth regulatory 
pathways are perturbed and deregulated. It can occur 
at various steps of signal transduction: 1) excessive 
production of autocrine growth factors, which 
substitutes for exogenous growth factor requirements; 
2) resistance to physiologically inhibitory exogenous 
growth factors by excessive production of ligand 
traps; 3) mutation or altered expression of stimulatory 
and/or inhibitory receptors; 4) mutation or altered 
expression of second messengers. Table I.1 
summarizes the current information on genes that 
have been found to be mutated in melanoma. The 
possible contribution of these mutant proteins to 
melanomagenesis is depicted schematically in Figure 
I.1.  
 
A family of genes that is frequently found to 
harbor a mutation in human tumors is that of the ras 
genes. This family consists of three functional genes, 
H(Harvey)-ras, K(Kirsten)-ras and N-ras, which 
encode highly similar 21 kD proteins with GTPase 
function (Bos et al., 1989). Whereas mutation of K- or 
H-ras is rare in melanoma, mutations of N-ras are 
found in 5-30% of cases (Albino et al., 1984; 
Raybaud et al., 1988; Ball et al., 1994; Demunter et 
al., 2001a,b; Omholt et al., 2003; Alsina et al., 2003). 
These are mostly missense mutations, affecting 
codons 61 (most frequently Q61R and Q61K), 12 or 
13. The resulting protein has a defective GTPase 
activity and can no longer be switched off by GTPase 
activating proteins (GAPs), rendering it constitutively 
active.  
A major breakthrough of The Cancer Genome 
Project, an initiative launched in 1999 to identify new 
cancer-causing genes, was the identification of BRAF 
(v-raf murine sarcoma viral oncogene homolog B1) as 
a new oncogene (Davies et al., 2002). As is the case 
for N-ras, mutations in BRAF lead to a constitutively 
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active protein, causing aberrant activation of the Ras-
Raf-MEK-ERK or MAPK pathway (Mercer and 
Pritchard, 2003) (Figure I.1). BRAF is mutated in a 
variety of cancer types, including gliomas, cholangio-
carcinomas, ovarian, lung and colorectal cancers, 
although for some of these mutation is a rare event. 
Cancers where it is mutated at high rate (up to 70%) 
include thyroid cancer and cutaneous melanoma 
(Davies et al., 2002; Brose et al., 2002; Pollock et al., 
2003; Dong et al., 2003; Kumar et al., 2003; Gorden 
et al., 2003; Omholt et al., 2003; Alsina et al., 2003; 
Tsao et al., 2004). In melanoma, the vast majority of 
mutations comprises a transversion at codon 599, 
exchanging valine for glutamic acid. This mutation 
most likely interferes with negative regulatory 
phosphorylation at sites Thr598 and Ser601, resulting 
in a higher kinase activity (Davies et al., 2002; 
Mercer and Pritchard, 2003). BRAF mutation in 
melanoma is an acquired event, occurring early during 
melanocytic dysplasia, as it is already frequently 
found in nevi and early during melanoma 
pathogenesis (Pollock et al., 2003; Omholt et al., 
2003). Strikingly, BRAF and NRAS mutations almost 
never  co-exist   in   the   same  lesion,  supporting the  
hypothesis that these mutations are complementary 
and may have similar effects during tumor 
Table I.1. Genes that have been found to be mutated in melanoma. In grey are genes that, upon mutation, 
become oncogenes, in white are tumor suppressor genes. 
Mutated Gene  Remark Selected references 
B-Raf Gene most commonly mutated (70-90%) in melanoma, from early stages on 
See text for details 
Davies et al., 2002 
Brose et al., 2002 
Alsina et al., 2003 
Dong et al., 2003 
Gorden et al., 2003 
Kumar et al., 2003 
Tsao et al., 2004 
CDKN2A 
(p16INK4A) 
(p14ARF) 
Germline mutations are most common cause of inherited susceptibility to 
melanoma (mutations on average in approximately 25% of melanoma-prone 
families). The frequency of mutations in probands increases with: 
• the number of affected relatives 
• the presence of multiple melanomas in the same patient 
• a history of pancreatic cancer cases in the family 
Mutations are much less frequent in sporadic melanoma.  
Kamb et al., 1994  
Hussussian et al., 1994 
Piepkorn et al., 2000 
Bishop et al., 2002 
Soufir et al., 2004 
N-Ras Relatively common (5-24%) in malignant melanoma, only occasionally found 
in dysplastic nevi 
Albino et al., 1984 
Raybaud et al., 1988 
Ball et al., 1994 
Demunter et al., 2001a,b 
Omholt et al., 2003 
Alsina et al., 2003 
p53 Relatively few mutations (1-5%, higher in cell lines), when compared to many 
other cancers 
Typically found at dipyrimidine sites (C→T and CC→TT transitions) 
Levine et al., 1991 
Hollstein et al., 1991 
Oren et al., 1992 
Hussein et al., 2003 
β-catenin Relatively few mutations See chapter II 
PTEN Phosphatase that downregulates the activity of PKB/AKT. PKB/AKT  becomes 
activated by PIP3 and participates in e.g.: 
*activation of p70S6K (stimulation of protein synthesis) 
*suppression of apoptosis by phosphorylating (inactivating) Bad and caspase-9 
*CREB (cAMP response element binding protein) activation (→targeting gene 
expression) 
Guldberg et al., 1997b 
Robertson et al., 1998 
Tsao et al., 1998 
PKCα Mutation of protein kinase Cα has only been shown in a cell line Linnenbach et al., 1988 
c-myb Mutation  of this transcription factor has only been shown in a cell line 
Overexpression rather than mutation may be of importance in melanoma 
Linnenbach et al., 1988 
CDK-4 Mutations in cyclin dependent kinase-4 are a rare cause of inherited 
susceptibility to melanoma. Only four germline alterations have been described 
to date, in four melanoma-prone kindreds and in one melanoma patient with no 
known family history. 
Zuo et al., 1996 
Bartkova et al., 1996 
Flores et al., 1997 
Guldberg et al., 1997a 
Soufir et al., 1998 
NF-1 Mutations in neurofibromin (NF-1 gene product), a protein with GTPase-
activating activity for Ras molecules, are found in patients with type 1 
neurofibromatosis. 
Disruption of the NF1 gene is rare in melanoma in general, but is frequently 
found in subtypes such as desmoplastic neurotropic melanoma 
Andersen et al., 1993 
Johnson et al., 1993 
Gomez et al., 1996 
Gutzmer et al., 2000 
APC Mutations in adenomatous polyposis coli (APC) have only been found in cell 
lines (2/27) 
Rubinfeld et al., 1997 
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development (Davies et al., 2002; Omholt et al., 
2003). Taken together, a single genomic event, 
leading to mutational activation of the MAPK 
pathway, takes place in up to 90% of melanoma cases, 
rendering it a likely early key step in the initiation of 
melanocytic dysplasia (Cohen et al., 2002; Omholt et 
al., 2003). However, since the frequency of mutation 
is similar throughout all stages, including metastases, 
these mutations seem insufficient to trigger melanoma 
progression, but may be required for melanoma 
maintenance. Consistent with this hypothesis is the 
observations that BRAF and NRAS mutations don’t 
show a significant correlation to any clinical 
parameter (Omholt et al., 2003). An additional 
genetic hit may be mutation of PTEN (phosphatase and 
tensin homolog deleted in chromosome ten), as suggested by 
Tsao et al. (2004). The PTEN protein functions as a 
phosphatase for both lipids and proteins. Best 
documented in its involvement in tumorigenesis is its 
lipid phosphatase activity, which decreases the levels 
of phosphatidylinositol-3-phosphate and downstream 
protein kinase B (PKB/Akt) activity. As a result, 
proliferation is inhibited and apoptosis is promoted. 
As a protein phosphatase, PTEN is involved in 
inhibition of focal adhesion formation, cell spreading 
and migration. Inactivating mutations of PTEN, 
mostly a late event in melanoma, abolish these effects 
(Wu et al., 2003). Upon testing a large panel of 
melanoma cell lines and a small cohort of patient 
samples for the co-existence of NRAS, BRAF and/or 
PTEN mutations, Tsao et al. found that nearly all 
cases with a PTEN mutation had a BRAF mutation as 
well. This suggests the existence of a possible 
cooperation between BRAF activation and loss of 
PTEN in melanoma development. However, 
extending this observation to large patient groups is 
necessary. In addition, constitutive MAPK activation 
could render immortalized melanocytes tumorigenic, 
with increased production of downstream target genes 
as vascular endothelial growth factor (VEGF) and 
matrix metalloproteinases (MMPs) (Govindarajan et 
al., 2003), both known to be involved in malignant 
progression. 
In conclusion, based upon the high rate of MAPK 
activation in melanoma (either by mutated NRAS or 
BRAF, or by autocrine growth factor loops, see 
further), this pathway seems THE pathway to be 
targeted in melanoma (Satyamoorthy et al., 2003; 
Figure I.1. Involvement of oncogenes and tumor suppressor genes in signal transduction pathways.  Genes 
that have been found to be mutated in human melanoma are represented in star-shaped forms. See text for details. 
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Tuveson et al., 2003). As a consequence, the 
development of potent and selective kinase inhibitors 
may represent a boost in melanoma therapy. 
 
Familial melanomas comprise from 8% to 
12% of all cutaneous malignant melanoma cases 
(Greene, 1999; Hayward, 2003). Two highly 
penetrant melanoma-predisposing genes have been 
identified to date, INK4a-ARF (Inhibitor of Cyclin 
dependent kinase (CDK) 4 – Alternative reading frame) and 
Cdk4 (Hussussian et al., 1994; Kamb et al., 1994; 
Zuo et al., 1996). The INK4a-ARF gene on 
chromosome 9p21 encodes two structurally distinct 
tumor-suppressor proteins, p16INK4a and p14ARF, by 
virtue of different 5’ exons (1α and 1β, respectively), 
spliced in different reading frames to common exons 
2 and 3. p16INK4a is part of the G1-S cell cycle 
checkpoint mechanism that involves the 
retinoblastoma-susceptibility tumor suppressor 
protein (pRb) (Figure I.1). pRB, in its 
unphosphorylated state, inhibits G1→S cell cycle 
progression by sequestering the transcription factor 
E2F1. Phosphorylation of pRB by the cyclin-
dependent kinases CDK4 and CDK6, in complex with 
cyclin D, releases E2F1, allowing progression through 
the G1-S checkpoint (Serrano et al., 1995; Zhang et 
al., 1996). Since p16INK4a binds to and inhibits CDK4 
and CDK6 by preventing their association with cyclin 
D, mutations in both p16INK4a and CDK4 that abolish 
this inhibitory binding will result in constitutively 
hyper-phosphorylated pRB, allowing the cell to 
escape from cell cycle arrest in G1. 
The other product of the INK4A-ARF locus, p14ARF 
(ARF in mice), also acts as a tumor suppressor, 
inducing cell cycle arrest or apoptosis. This protein 
mediates G1 and G2 arrest, at least partly by its 
interaction with MDM2, a protein that binds both p53 
and pRB. MDM2 targets p53 for degradation by 
ubiquitination and also inhibits pRB growth-
regulatory function (Sharpless and Chin, 2003). ARF 
binds to MDM2 and promotes MDM2 degradation. 
As a result, p53 is not degraded anymore and 
accumulates, leading to stimulation of its downstream 
target genes, such as p21, an inhibitor not only of 
CDK4 and CDK6, but also of other CDK’s. Thus, 
inactivating mutations of p14ARF result in reduced 
levels of p53 and p21, again relieving a brake on cell 
cycle progression (Zhang et al., 1998; Pomerantz et 
al., 1998). 
Although for these genes it is not clear at which point 
the second allele is lost, their frequent mutation in 
familial melanoma suggests that their loss is directly 
involved in melanoma progression (Kamb et al., 
1994). 
 
Melanoma cells express a variety of growth 
factors and cytokines and their receptors (see Figure 
I.2 and references therein). Depending on the stage of 
tumor progression, melanocytic cells have different 
growth factor requirements. Unlike normal 
melanocytes, melanoma cells often constitutively 
express a variety of growth factors and cytokines and 
their respective receptors, enabling the cells to 
progress to a more aggressive phenotype. Autocrine 
growth factors (e.g. basic fibroblast growth factor 
(bFGF), interleukin-8 (IL-8), hepatocyte growth 
factor (HGF), platelet derived growth factor A 
(PDGF-A)) act on the producing melanoma cells 
themselves, stimulating proliferation and/or 
migration. Paracrine growth factors produced by the 
melanoma cells (e.g. PDGF, bFGF, transforming 
growth factor-β (TGF-β), vascular endothelial growth 
factor (VEGF)) modulate the micro-environment, 
especially stromal fibroblasts, and are involved in 
stroma induction and angiogenesis and/or interaction 
with the host defense mechanism (i.e. specific T-cells 
and non-specific inflammatory cells). Melanocytes 
and melanoma cells are also subject to the paracrine 
action of stimulatory (e.g. insulin-like growth factor 1 
(IGF-1), PDGF, HGF) and inhibitory (e.g. IL-1 and -
6, TGF-β, interferons, tumor necrosis factor-α) 
factors, released by keratinocytes, endothelial cells, 
An example of the complex cross-talk between 
melanoma cells and the micro-environment 
 
Melanoma cells secrete PDGF, which may stimulate 
growth in an autocrine way or may activate fibroblasts 
in a paracrine way. Besides its mitogenic activity on 
fibroblasts, PDGF stimulates the production of ECM 
components and induces the production of growth 
factors, such as HGF, bFGF, endothelin-3 (ET-3) and 
insulin-like growth factor 1 (IGF-1) by the activated 
fibroblasts. IGF-1, in turn, may act on the IGF-1 
receptor, which is expressed by all melanocytic cells, 
promoting their survival, growth and migration, either 
directly, or indirectly through the upregulation of 
other growth factors (such as VEGF and CXCL8/IL-
8). CXCL8, besides having an autocrine function 
(growth stimulatory, inducing haptotactic migration, 
inducing MMP production and the selection of 
metastatic tumor clones), may also act on nearby 
cells, thereby extending the cascade of events taking 
place (Satyamoorthy et al., 2001, 2002). 
 
 
Fibroblast Melanoma 
cell
IL-8 
ECM 
PDGF 
IGF-1 
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fibroblasts, lymphocytes, monocytes and 
granulocytes. These exogenous paracrine factors may 
either inhibit tumor growth and cause differentiation 
or enhance tumor growth, angiogenesis, adhesion or 
motility or promote dissemination. As progression 
occurs, disturbance of the balance between inhibitory 
and stimulatory factors increases. In some cases, a 
growth factor can switch from a paracrine or autocrine 
inhibitor to an autocrine stimulator (e.g., interleukin-
6, TGF-β). Of particular importance in melanoma are 
the growth factors influencing the stromal fibroblasts. 
These melanoma-derived paracrine growth factors act 
as mitogens for the fibroblasts and/or stimulate the 
deposition and secretion of extracellular matrix 
(ECM) and growth factors by the latter. In turn, the 
deposited ECM provides a scaffold for the melanoma 
cells, enhancing their survival, while fibroblast-
derived growth factors contribute to the growth and 
motility of melanoma cells. Figure I.2 presents the 
main autocrine and paracrine growth factors and 
cytokines involved in the growth regulation of 
melanoma cells. Recently, the group from Dr. Herlyn 
found that, although many growth factors promote 
growth and/or survival of melanocytes, 
overexpression of a single growth factor, combined 
with ultraviolet B (UVB) irradiation or with other 
growth factors could not induce melanoma in 
xenograft studies. However, when overexpression of 
several growth factors was combined with 
intermittent UVB exposure (presumably resulting in 
acquired mutations), a melanoma phenotype was 
found in these models (Berking et al., 2004). 
Although these lesions regressed spontaneously upon 
withdrawal of the growth factors (likely because they 
did not acquire enough stable mutations), they 
highlight the causative role that growth factors may 
play in melanomagenesis. 
The two articles in this chapter describe our 
identification of two new growth factor systems that 
may play a role in human melanoma. These are 
preceded by a review on the role of neuregulins, 
ligands for receptor tyrosine kinases, in cancer.
Melanoma 
cell 
    
  FGF-2 (↑,+) 
      PDGF-A/B (↑,+) 
               TGF-β1/3 (↑,+) 
                        VEGF (↑,+) 
                     
                            EGFR/HER1 (↑,=), HER2 (=), HER3 (=) 
                        IGF-1R (↑,=) 
                        PDGFR-α (↑,=), KIT (↓), 
                        FGFR1 (=), FGFR4 (↑) 
                       VEGFR1/FLT1 (↑), VEGFR2/FLK1/KDR (↑) 
                       HGFR/Met (↓,=,↑) 
                       Trk 
                       EPH-A2 (↑), EPH-A3, EPH-A4 (↓), EPH-B3 (↑) 
                       TIE1 (↑) 
                       DDR1 (=), DDR2 (↑) 
                        RET 
                        AXL, TYRO1 (↓), TYRO3 (↓) 
                         CCK4 (↓) 
                           RYK 
     
    ECM  
  TGF-β (↑,+) 
            VEGF (↑,+) 
                Wnt5a (↑,mo) 
 
          
 
                  CXCL1-3 (+) 
                CXCL8 (+,mo) 
     CXCL9 (Mig)(mo,ad) 
             CXCL10 (IP-10) 
                      IFN-α/γ (-) 
                    TNF-α (-) 
      
               
                               Amphiregulin (+) 
                                       CCL27 (+,mo) 
                                        CXCL1 (+) 
                                 CXCL8 (+,mo) 
                             Epiregulin (+) 
                                ET-1 (+) 
                         FGF-2 (+) 
                 HB-EGF (+) 
                   HRG (+) 
                IL-1 (+)                  
          SCF (+/-) 
TGF-α (+) 
 
 CCL2/MCP-1 (↑,ch) 
  CCL5/RANTES (↑,+,ch) 
 CXCL1-3 (↑,+,ch) 
 CXCL8 (↑,ch) 
 
      
                    
               CXCL8 
           FGF-2 (+) 
       TGF-β (-) 
                        
      
    
 
               CCL21 (ch) 
CCL27 (CTACK) (ch) 
               CXCL12 (ch) 
                     HGF (ch) 
 
      
                 
               Melatonin 
        α-MSH (+) 
     NGF (-) 
      
TGF-β R III (↑) 
ActRI 
ActRIB 
ActRII 
ActRIIB 
                                             IL-2R  
                                             IL-6Rα↓ 
                                            AMFR/gp78 (↑) 
                CXCR1 (↑) 
                CXCR2 (↑) 
                CXCR3 
                CXCR4 (↑) 
                CCR7 (↑) 
                CCR10 (↑) 
                Fz 
                Histamine H1R 
                 MC1-R (=) 
                 PAR-1 (↑) 
 
                                 CXCL1 (↑,+) 
                             CXCL8 (↑,+) 
                   Ephrin-A1 (↑,+)      
                     FGF-2 (↑,+) 
                     IL-6 (↑,+) 
     PDGF-A/B (↑,+) 
         VEGF (↑,+) 
         
                      Ephrin-A1 (+) 
                  CXCL8 (+) 
             CXCL1-3 (+) 
Keratinocyte
            AMF (+,mo) 
          CXCL1-3 (MGSA/GRO-α/β/γ) (↑,+) 
          CXCL8 (IL-8) (↑,+,mo) 
           Ephrin-A1/B2 (↑,+) 
            FGF-1, -2, -5 (↑,+) 
             HGF (↑,+) 
             Histamine 
              HRG (↑,+) 
               IL-1α/β (+) 
                IL-6 (+,↑) 
                IL-10 (+,↑) 
                MIA (↑,-) 
                α-MSH (↑,+) 
               PDGF-A (↑,+) 
            TGF-α  (↑,+) 
            
Immune cells
Metastatic site (e.g. lymph 
node, lung, liver, bone marrow, skin,...) 
Other
sites  
  Endothelial 
              cell 
         CXCL8 (+,mo) 
CXCL12 (SDF1α) (+,ad) 
                                ET-3 (+) 
                                FGF-2, -7 (+) 
                                              HGF (+) 
                                               IGF-1(+,mo) 
                                                                IL-1 (-) 
                                                                       IL-6 (-) 
                                                                                KGF 
                                                                          TGF-α (+)      
                                                                     TGF-β (+/-) 
 Fibroblast 
Figure I.2. Regulation of melanoma cells by autocrine and paracrine factors. Figure was based upon Plaisance et al.,
1993; Werner et al., 1994; Rodeck et al., 1994; Easty et al., 1997; Rodeck et al., 1999; Halaban, 2000; Easty and Bennett,
2000; Lázár-Molnár et al.,,2000; Biitner et al., 2000; Schelfhout et al., 2000; Shirakata et al., 2000; Strachan et al., 2000;
Meier et al., 2000; Müller et al., 2001; Robledo et al., 2001; Satyamoorthy et al., 2001, 2002; Payne and Cornelius, 2002;
Ruiter et al., 2002; Schelfhout et al., 2002; Murakami et al., 2002, Bogenrieder and Herlyn, 2002; Hsu et al., 2002; 2003;
Meier et al., 2003; Gruss et al., 2003; Li et al., 2003; Tellez and Bar-Eli, 2003; Streit and Detmar, 2003 and references in
these articles. The indications between brackets indicate the following: ↑, increased expression/secretion in melanoma
(compared to normal melanocytes); +/-, stimulation/inhibition of growth and/or survival; mo, stimulation of motility
(migration, metastasis); ch, chemotactic factor; ad: stimulation of adhesion.  
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ABSTRACT 
 
The human epidermal growth factor (EGF) 
receptor (HER) family of receptor tyrosine kinases 
has frequently been implicated in cancer. Apart 
from overexpression or mutation of these 
receptors, also the aberrant autocrine or paracrine 
activation of HERs by EGF-like ligands may be 
important in cancer progression. Neuregulins 
constitute a family of EGF-like ligands that bind to 
HER3 or HER4, preferably forming heterodimers 
with the orphan receptor HER2. Mesenchymal 
neuregulin typically serves as a pro-survival and 
pro-differentiation signal for adjacent epithelia. 
Disruption of the balance between proliferation 
and differentiation, because of autocrine 
production by the epithelial cells, increased 
sensitivity to paracrine signals or disruption of the 
spatial organization, may lead to constitutive 
receptor activation, in the absence of receptor 
overexpression. Consequently, the analysis of 
ligand expression and/or activated receptors in 
tumor samples may broaden the group of patients 
that can benefit from targeted therapies.  
 
 
The human epidermal growth factor receptor 
family 
On the basis of their sequence homology and 
structural characteristics, growth factor receptors can 
be classified into different groups. The human 
epidermal growth factor (EGF)1 receptor (HER) 
family of receptor tyrosine kinases consists of four 
members: HER1 (EGFR, ERBB1), HER2 (neu, 
ERBB2), HER3 (ERBB3) and HER4 (ERBB4). They 
are widely expressed in epithelial, mesenchymal and 
                                                 
1 Abbreviations used: ARIA, acetylcholine receptor-inducing 
activity; CDK, cyclin-dependendent kinase; COX-2, 
cyclooxygenase-2; EGF, epidermal growth factor; E2, estradiol; 
ER, estrogen receptor; FAK, focal adhesion kinase; GAP, GTPase-
activating protein; GGF, glial growth factor; HER, human EGF-like 
receptor; HRG, heregulin; MAPK/ERK, mitogen-activated protein 
kinase/extracellular-regulated kinase; MMP, matrix 
metalloproteinase; MMTV, murine mammary tumor virus; MTA1, 
metastasis and tumor-associated protein 1; NDF, neu differentiation 
factor; NRG, neuregulin; Pak1, p21-activated kinase 1; PGE2, 
prostaglandin E2; PI3K, phosphoinositide-3 kinase; PKB/Akt, 
protein kinase B/a kinase on threonine; PR, progesterone receptor; 
RAFTK, Related Adhesion Focal Tyrosine Kinase; SMDF, sensory 
and motor neuron-derived factor; VEGF, vascular endothelial 
growth factor. 
neuronal tissues, playing fundamental roles during 
development and being implicated in the regulation of 
a variety of biological processes, including cell 
proliferation, apoptosis and differentiation [1, 2]. 
Structurally, they consist of a ligand-binding 
extracellular domain, a single transmembrane domain 
and an intracellular tail. The latter contains the kinase 
domain and multiple tyrosine residues that become 
phosphorylated upon activation and may serve as 
docking sites for signal transduction molecules. 
Although all family members share considerable 
homology, two members deviate from this general 
description: the extracellular domain of HER2 has not 
been shown to be involved in ligand binding (orphan 
receptor) and the HER3 intracellular tail is devoid of 
kinase activity (kinase dead receptor) [3, 4]. This 
receptor family has been implicated frequently in 
human malignancies. This is particularly the case for 
HER1 and HER2. HER2 overexpression has been 
described in a wide variety of cancer types (e.g. breast 
and ovarian) and correlates with poor prognosis [5, 6]. 
Overexpression of this receptor leads to ligand-
independent homodimerization, resulting in 
constitutive receptor activation, sufficient to induce 
transformation. Alternative mechanisms leading to 
ligand-independent constitutive HER2 signaling 
include a point mutation in the transmembrane 
domain (only found in rodents) and truncation of non-
catalytic sequences [7]. 
 
 
Neuregulins 
Based on distinct biological activities, neuregulins 
were initially purified as related factors released by a 
variety of cell types, and were subsequently given 
different names (NDF, HRG, GGF, ARIA), leading to 
a confusing nomenclature. Using HER2 activating 
potential as a read-out, Peles et. al. and Wen et. al. 
identified neu differentiation factor (NDF) as a factor 
released by H-Ras-transformed rat fibroblasts [8, 9], 
whereas Holmes et al. isolated heregulin (HRG) from 
medium conditioned by the MDA-MB-231 human 
mammary cancer cell line [10]. Other groups used 
neuronal tissue extracts as a source for protein 
purification: glial growth factor (GGF) was purified 
from bovine pituitary glands as a Schwann cell 
mitogen [11] and acetylcholine receptor inducing 
activity (ARIA) was purified from chicken brain 
extracts [12]. All these factors, identified in different 
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species, are derived from alternative splicing of a 
single gene, neuregulin-1 (NRG-1) [11, 13]. Although 
it was initially thought that NRG-1 would directly 
bind to and activate HER2, the observation that 
certain cell lines which express a functional HER2 did 
not respond to NRG, indicated that another 
component was needed to mediate the tyrosine 
phosphorylation of HER2. This was confirmed by the 
cloning of HER3 and HER4 and their subsequent 
identification as the primary NRG-binding receptors 
[14-16]. 
NRG-1 isoforms are widely expressed in numerous 
tissues, including brain, heart, skeletal muscle, breast, 
liver and lung [17, 18] Based on sequence homology 
with NRG-1, neuregulin-2 (also termed Divergent of 
neuregulin-1 (Don-1) or Neural- and thymus-derived 
activator of ErbB kinases (NTAK)), was cloned [19-
21]. Later, two additional neuregulin families 
(neuregulins-3 and -4) were identified [22, 23]. The 
latter two only induce activation of HER4, whereas 
NRGs-1 and -2 bind and activate both HER3 and 
HER4. 
 
 
Structural features of neuregulin-1 
At present, at least 26 different neuregulin-1 isoforms 
have been identified in different species. Ten of these 
were identified in human, all resulting from 
alternative splicing of a single gene, located in the 
short arm of chromosome 8 [24] (Figure 1). Based on 
the N-terminal domain, they are subdivided into three 
types: HRG (Type I) [10], GGF (Type II) [11] and 
sensory and motor neuron derived factor (SMDF, 
Type III) [25] [reviewed in 13]. Although the N-
terminal domain of all three types is involved in cell-
surface association, it does so in different ways. HRG 
and GGF can be distinguished from SMDF by the 
presence of a heparin-binding immunoglobulin-like 
sequence in their N-terminal domain. This feature was 
shown to improve receptor binding by association 
with cell surface heparin sulphate binding 
proteoglycans, and may function to sequester these 
factors in the extracellular matrix as well [26]. 
Instead, the N-terminal domain of SMDF contains an 
additional hydrophobic domain that may function as a 
transmembrane sequence. Insertion of this sequence 
into the membrane results in the formation of a type II 
transmembrane protein, with the receptor-activating 
domain exposed [27-29]. The only exon that is shared 
by all isoforms is the one encoding the major part of 
the EGF-like domain. It encodes five of the six 
cysteines present in the EGF-like domain, the sixth 
encompassed in the sequence encoded by either the α 
or β exon. This EGF-like domain is both necessary 
and sufficient for receptor activation, with β-isoforms 
having higher receptor affinity and generally being 
more potent than α-isoforms [30].  
In transmembrane isoforms, the EGF-like domain is 
connected to the transmembrane domain by a 
juxtamembrane domain of variable length (α/β 1 or 
2), which is susceptible to proteolytic cleavage, 
releasing the ectodomain [30, 31]. Alternatively, read-
through of the β-encoding exon results in isoforms 
lacking the transmembrane domain, which are 
presumably retained intracellularly. Further 
alternative splicing leads to different lengths of 
intracellular tails, a, b and c, the a- and c-tail being the 
longest and shortest, respectively [32]. The role of 
this intracellular tail is mainly unknown. The two 
interacting molecules that have been identified are 
both zinc finger proteins: LIM kinase 1 [33], a 
serine/threonine kinase that blocks the actin 
depolymerizing activity of cofilin and has been 
implicated in cancer cell invasion [34], and a PLZF-
related protein of undetermined function [35]. 
However, the functional relevance of these 
interactions has not been established, yet. In addition, 
the cytoplasmic tail was shown to be necessary for the 
apoptosis-inducing properties of neuregulins (see 
below) and may play a role in ‘reverse’ signaling. The 
latter occurs following binding of the extracellular 
domain of the HRG type III precursor to HER2/4 
dimers (reverse juxtacrine signaling) and involves the 
γ-secretase-mediated proteolytic release of the HRG 
 
 
Figure 1. Schematic representation of the exon organization and possible alternative splicing of the NRG1 
gene. Closed boxes indicate exons (on scale), lines between these indicate possible splicing events, open boxes 
represent untranslated regions. Introns, which may be very large, are not on scale. An asterisk indicates the 
position of stop codons. Three different start codons may be used, generating glial growth factor (GGF), 
heregulin (HRG) or sensory and motor neuron derived factor (SMDF). The epidermal growth factor (EGF)-like 
domain is composed of a common exon and an α or β exon. A combination of an α and β exon, found 
infrequently, leads to the generation of a premature stop codon within the β exon (not indicated). Readthrough of 
the β-exon leads to the generation of a stop codon, while further splicing generates α/β-1 or -2 isoforms. 
Following the sequence encoding the transmembrane (TM) domain, alternative splicing leads to isoforms having 
a-, b- or c-type intracellular tails. 
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intracellular domain and its subsequent nuclear 
translocation, where it may influence the transcription 
of target genes [35]. This nuclear translocation was 
dependent on the presence of a nuclear localization 
sequence in the HRG juxtamembrane domain [35] 
and has been observed in several types of cancer [36-
38] Other roles for the transmembrane/cytoplasmic 
domain include the regulation of the proteolytic 
release of mature HRG [39-41] and the correct 
trafficking and subcellular targeting of neuregulins to 
e.g. rafts, specialized membrane platforms rich in 
cholesterol [32, 42, 43]. 
Transmembrane heregulins (with an a-tail) are 
synthesized as transmembrane precursor proteins of ± 
105kDa. Following cleavage in the juxtamembrane 
domain by metalloproteinases [44, 45], they are 
released as ±45kDa secreted factors that may bind to 
nearby receptors and thus function as 
autocrine/paracrine factors [42, 31]. Alternatively, 
intact transmembrane HRG molecules may activate 
HERs, leading to juxtacrine signaling [46], which 
may be bi-directional: ‘forward’, leading to HER 
activation and ‘reverse’, leading to modulation of 
intracellular pathways by the HRG cytoplasmic tail, 
as described above. 
Based upon its expression in vivo, heregulin is often 
referred to as a neuronal (β isoforms) or mesenchymal 
(α isoforms) factor [17, 18, 32]. In the latter case, it 
has been suggested to function as a paracrine factor 
for the neighboring cells, such as glia, muscle or 
epithelia, which express HER3 and/or HER4 [17]. 
The importance of such paracrine signaling is 
exemplified in NRG-1 knockout mice, where targeting 
of the EGF-like domain results in disruption of all 
NRG-1 isoforms. These mice die in utero at 
embryonic day 10.5 due to a lack of trabeculation, a 
developmental process involved in ventricular 
differentiation during heart formation. This process 
requires the activation of ErbB2 and ErbB4 in the 
myocytes by HRG, which is normally released from 
the nearby endocardium [47]. 
 
 
Signaling induced by neuregulins 
Based upon the recent elucidation of the crystal 
structures of HER1, HER2 and HER3, a unique 
model has been proposed for HRG-induced receptor 
activation. In this model, binding of HRG to HER3 
leads to a ligand-driven conformational change of 
HER3, allowing a back-to-back association with 
HER2 [reviewed in 48]. On its turn, HER2 will auto-
phosphorylate and trans-phosphorylate HER3, 
resulting in the generation of multiple docking sites 
for signal transduction molecules in their cytoplasmic 
tails [reviewed in 1]. Thus, this represents a unique 
system in which an orphan receptor (HER2) and a 
kinase-dead receptor (HER3) cooperate to generate a 
potent signal [reviewed in 49]. Following HER2 
activation, many phosphotyrosines in its carboxy-
terminal tail serve as docking sites for Src homology-
2- and phosphotyrosine-binding-domain containing 
proteins, such as Shc, Grb2 and Grb7, generating a 
highway leading to mitogen activated protein 
kinase/extracellular regulated kinase (MAPK/ERK) 
activation [50]. Activated HER3, in contrast, harbors 
multiple docking sites for the p85 subunit of 
phosphoinositide-3-kinase PI3K [51]. Thus, it is not 
surprising that the combined activation of both HER2 
and HER3 by HRG provides the cells with a very 
potent signal. In addition to the ‘classical’ MAPK and 
PI3K pathways, multiple other pathways have been 
shown to be activated by HRG. Examples include the 
p38MAPK, ERK5, protein kinase C, phospholipase 
Cγ and signal transducer and activator of transcription 
(STAT) pathways. These have been reviewed recently 
and will not be discussed into detail here [49,52]. In 
addition, HRG-mediated activation of HERs may 
result in the nuclear localization of full-length or 
cleaved receptors, suggesting direct, receptor-
mediated signaling [53, 54]. Moreover, adding an 
additional level of complexity to the system, also 
trans-activation of other receptors may contribute to 
HRG’s actions [52]. For example, HRG has been 
shown to trans-activate the progesterone receptor, in a 
HER2- and MAPK-dependent way, leading to 
enhanced proliferation of mammary cancer cells [55]. 
The combined action of all or of several of these 
pathways on transcriptional and post-transcriptional 
(mRNA stability, translation, post-translational 
modifications, and protein stability) events determines 
the final outcome in a given system. 
In cancer, aberrant receptor activation may be the 
result of truncation, mutation, association with other 
cell-surface proteins, transactivation via other 
receptors or the presence of autocrine loops [7,56]. 
Recently, an interesting physiological control 
mechanism for the HRG-HER system was described 
in human differentiated airway epithelia, in which 
both HRG-α and its receptors are expressed. In these 
epithelia, HRG, which is apically expressed, is 
physically segregated from the basolaterally 
expressed receptors, preventing HER activation. 
However, upon disruption of the integrity of the tight 
junctions, HRG may locally activate its receptors 
[57]. Thus, this model suggests an additional 
mechanism for abnormal receptor activation in 
diseases, such as inflammation and cancer, in which 
increased epithelial permeability occurs. 
Although the exact mechanism(s) by which NRG-1 
may lead cells towards malignancy may be distinct 
for different cell types, some general aspects hold for 
the majority of these. Cancer cells that aberrantly 
produce NRG-1 are likely to use it in an autocrine 
manner, resulting in constitutive activation of HERs 
and the downstream signaling molecules. This, in 
turn, leads to increased proliferation, alterations in the 
phosphorylation state of molecules implicated in the 
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cytoskeleton, and modulation of neuregulin-
responsive genes. All these events may drive the cell 
towards a more malignant phenotype. 
Since far most studies related to the potential role of 
HRGs in regulating normal and oncogenic signals 
through its receptors have focused on its effects on 
mammary (cancer) cells, we have made a distinction 
between the studies focusing on the involvement of 
HRG in normal mammary gland physiology and 
breast cancer and its involvement in other cell types. 
  
 
Distinct roles for heregulin in mammary 
epithelial cells 
 
Heregulin as a mammary gland mitogen regulating 
differentiation 
In vivo, in the mouse mammary gland, the only 
neuregulin-1 identified is heregulin-α. Its expression 
by the mammary mesenchyme, adjacent to 
lobuloalveolar structures, is suggestive for a role in 
the morphogenesis and ductal migration of mammary 
epithelial cells [58]. Expression is virtually absent in 
virgin glands, peaks at mid to late pregnancy and then 
sharply decreases after several days of lactation, 
becoming undetectable again during involution [58]. 
A crucial role for HRG in the differentiation of the 
mammary epithelium into secretory lobuloalveoli was 
confirmed by studies using mammary gland organ 
cultures [58] or mammary implants containing HRG 
[59]. This differentiation is characterized by an 
increase in nuclear size, large cytoplasmic vesicles, 
synthesis of milk protein (β-casein) and appearance of 
cytoplasmic fat droplets [58-60]. HRG-mediated 
upregulation and increased membrane targeting of 
Rab3A, a low molecular weight GTPase involved in 
vesicular trafficking, has been suggested to play a role 
in these processes [61]. Direct evidence for a role of 
HRG in lobuloalveolar development came from the 
generation of HRG-α knockout mice. In contrast to 
HRG-null mice, these mice survive to adulthood, but 
have transient defects in lobuloalveolar development, 
showing abrogated proliferation of luminal mammary 
epithelial cells during pregnancy and lactation. During 
lactation, this was accompanied by a dramatic 
reduction in β-casein expression [62]. Similar defects 
in lobuloalveolar development and lactation were 
observed in mice expressing dominant negative 
mutants of HER2 or HER4 in the mammary gland 
[63, 64]. 
In conclusion, HRG-α expression in the mammary 
gland may have a dual function, supporting survival 
and proliferation, while at the same time inducing 
differentiation. Deregulation of this balance between 
proliferation and differentiation, by alterations in 
expression levels of ligands or receptors, may 
contribute to transformation, tumor progression and 
metastasis. The dual action of HRG is also evident 
from its effects in vitro on cell lines: whereas 
sometimes proliferation is induced [10, 65-69], HRG 
treatment may lead cells to differentiation as well [8, 
60, 66, 67, 70, 71]. Important determinants for these 
distinct effects likely include the system/cell line 
examined, methodology used, HRG isoform(s) 
involved, the concentration used, receptor expression 
profile, receptor-receptor interactions, as well as the 
intensity and duration of activation.  
 
 
Heregulin as a growth-inhibiting, pro-apoptotic 
differentiation factor for mammary cancer cells 
Heregulin has been shown to exert differentiating 
effects on breast cancer cell lines in in vitro cell 
culture systems. As was observed in mammary 
glands, HRG may induce a differentiated phenotype 
of cultured cell lines, characterized by a flattened 
morphology, increased nuclear size, large cytoplasmic 
vesicles, synthesis of milk protein (β-casein), 
appearance of fat droplets and increased ICAM-1 
expression [66, 72, 73]. In 3-D cultures inside 
collagen type I of immortalized non-tumorigenic 
mammary epithelial cells and SKBR-3 and T47D 
mammary carcinoma cell lines, HRG treatment 
induced a more differentiated phenotype [74]. When 
combined with retinoids, which are known inducers 
of differentiation in breast cancer cell lines [75], this 
differentiation was even more pronounced, possibly 
due to the induction of retinoid acid receptor α by 
HRG in these cells [76]. The increase in 
differentiation was associated with elevated cell 
adhesion to cell surfaces, brought about by alterations 
in the level and distribution of integrins α2 and β1 
[74]. Increased cell-cell adhesion, dependent on PI3K 
activity, has been observed in several breast cancer 
cells following exposure to HRG [77]. Since this 
increase in cell-cell adhesion was present in E-
cadherin negative cell lines and could take place at 
4°C, it is cadherin-independent. Thus, also here, 
HRG-mediated modulation of integrins may play a 
role. In addition, using an MCF-7 variant with a 
functionally deficient E-cadherin, we found that HRG 
could stimulate E-cadherin mediated adhesion as well. 
This was accompanied by decreased invasion of these 
cells into a precultured chick heart fragment (Stove et 
al., manuscript submitted). On solid substratum, 
NRG-1 may induce a morphogenetic effect, 
rearranging epithelial islands into ring-shaped arrays 
with internal lumens [78], which may be a reflection 
of its function in lobuloalveolar morphogenesis in 
vivo [58]. Primary human mammary epithelial cells 
produce endogenous HRG [69], which possibly 
contributes to spontaneous differentiation of these 
cells. 
HRG is involved in the development of the mammary 
gland, possibly through the regulation of the apoptotic 
process. In general, apoptosis may result from the net 
impact on pro- versus anti-apoptotic pathways. A 
critical determinant in this balance may be the 
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expression levels of HER2, resulting in increased 
proliferation in cells that express low levels and 
leading to growth inhibition in HER2 overexpressing 
cells. This is evident from the fact that HRG is able to 
inhibit the growth of several breast and ovarian cancer 
cell lines that overexpress HER2 [8, 70, 73, 76, 79-
83]. However, no growth inhibition of HER2-
overexpressing cell lines was seen by others [69], 
indicating the important influence the test conditions 
may have on the outcome. HRG-mediated growth 
inhibition of the HER2 overexpressing SKBR3 breast 
cancer cell line relates to its induction of apoptosis, 
cell cycle G2-M arrest and cell differentiation [70, 79, 
82]. These effects were suggested to be mediated via a 
mitochondrial pathway, involving downregulation of 
the anti-apoptotic protein Bcl-2 and activation of 
caspase-7 and -9, and being potentiated by inhibition 
of protein kinase Cα [83]. Alternative pathways by 
which HRG may induce apoptosis include the 
p70S6K/mTOR pathway, sustained activation of the 
JNK or MAPK pathway and late activation of p38 
MAPK (day2-3) [70, 80, 82]. Again, the pathway 
used may differ among different cell lines tested and 
even with a given cell line, may depend on the assay 
conditions. Although HRG-mediated induction of 
apoptosis and differentiation often coincide, different 
pathways seem to be involved, as is evident from the 
involvement of the PI3K pathway in HRG-mediated 
induction of differentiation, but not apoptosis, of 
SKBR-3 cells [70]. 
In contrast to the above mentioned mechanisms, in 
which HER activation leads to growth inhibition and 
apoptosis in selected cell lines, another mechanism 
for the pro-apoptotic activity of HRG has been 
suggested. This was based upon the identification of 
HRG-β2b as a dominant apoptosis-inducing gene, the 
transmembrane domain and intracellular tail being 
important for this effect [81, 84, 85]. The fact that this 
HRG isoform could induce apoptosis in the absence 
of HER-binding, illustrates the dual function HRG 
might have: while cleavage may lead to secretion of 
HRG, which may have a transforming activity on 
HER-expressing cells (see below), the producing cell 
may undergo apoptosis when intracellular levels of 
the HRG cytoplasmic tail become too high. This 
selective killing of HRG-overexpressing cells might 
represent an auto-regulatory physiological mechanism 
protecting the organism against tumorigenesis. 
Consequently, loss of this sensitivity to apoptosis in 
HRG-overexpressing cells allows the continuous 
secretion of high amounts of HRG and may represent 
a step towards tumorigenesis. Consistent with these 
observations, epithelial cells from MMTV/heregulin-
induced tumors exhibit high levels of apoptosis, in 
contrast to tumors induced in transgenic mice by 
HRG lacking the intracellular tail [81, 85, 86] 
Overexpression of HRG-β2b in MCF-7 cells induced 
apoptosis as well, which depended on caspase 
activation and was accompanied by a downregulation 
of Bcl-2 [81]. In addition, constitutive overexpression 
of rHRG-β2 in MCF-7 cells has been shown to 
markedly increase their sensitivity to doxorubicin and 
etoposide treatment [87].  
Finally, it should be noted that inhibition of 
proliferation does not necessarily coincide with a less 
aggressive phenotype. This is evident from the effects 
of HRG and agonistic anti-HER2 antibodies on 
SKBR-3 mammary cancer cells: although 
proliferation of these cells is inhibited following 
receptor activation, invasion of these cells is increased 
[73]. 
 
 
Heregulin as a mitogenic, pro-invasive and 
metastatic factor in breast cancer 
As already mentioned above, the role of HRG in 
cancer has been particularly investigated in breast 
cancer. More than 60% of human breast cancers 
express estrogen receptor (ER) and hormone therapy 
is a commonly applied adjuvant therapy for breast 
cancer patients. Although ER expression is used to 
predict which patients will respond to hormone 
therapy, not all patients with positive ER will benefit 
from endocrine therapy [88]. It is being increasingly 
recognized that altered expression of a variety of 
growth factors and their receptors may activate 
signaling pathways that influence ER signaling [89-
91]. One of such factors is HRG. Elevated expression 
of HRG was found in a subset of breast cancer cell 
lines and in 25-30% of human primary breast cancers 
[92, 93], a percentage similar to that of HER2 
overexpression in breast cancer [5, 6]. HRG 
expression in mammary tumors was found both in the 
stroma as in the tumor cells themselves, with stromal 
expression correlating with increased recurrence [94] 
or with activated protein kinase B (PKB/Akt), a 
downstream intermediate of PI3K, whose activation 
predicts a worse outcome among breast cancer 
patients [95]. Interestingly, HRG is particularly 
present in cell lines and tumor biopsies that do not 
overexpress HER2, inversely correlating with 
expression of estrogen receptor-α [93, 95]. The fact 
that the HRG-overexpressing population of breast 
tumors is distinct from that overexpressing HER2, 
combined with the ability of HRG to promote tumor 
formation in the absence of overexpression of HER2 
(see below), suggests an important role for the 
HRG/HER system in the etiology of breast cancer. 
This may be of clinical significance, since nowadays 
only HER2 expression levels are being evaluated in 
tumor samples. Therefore, assessment of both 
receptor and ligand levels, or alternatively of receptor 
activation status [96], may provide a better basis for 
evaluation of the role these molecules play in 
particular cancers. This may result in a better 
identification of patients that may benefit from 
targeted therapies. 
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HRG is a potent mitogen for most breast cancer cell 
lines, provided they express HERs. Using a panel of 
different assays applied on a series of breast cancer 
cell lines with varying HER2 levels, Lewis et al. [68] 
and Aguilar et al. [69] demonstrated a clear growth-
stimulatory role for HRG, both in vitro and in vivo. 
Supporting these findings, the mitogenic action of 
exogenous HRG was less pronounced or absent in 
cells producing HRG in an autocrine way, although 
increasing HER2 levels in these cells increased their 
responsiveness. Its potency is evident from its ability 
to act as a dual specificity growth factor for the 
human mammary epithelial cell line MCF-10A, in 
which it drives signal transduction pathways that 
normally require both EGF and insulin-like growth 
factor-I [97]. The mitogenic action of HRG is likely 
to be achieved through the combined action of 
multiple pathways, including PI3K, MAPK and 
p38MAPK pathways [98, 99]. These affect proteins 
involved in cell cycle progression, as exemplified by 
the promotion of expression of c-Myc, A-, E- and D-
cyclins and p21cip1, activation of cyclin-dependent 
kinases (CDK) and phosphorylation of the 
retinoblastoma protein (pRB) [98, 100] 
Multiple studies suggest that HRG induces breast 
cancer progression towards an aggressive phenotype, 
as determined by hormone independence, antiestrogen 
resistance (loss of ER function and response), 
tumorigenicity [101], invasion [102-104], and 
metastasis [105-107]. It does so directly by increasing 
cell motility or indirectly, via the regulation of genes 
that regulate and control malignant progression (Table 
1, see below). 
In breast cancer cells, HRG can block both 
estradiol (E2) action and ER function. HRG 
antagonizes the E2-mediated downregulation of 
HER2 and is capable of enhancing tamoxifen-induced 
stimulation of the receptor [101, 108, 109]. HRG 
supplementation of ER-positive breast cancer cell 
lines results in resistance to the growth inhibitory 
effects of antiestrogens, which is more pronounced 
with partial than with full antiestrogens [110]. In 
addition, treatment/transfection of the ER-positive, 
E2-dependent MCF-7 breast cancer cell line with 
HRG-β1/2 resulted in a loss of E2 dependence and 
acquisition of antiestrogen resistance both in vitro and 
in vivo [101, 109, 106, 111]. Inoculation of HRG-
supplemented or HRG-producing MCF-7 cells in the 
mammary glands of ovariectomized nude mice 
resulted in spontaneous, E2-independent tumor 
formation [69, 106]. This model mimics what is seen 
in many breast cancer patients: ER-positive tumors 
acquire antiestrogen resistance during the course of 
the treatment, while still retaining some levels of ER. 
The fact that other growth factors, such as 
transforming growth factor α, which are also 
mitogenic for MCF-7 cells, cannot support this E2-
independent growth, pleads for the strength of HRG 
as a transforming factor [112]. Depending on the 
conditions applied, both suppression [101, 108, 113] 
and activation [109, 114] of the ER signaling pathway 
have been described. Both scenarios, likely resulting 
in differences in activation of several pathways, may 
lead to E2-independency. 
In the first scenario, low concentrations of 
HRG decrease ERα levels, activity and binding to its 
response element in a DNA mobility shift assay, as 
well as estradiol-induced growth of breast cancer cell 
lines [101, 108, 113]. A molecular mechanism, 
involving upregulation of metastasis-associated 
protein 1 (MTA1), has been proposed for the HRG-
mediated suppression of E2 response elements (ERE) 
and disruption of E2 responsiveness [115]. In 
accordance with the correlation between MTA1 
expression and the metastatic potential of several 
human cell lines and tissues [116] these authors found 
that MTA1 was increased in Harderian-gland tumors 
in MMTV-driven HRG transgenic mice and could 
induce invasion in vitro [115]. By physically 
interacting with the activation factor domain of ERα 
and with histone-deacetylase (HDAC) 1 and 2, MTA1 
recruits HDAC activity to ERE’s, suppressing 
transcription of target genes containing these ERE’s. 
Alternatively, MTA1s, an MTA1 splice variant 
containing a unique RLILL motif, has been shown to 
prevent E2-induced nuclear translocation by 
sequestering ERα in the cytoplasm. Expression of this 
splice variant was higher in breast cancers and 
correlated with absence of nuclear ER [117]. 
Hyperactivation of MAPK, accompanied by loss of 
ERα without activation of ERα responsive genes, may 
be a cause of estrogen unresponsiveness as well [118]. 
Interestingly, cells expressing the MTA1 splice 
variant had increased levels of MAPK activation, 
suggesting that expression of this protein may confer 
unresponsiveness to E2 while stimulating other 
pathways at the same time [117].  
For the second scenario leading to E2-
independency, in which ligand-independent ER 
activation occurs, Stoica et al. [114] recently 
presented an interesting mechanism. Using MCF-7 
cells, they showed that both the binding of HRG to 
HER3/HER2 ánd the presence and activity of 
membrane ERα (which may be physically associated 
with HER2 [119]) are required for PI3K/Akt 
activation. Akt activation, on its turn, leads to 
phosphorylation of ERα and a decrease of ERα 
mRNA and protein, coinciding with increased 
expression of progesterone receptor (PR) and pS2, 
two markers of ERα signaling [109, 114]. 
Interestingly, further demonstrating the intense cross-
talk between HERs and ERα, they also showed that 
ERα-mediated PI3K/Akt activation and activation of 
PR and pS2 target genes was abrogated by blocking 
HER2. Also the MAPK pathway is thought to play an 
important role in mediating the effect of HRG on cell 
proliferation and ERα. A possible crosstalk between 
the ER and MAPK pathways is supported by studies 
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in which ERα was found to be phosphorylated by 
MAPK and in which inhibition of the MAPK pathway 
restored the sensitivity to antiestrogens [120, 121]. In 
conclusion, HRG may provide cells with a phenotype 
that depicts the passage from an initial E2-responsive 
and antiestrogen-sensitive tumor cell to a later step in 
carcinogenesis, resembling the common progress of 
many human breast tumors. 
HRG promotes tumorigenicity and metastasis 
of breast cancer cells that do not overexpress any of 
the HERs [101, 106]. An increase in the invasive 
phenotype of MCF-7 cells exposed to HRG was 
found both in vitro and in vivo. In contrast to normal 
MCF-7 cells, HRG-expressing MCF-7 cells injected 
into the mammary fat pad of nude mice metastasize to 
the axillary lymph nodes and induce preneoplastic 
transformation of the adjacent mouse mammary 
epithelium [106]. Further substantiation for a role of 
HRG as a transforming and tumor progression factor 
was provided by transgenic mouse models in which 
HRGβ2c, either full length or lacking most of the 
cytoplasmic tail, was expressed under the control of 
the murine mammary tumor virus (MMTV) promoter. 
Overexpression of HRG in the mammary glands of 
these mice induces a persistence of the terminal end 
buds in the transgenic virgin females. More 
importantly, multiparous female mice have extensive 
mammary hyperplasia and develop mammary 
adenocarcinomas at 12-15 months of age [86, 122]. In 
addition, less apoptosis was observed in tumors from 
transgenic mice that overexpress the extracellular 
region of HRG, as compared with tumors from mice 
overexpressing full-length HRG, in line with a 
proposed role for the HRG cytoplasmic tail in 
apoptosis [86]. Conversely, upon treatment of HRG-
overexpressing breast cancer cell lines with HRG 
blocking antibodies, in vitro growth, motility and 
invasion of these cells is decreased [111]. This was 
further confirmed by Tsai et al. [107], using stable 
HRG-antisense transfectants of MDA-MB-231 
mammary carcinoma cells, endogenously expressing 
HRG. In these cells, reduction of HRG expression 
abrogated the pre-existing autocrine loop, resulting in 
decreases in proliferation, anchorage-independent 
growth, motility and invasion in vitro, the extent of 
these mirroring the decrease in HRG expression. 
Moreover, inoculation of these cells into the 
mammary fat pads of athymic nude mice resulted in 
tumors that were significantly smaller than those 
induced by the parental cells and that did not 
metastasize [107].  
 
 
Expression and role of neuregulin in other 
cancers 
Heregulin expression has been described in various 
normal epithelial and carcinoma cells. We recently 
reported that HRG may act as a potent paracrine 
growth factor for melanocytes and that multiple 
deregulations of the HRG/HER system are present in 
human melanoma cell lines. These included a lack of 
HRG responsiveness, owing to the absence of the 
HRG-receptor HER3, or owing to functionally 
inactive HER2, as well as autocrine growth 
stimulation by HRG. The latter resulted in 
constitutive activation of HER2 and HER3 and the 
downstream MAPK pathway [123]. Similarly, others 
have found that HRG may function as an autocrine 
and paracrine mitogenic factor for both normal lung 
epithelial cells and lung cancer cell lines. In normal 
human fetal lung, HRG expression is confined to the 
mesenchyme, suggesting a paracrine mechanism for 
stimulation of the adjacent epithelial cells. In contrast, 
in fetal lung explants, normal bronchial epithelial cell 
lines and lung cancer cell lines, HRG becomes 
expressed by the pulmonary epithelial cells as well, 
functioning as an autocrine, mitogenic ligand [124-
130]. Also in ovarian cancer cell lines, HRG 
expression has been found, with the majority of these 
cell lines showing a mitogenic response following 
treatment with HRG [68, 69, 131, 132]. Expression of 
HRG-α1 and -β1, as measured by RT-PCR and 
immunohistochemistry, was present in about 80% of 
ovarian carcinomas, the levels being higher in serous 
carcinomas than in endometrioid carcinomas, 
indicating the potential of autocrine regulation. 
Examination of HRG expression in normal 
endometrium revealed higher HRG-α and -β levels in 
the secretory phase of the menstrual cycle as 
compared with the proliferative phase. Cytoplasmic 
HRG-α immunoreactivity was significantly higher in 
the stroma (which also sometimes displayed nuclear 
staining) than in the glands, whereas HRG-β 
expression was weak to moderate in both the glands 
and stroma [132]. In endometrial cancer, HRG-β 
levels remained unchanged, whereas decreased HRG-
α levels paralleled loss of differentiation [133]. A 
similar loss of HRG-α expression in prostatic 
adenocarcinoma has been observed in one study 
[134], whereas another study on prostatic carcinoma 
reported upregulation of the protein [135]. HRG 
expression was absent in a panel of prostate 
carcinoma cell lines, but present in an immortalized 
non-transformed prostate epithelial cell line. 
Interestingly, similar to the differentiation effects that 
were seen in some breast cancer cell lines, HRG 
reduced growth of the LNCaP prostatic cancer cell 
line, which coincided with increased contact-
formation of these cells [71]. In colon cancer cells, 
autocrine HRG may give rise to constitutively 
activated HER2 and HER3, protecting against 
apoptosis and generating growth factor independence 
[136, 137]. In addition, HRG is able to upregulate 
cyclooxygenase-2 (COX2) in these cells, resulting in 
increased prostaglandin E2 (PGE2) secretion. The 
induction of COX-2 may have functional implications 
in colorectal cancer cells, as both the growth-
stimulatory and pro-invasive effects of HRG could be 
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blocked by a specific COX-2 inhibitor [136]. As 
discussed below, HRG also upregulated both uPA 
(PGE2-dependent and -independent) and uPAR 
(PGE2-independent) in these cells, the uPA/uPAR 
system being necessary and sufficient for HRG-
mediated invasion [138]. In addition, using a model of 
FET differentiated colon carcinoma cells plated on 
Matrigel, these authors showed that HRG affected 
colonic tissue remodeling, leading to the formation of 
three-dimensional, multiluminal structures. Formation 
of these lumen-containing structures was dependent 
on uPA/uPAR interaction as well and may also, at 
least in part, depend on upregulation of PGE2. In 
papillary thyroid carcinomas, immuno-
histochemistry revealed increased levels of HRG (α, 
β1, β2 and/or β3) in both primary tumors and lymph 
node metastases, as compared to normal tissue [38]. 
No association was found between HRG protein 
expression and clinical parameters in these patients. 
Interesting is that, apart from an increase in 
membrane and cytoplasmic HRG, the vast majority of 
tumors had positive nuclear immunostaining, whereas 
this was never seen in normal thyroid tissue or in 
diffuse hyperplasia. This nuclear staining was only 
observed with an antibody recognizing the 
cytoplasmic tail of the HRG precursor, rendering 
papillary thyroid carcinoma a candidate system for the 
recently described nuclear signaling function of the 
HRG cytoplasmic tail [35]. Nuclear HRG-β staining 
has also been observed in medulloblastomas, 
embryonal tumors of the cerebellum believed to arise 
from the cerebellar external granule cell layer. While 
newly acquired HRG-α expression was found in about 
one third of these tumors, almost all were positive for 
HRG-β, which is already present in normal human 
cerebellum during development. HRG was often co-
expressed with HER4 and newly acquired HER2, 
suggesting the presence of an autocrine loop in the 
progression of medulloblastoma [37, 139]. Having in 
mind the widespread expression of HRG in neurons 
and glia, it is not surprising that HRG expression has 
also been found in gliomas, which are though to arise 
from central nervous system glial cells [140]. HRG 
treatment of glioma cells has been shown to increase 
both motility and invasion, which was accompanied 
by increased phosphorylation and association of focal 
adhesion kinase with HER2 [141]. HRG transcripts 
were detected in esophagus, stomach and duodenum, 
with no changes observed in gastric cancers. HRG-α, 
which is secreted by gastric fibroblasts, was shown to 
be mitogenic for gastric epithelial cells, which may be 
of relevance since the high expression of HER3 and 
HER4 in gastric cancers [142, 143]. Activated 
monocytes may serve as a source of HRG as well 
[144]. Since these cells cannot use the secreted HRG 
themselves, and since activation and infiltration of 
monocytes may be triggered by tumors, the secreted 
HRG may serve as a paracrine growth factor for the 
tumor cells. Paget’s disease of the breast occurs in 
about 1% of the patients with breast cancer and is 
characterized by the invasion of large neoplastic cells 
originating in the mammary gland into the epidermis 
of the nipple. Normal keratinocyte-derived HRG-α 
has been suggested to play a crucial role in this 
process, by inducing chemotaxis of the mammary 
cancer cells, which frequently overexpress HER2 
[145]. Conflicting reports have been published 
considering the correlation between HRG expression 
and the differentiation state of keratinocytes and its 
mitogenic effects on these cells [146-148]. The 
primary role of HRG production by keratinocytes 
does not seem to be growth stimulation [147, 149-
151], but would rather involve the stimulation of 
motility, playing a central role in wound healing 
processes [146, 151, 152]. Elevated HRG expression 
has been suggested to play a role in hyperproliferative 
skin disorders [148], and may play a role in neoplasia 
as well, as suggested by its high expression in a skin 
squamous cell carcinoma cell line [123, 153]. 
Autocrine growth stimulation by HRG has been 
described in head and neck squamous carcinomas, 
where 11/14 cell lines displayed mRNA for HRG and 
secreted HRG in the medium [154]. The majority of 
these cell lines showed a mitogenic response to 
exogenously added HRG, which was accompanied by 
increased matrix metalloproteinase (MMP) 
production and invasion [155]. Low HRG expression 
was found in both normal human urothelium and a 
transitional-cell carcinoma. However, in contrast to 
primary cultures of human urothelial cells, which 
were growth stimulated by a variety of EGF-like 
growth factors, but not by HRG, the latter was a 
potent mitogen for the transitional-cell-carcinoma cell 
line [156, 157]. Finally, increased heregulin 
expression has been found in a malignant melanoma 
of soft parts cell line [158]. 
 
 
Involvement of neuregulin-responsive genes in 
malignant progression 
Several neuregulin-responsive target genes are known 
candidate genes for malignant transformation. These 
genes may fulfill important roles in distinct steps of 
cancer progression. One of the important steps for 
tumor progression, invasion and eventually metastasis 
is the destruction of the extracellular matrix that 
separates the epithelial and stromal compartments. 
Several proteases have been involved in this process. 
Of these, the matrix metalloproteinases (MMP’s), a 
family of more than 20 zinc-dependent 
endopeptidases, are involved in the breakdown of 
extracellular matrix during tissue remodeling. 
Aberrant expression of MMP’s has been widely 
recognized in cancer progression, being involved in 
tumor cell invasion and metastasis [159]. One such 
enzyme is MMP-9 (gelatinase B), which plays a role 
in the degradation of type IV collagen (gelatin) and is 
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highly expressed in breast carcinomas, correlating 
with increased metastatic potential [160, 161]. HRG is 
known to upregulate MMP-9 expression and 
enzymatic activity [73, 104, 106, 107, 155]. Multiple 
signaling pathways, including PKC, p38MAPK and 
MAPK pathways, were found to contribute to this 
upregulation [104]. Moreover, using a specific MMP-
9 inhibitor, the invasive phenotype of HRG-
expressing cells can be blocked [106], thus providing 
evidence for an important role for MMP-9 in HRG-
induced invasion. Other MMP’s that were upregulated 
following treatment of head and neck squamous 
carcinoma cell lines with HRG included collagenases, 
stromelysins and matrilysins, but not gelatinase A 
(MMP-2) [155]. In both breast and colon cancer cell 
lines, HRG upregulates the serine protease urokinase 
plasminogen activator (uPA) and its receptor (uPAR) 
[103, 138]. Following HRG treatment, an increase in 
membrane-bound uPA was observed, being 
redistributed to focal adhesion points, most frequently 
at the leading edges of the cell. A role for the 
uPA/uPAR system in HRG-mediated invasion could 
be deduced from the fact that invasion could be 
counteracted by blocking uPAR [138]. These findings 
are consistent with the frequent expression of 
uPA/uPAR at the leading edge of tumor cells and its 
correlation with tumor cell invasiveness and 
aggressiveness [reviewed in 162]. Whether uPA 
plasminogenic activity or uPAR-induced signaling is 
involved in the effects of HRG, has not been studied. 
It should be noted that the induction of proteolytic 
enzymes by HRG is not observed in all cell lines 
under all conditions tested [163]. For instance, in the 
invasive LM3 mouse mammary adenocarcinoma cell 
line, HRG treatment resulted even in a decreased 
activity of uPA and MMP-9, correlating with 
decreased proliferation and migration [164]. 
Increased de novo formation of vascular and 
lymphatic systems contributes to several aspects of 
tumor progression: they do not only supply the tumor 
with fresh blood, which is a key factor for the growth 
and survival of solid tumors, they comprise systems 
by which tumor cells can easily spread to nearby or 
distant tissues as well. Critical growth factors known 
to mediate these processes belong to the vascular 
endothelial growth factor (VEGF) family. 
Overexpression of VEGF family members has been 
detected in tumor specimens and correlated with an 
advanced invasive phenotype [165]. HRG has been 
implicated in (lymph)angiogenesis by its mitogenic 
effects on endothelial cells and its induction of 
VEGF-A and -C in breast cancer cells in vitro and in 
vivo [166-172]. This induction was not observed in 
normal mammary or bronchial epithelial cells [168]. 
HRG treatment of head and neck squamous 
carcinoma cells resulted in an upregulation of VEGF-
A, and –C, did not affect VEGF-B levels, and 
downregulated VEGF-D [173]. Interesting in this 
respect is that such differential regulation of different 
VEGF family members has been associated with 
malignant progression and lymph node metastasis in 
lung cancers [174]. Several mechanisms have been 
proposed for the HRG-mediated increase in VEGF-A 
and –C. For VEGF-A, upregulation may occur in a 
PI3K-dependent manner, by activation of p21-
activated kinase 1 (Pak1); by increased translation of 
hypoxia inducible factor (HIF)-1α, which, together 
with HIF-1β, acts as a transcriptional activator of the 
VEGF-A gene; and/or by MAPK-dependent 
activation of Sp-1 and AP-2 transcription binding 
sites in the VEGF-A promoter [167, 170, 171]. 
Consistent with this, it has been shown that the Sp-1 
transcription factor is stimulated by phosphorylation 
following HRG-induced HER activation [175]. 
Alternatively, or in combination, HRG-induced 
transient activation of p38MAPK results in enhanced 
VEGF-A and -C transcription and secretion of VEGF 
protein in breast cancer cells [169, 172]. For the 
lymphangiogenic VEGF-C, this was shown to depend 
on a p38MAPK-dependent phosphorylation and 
inactivation of IκBα, releasing the transcription factor 
NFκB, which, after nuclear translocation, binds to and 
activates a NFκB-binding site in the VEGF-C 
promoter [172]. 
Another angiogenic factor that is upregulated by HRG 
is Cyr61, a cysteine-rich ligand that associates with 
the cell surface and extracellular matrix and functions 
as a ligand for αvβ3 integrin, promoting cell adhesion 
and migration. Cyr61 was overexpressed in about 
30% of breast tumor specimens, its expression in 
breast cancer cell lines correlating with the presence 
and absence of HRG and ER, respectively [102]. 
Moreover, Cyr61 overexpression was shown to 
support estrogen-independent growth in vitro and in 
vivo [176]. Furthermore, angiogenic effects have also 
been attributed to MMP-9 and the uPA/uPAR system, 
extending the roles these molecules may play in 
HRG-induced tumorigenesis. 
Tumor cells must adhere to endothelial cells and 
interact with components of the extracellular matrix to 
establish metastatic foci. In this context, the 
upregulation of cell adhesion molecules may 
contribute to increased invasion by HRG. Examples 
include ICAM-1 (CD54) and HCAM (CD44), which 
are both upregulated following HRG treatment of 
SKBR-3 breast cancer cells [72, 73]. HRG increased 
adhesion to plastic and induced invasion of SKBR-3 
cells. This invasion could be partially blocked by 
either anti-CD44 or anti-CD54 antibodies, indicating 
a role for these molecules in the invasion process 
[73]. 
HRG treatment of breast cancer cells results in the 
upregulation of autocrine motility factor (AMF), a 
growth factor whose expression has been proposed to 
play a role in metastasis and correlates with disease 
progression in various cancers [177, 178]. Roles for 
HRG-induced AMF include the promotion of 
motility, since HRG-induced scattering and invasion 
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could be reduced upon blocking AMF function, as 
well as growth support, based on the additive growth 
inhibitory effect of a HER2-blocking antibody and 
AMF inhibitors. 
Amplification of the HRG signal may occur by 
upregulation of proteins involved in transcription, 
since these, on their turn, may activate a subset of 
target genes. Among the proteins involved in 
transcription that have been shown to be upregulated 
by HRG are HIF-1α [170], heterogeneous nuclear 
ribonucleoprotein K (hnRNP K, a known activator of 
c-myc) [179] and the basic leucine zipper 
transcription factors activating transcription factor 4 
(ATF4) [180] and GADD153 (growth-arrest and 
DNA-damage 153)[181]. Interestingly, the latter 
could activate transcription of the β-casein promoter 
in a Stat5a-dependent way. Since GADD153 
expression in the mouse mammary gland is 
predominantly restricted to early lactation, it 
represents a good candidate gene for the induction of 
β-casein by HRG in vivo. Also translation may be 
enhanced, since elongation factor-1α (EF-1α), a 
ubiquitously expressed protein that is involved in the 
elongation cycle during translation, was identified as 
a HRG target gene as well. Upregulation of this 
protein was mediated by a Sp-1 transcription site in its 
promoter and involved increased chromatin 
acetylation [182]. Further upstream, upregulation of 
proteins with chaperoning function may facilitate 
correct protein folding and processing. Examples 
include the induction of heat shock protein-70 and 
calnexin [183, 184]. 
Stimulation of cells with HRG does not lead 
exclusively to upregulation of responsive genes. As 
already mentioned above, estrogen and progesterone 
receptor levels decrease following HRG treatment. 
BRCA1, a tumor suppressor gene whose inactivation 
is associated with a high incidence of familial breast 
and ovarian cancer, represents another HRG-repressed 
gene [185]. HRG treatment of breast cancer cells was 
shown to affect BRCA1 in two ways: first, receptor 
activation results in a phosphorylation of BRCA1 in a 
PI3K-dependent manner and by cyclin-dependent 
kinase 4; second, HRG stimulation causes a decrease 
in BRCA1 mRNA levels, which is dependent on 
protein synthesis. Both effects were enhanced upon 
culturing the cells on extracellular matrix. 
 
Table 1. Genes, whose functional relevance has been described, that are regulated by HRG. Upregulated genes are 
indicated in the upper part of the table, downregulated genes are at the end of the table. Abbreviations used for cell types: 
BC, breast cancer, CC, colon cancer, HNSCC, head and neck squamous cell carcinoma, OC, ovarian cancer, KC, 
keratinocytes; for level of regulation: mRNA: altered mRNA levels, but mechanism not specified, TC: altered transcription; 
TL: altered translation, ↑t1/2: increased halflife. When regulatory level or pathway is not indicated, it was not described in 
literature. 
 
Gene Cell-type Level Pathway Function Reference 
ATF4 (activating transcription 
factor 4) 
BC, CC TC MAPK TRANSCRIPTION [180] 
GADD153 (growth-arrest and 
DNA-damage 153) 
BC TC  
protein 
(↑ t1/2) 
 TRANSCRIPTION [181] 
HIF-1α (hypoxia inducible 
factor-1α 
BC TL PI3K 
(AKT/FRAP) 
TRANSCRIPTION [170] 
hnRNP K (heterogeneous nuclear 
ribonucleoprotein K) 
BC mRNA  TRANSCRIPTION [179] 
MTA1 (Metastasis and tumor 
associated protein 1) 
BC TC  TRANSCRIPTION 
REPRESSOR 
[115] 
EF-1α (elongation factor- 1alpha) BC TC p38MAPK 
MAPK 
TRANSLATION [182] 
G3BP (GTPase-activating protein 
SH3 domain-binding protein) 
BC TC  RNASE AND HELICASE 
ACTIVITIES 
[186] 
HSP70 (heat shock protein-70) BC mRNA  CHAPERONE [183] 
Calnexin BC TC  CHAPERONE [184] 
VEGF-A (vascular endothelial 
growth factor A) 
BC, 
HNSCC 
TC 
Post-TC 
PI3K 
(Pak1)(HIF-1α) 
MAPK 
P38MAPK 
ANGIOGENESIS [166-171, 
173] 
VEGF-C BC, 
HNSCC 
TC P38MAPK 
(NFκB) 
LYMPHANGIOGENESIS [172, 173] 
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Cyr61 BC mRNA  ADHESION 
MIGRATION 
ANGIOGENESIS 
[102] 
ICAM-1(CD54) BC mRNA PKC ADHESION [72, 73] 
HCAM (CD44) BC   ADHESION [73] 
Integrin alpha 5/6 KC   ADHESION [146] 
Integrin alpha6beta4 KC   ADHESION [147] 
AMF (autocrine motility factor) BC, CC TC P38MAPK 
MAPK 
MOTILITY [177] 
Rab3A BC TC PI3K VESICULAR TRAFFICKING [61] 
COX-2 (Cyclooxygenase-2)  CC (not 
BC, OC) 
TC  PROSTAGLANDIN 
SYNTHESIS 
[136] 
RARα (Retinoic acid receptor α) BC mRNA  TRANSCRIPTION [76] 
MMP-9 (matrix metalloproteinase -
9) 
BC, 
HNSCC 
TC PKC 
p38MAPK 
(MAPK) 
PROTEOLYSIS [104, 106, 
107, 155] 
MMP-1, -3, -7, -10, -11, -13 
 
HNSCC TC 
Post-TC 
 PROTEOLYSIS [155] 
uPA (urokinase plasminogen 
activator) 
BC, CC TC MAPK 
NFKB 
PROTEOLYSIS [103, 138] 
uPAR (uPA receptor) BC, CC TC MAPK 
p38MAPK 
PROTEOLYSIS [103, 138] 
β-casein BC mRNA  DIFFERENTIATION 
MARKER 
[58, 59, 60, 
62] 
c-Myc BC, OC, 
CC 
TC  CELL CYCLE [98, 100, 
136] 
p21cip1 BC TC PI3K 
p38MAPK 
CELL CYCLE [98, 100] 
Cyclin A BC TC  CELL CYCLE [82, 100] 
Cyclin B    CELL CYCLE [82] 
Cyclin E BC TC  CELL CYCLE [100] 
Cyclin D1 BC TC PI3K 
MAPK 
p38MAPK 
CELL CYCLE [98, 100] 
Cyclin D2 BC mRNA PI3K 
MAPK 
p38MAPK 
CELL CYCLE [98] 
Cyclin D3 BC mRNA PI3K 
MAPK 
CELL CYCLE [98] 
 
                                                                            DOWNREGULATED GENES: 
ERα (estrogen receptor α) BC TC PI3K/AKT 
MAPK 
TRANSCRIPTION [109, 113, 
114] 
BRCA1 BC mRNA 
protein 
PI3K TRANSCRIPTION 
UBIQUITIN 
POLYMERIZATION 
 
Keratin 1, 10 KC mRNA  CYTOSKELETON [147] 
Involucrin, loricrin KC mRNA  DIFFERENTIATION 
MARKER 
[147] 
 
 
Non-genomic effects of HRG on cell motility 
Members of the small GTPase superfamily have 
emerged as key regulators of the actin cytoskeleton, 
which has been implicated in many cellular functions, 
including motility, chemotaxis, cell proliferation, 
differentiation, endocytosis, secretion and cell 
polarization [187]. HRG stimulation of non-invasive 
breast cancer cells enhanced the conversion of 
globular actin to filamentous actin and the formation 
of membrane ruffles, stress fibers, filopodia, and 
lamellipodia, which was accompanied by increased 
cell migration [188]. These prominent cytoskeletal 
changes induced by HRG are accompanied by 
dramatic changes in phosphorylation status of several 
proteins present in focal adhesions, regions where 
cells make integrin-mediated contacts with the 
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extracellular matrix and that serve as anchorage points 
for actin stress fibers. Concomitantly, β1-integrin-
mediated adhesion to extracellular matrices is rapidly 
upregulated [189]. A protein which is localized at 
focal contacts is paxillin, a cytoskeletal 
phosphoprotein that becomes phosphorylated on a 
serine residue following HRG treatment. This occurs 
in a p38MAPK-dependent manner and results in 
disassembly of paxillin from the focal adhesion 
complexes during HRG-induced cell shape alterations 
and motility [190]. In addition, HRG triggered a 
redistribution of paxillin to the perinuclear regions. 
Regulation of cytoskeletal reorganization and cell 
migration by HRG were found to be mediated by a 
PI3K-dependent activation of p21-activated kinase-1 
(Pak1), which was redistributed to the leading edges 
of motile cells upon HRG treatment. Another target of 
HRG signaling includes Tiam1, a guanine nucleotide 
exchange factor that has been implicated in regulation 
of cell migration [191]. HRG stimulation of breast 
cancer cells induces phosphorylation and 
redistribution of Tiam1 to membrane ruffles. This is 
accompanied by loosening of intercellular junctions 
and tyrosine phosphorylation of β-catenin, which is 
redistributed from the membrane to the cytosol and 
nucleus, where it may serve as a transcription factor. 
Also focal adhesion kinase (FAK), a well-
characterized protein in focal adhesion complexes that 
has been implicated in the regulation of cell motility, 
invasion, adhesion and anti-apoptotic signaling [192], 
is subject to regulation by HRG [193]. At low 
concentrations, in which increased cell adhesion and 
formation of well-defined focal points took place, 
phosphorylation of FAK was induced. At these 
concentrations, association of FAK with HER2 could 
be observed. High doses of HRG, which led to 
increased migratory potential of the cancer cells, 
resulted in a dephosphorylation of FAK. This was 
accompanied by a decreased association of FAK with 
HER2, but an increased association of the tyrosine 
phosphatase SHP-2 with the activated receptor, which 
may be responsible for the observed 
dephosphorylation of FAK. HRG treatment of breast 
cancer cells resulted in phosphorylation of RAFTK 
(Related Adhesion Focal Tyrosine Kinase), a 
cytoplasmic protein related to focal adhesion kinase, 
leading to its localization in a multiprotein complex 
containing HER2, Src, and the GTPase activating 
proteins (GAPs) p190 RhoGAP and RasGAP. 
Formation of this complex, in which p190RhoGAP 
becomes phosphorylated by Src, has been shown to 
play a role in various aspects of HRG function, 
including HRG-induced invasion and MAPK 
activation [194]. Alternatively, HRG treatment 
increased the association of RAFTK with Csk 
homologous kinase (CHK), which, via inhibition of 
RAFTK phosphorylation, may negatively regulate 
HRG-mediated signaling [195]. Consistent with this, 
CHK was shown to inhibit in vitro cell growth, 
transformation and invasion induced upon HRG 
stimulation [196]. 
 
 
Regulation of HRG expression 
Relatively little is known about the regulation of HRG 
expression. This may be due to the complexity of the 
NRG-1 gene, where the expression of the distinct 
isoforms is most likely regulated through the usage of 
alternative promoters. However, upregulation of NRG 
expression has been described in several cell systems. 
As can be expected from its prominent increase in the 
mammary gland during pregnancy [58], HRG 
expression is under the influence of hormonal control. 
Thus, HRG not only influences steroid receptor 
signaling, it is itself subject to regulation by steroid 
receptors. Upregulation of HRG expression in 
epithelial tumor cells was observed in an in vivo 
model of mammary carcinogenesis induced by the 
synthetic progestin medroxyprogesterone acetate 
(MPA) [197]. This upregulation was found in MPA-
dependent and –independent ER/PR-positive ductal 
tumors but was absent in ER/PR-negative lobular 
carcinomas. These findings are consistent with the 
suggestion of Jones et al. [59] that progesterone might 
contribute to the HRG-induced lobuloalveolar 
development in vivo. In the mouse mammary gland, 
stromal HRG expression required the presence of 
adjacent epithelia, suggesting a reciprocal interaction 
between these cell types, possibly mediated by 
secreted proteins [58]. Growth factors such as 
keratinocyte growth factor (KGF) and hepatocyte 
growth factor (HGF) and EGF, but not insulin-like 
growth factor-1 or transforming growth factor-β were 
able to upregulate HRG expression in keratinocytes, 
although the underlying mechanisms are not clear. 
This induction was confirmed in two in vivo models 
of tissue repair in mice: in full-thickness skin wounds, 
following locally increased KGF production, and in 
kidney after partial hepatectomy, following elevation 
of increasing HGF levels [152]. Cross-induction, i.e. 
upregulation of an EGF-like growth factor following 
stimulation with a family member, frequently occurs 
in human carcinomas. As a result, two or more EGF-
like peptides are often co-expressed, leading to a 
sustained mutual co-amplification mechanism. Using 
a squamous carcinoma cell line as a model, O-
charoenrat et al. found that HRG mRNA was strongly 
upregulated following treatment with any of the EGF-
like ligands tested (EGF, transforming growth factor-
α, betacellulin, heparin-binding-EGF, amphiregulin 
and HRG-β1 itself). This was suggested to involve 
both transcriptional and post-transcriptional 
mechanisms [154]. Consistent with its identification 
as a factor released by ras-transformed fibroblasts [8, 
9], the insertion of activated H-or K-ras also resulted 
in upregulation of NRG-expression in breast cancer 
cells [198]. However, our analysis in melanoma cells, 
in which activated N-ras was present, could not 
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provide a role for Ras-signaling in upregulation of 
HRG expression (unpublished data). Another 
oncogene, cph, was suggested to underlie the high 
HRG expression observed in a hamster embryo 
fibroblast cell line [199]. Regulation of HRG 
expression by its co-receptor HER2 has been 
described. However, whereas in ovarian cancer cell 
lines HER2 overexpression induced HRG, its 
expression in both normal immortalized and cancer-
derived breast cell lines significantly decreased or 
remained unchanged [69]. Stimulation of a monocytic 
cell line and normal peripheral blood monocytes with 
phorbolester resulted in increased HRG mRNA and 
protein levels [144]. Consistent with this, we found 
increased levels of HRG mRNA in primary human 
melanocytes cultured in the presence of phorbolester 
(unpublished data). In keratinocytes, a decrease in the 
level of HRG transcripts occurred upon attaining 
culture confluence, conversely correlating with the 
levels of HER2 and HER3 in these cells [147]. 
In addition to the several pathways that have been 
described to upregulate HRG expression, 
improvement of its release by the cells may contribute 
to its effects as well. This was evident from a study in 
which growth inhibition of squamous cell carcinoma 
cell lines by MMP inhibitors could be attributed to 
their inhibitory effects on the release of EGF-like 
ligands, including HRG [200]. Since the HRG 
precursor could not be cleaved anymore, no HRG was 
available anymore to function in an autocrine loop. 
Also in a physiological context, this 
metalloproteinase-mediated cleavage of neuregulins is 
important, as exemplified by Meltrin-β (ADAM19) 
knockout mice, in which heart development is 
compromised because of a lack of neuregulin-
mediated paracrine signaling [201]. 
 
 
The NRG1 locus as a target of recurrent 
chromosome translocation breakpoints 
Recently, disruption of the 1.1 Mb-spanning NRG1 
locus at 8p12 was found in several human breast (5 
out of 34) and pancreas cancer cell lines (2 out of 9) 
[202]. These breakpoints differed among the different 
cell lines. In the human breast cancer cell line MDA-
MB-175, a t(8;11) translocation leads to a fusion 
product consisting of the N-terminal part of DOC4, a 
stress-induced gene of unknown function located on 
chromosome 11q13, and HRG [202-204]. Expression 
of this novel secreted chimeric ligand, coined γ-
heregulin, is under the control of the DOC4 promoter, 
thus generating an autocrine loop which gives rise to 
constitutive activation of HERs in these cells [205]. A 
survey for this particular translocation in a series of 
141 breast cancer patients did not reveal any 
abnormalities [206]. However, since in all of the cell 
lines with disruption of the NRG1 locus the 
breakpoint differed, thorough examination of the 
entire NRG1 locus rather than a screening for a 
specific breakpoint is needed. Although the MDA-
MB-175 example likens NRG1 to be an oncogene, in 
the majority of the cell lines with a NRG1 locus 
breakage the result of the translocation is unknown. 
Although no correlation could be found between the 
presence of a breakpoint and the (pattern of) secretion 
of NRG isoforms, it is interesting to mention that in 
the initial characterization of one of the affected cell 
lines, SUM-52PE, a juxtacrine HRG autocrine loop 
was described [207]. Yet, it remains to be determined 
whether in this and other cell lines the chromosomal 
translocation directly contributes to malignancy. If so, 
either activation by promoter swapping or protein 
fusion, or inactivation may contribute to tumor 
progression. Alternatively, it is possible that, 
depending on the site of breakage and the isoform(s) 
targeted, cell behavior is affected in a different way. 
The observation that loss of heterozygosity at 
microsatellite markers from region p11-21 of 
chromosome 8, which encompasses the NRG1 locus, 
is a frequent event in microdissected breast tumor 
samples, but not in peritumoral cells [208], offers an 
intriguing possibility that disruption of this locus may 
indeed represent an important event in cancer. In 
conclusion, the evidence that the NRG1 locus may 
encompass a fragile site in cancer, warrants further 
research, both in the clinic, verifying whether 
rearrangement of this locus is also present in fresh 
tumor samples, as in basic research, elucidating the 
mechanisms underlying the breakage and resulting 
from it.  
 
 
Is there a role for neuregulins-2, -3 and -4 in 
cancer? 
As is evident from the above, the vast majority of 
publications describing the role of NRGs in cancer 
focuses on members of the NRG-1 family. Recently, 
however, some attention is being given towards the 
other neuregulins and their possible role in malignant 
progression. Like neuregulin-1, also neuregulin-2, -3 
and -4 were described to stimulate cell proliferation, 
provided the cells express the appropriate receptors 
[21, 23, 209, 210]. Moreover, suggesting a similar 
dual function as has been described for neuregulin-1, 
also neuregulin-2 can induce differentiation of breast 
cancer cells in vitro, the strength and biochemical 
characteristics of the effect depending on the isoform 
applied [211-213]. No reports have been published on 
aberrant expression or signaling of neuregulins-2, -3 
or -4 in cancer, yet. Recently, an anti-angiogenic role 
has been attributed to a neuregulin-2/NTAK isoform, 
NTAKγ, on basis of its ability to inhibit proliferation 
of endothelial cells [214]. Since this effect was not 
mediated by its EGF-like domain but, instead, 
depended on its N-terminal domain, this may open a 
wide array of novel functions attributed to domains 
outside the EGF-like domain. 
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Conclusion 
In conclusion, the neuregulin-HER system is of 
critical importance in regulating a variety of 
physiological events. A tightly regulated balance 
exists between differentiating and growth-promoting 
effects of neuregulins. Deregulation of this balance 
may contribute to malignant transformation. While 
most studies have focused on overexpression of HERs 
as a mechanism leading to constitutive receptor 
activation, it is becoming increasingly clear that, in 
the presence of normal receptor levels, aberrant 
constitutive signaling may occur as well, due to the 
presence of autocrine or paracrine loops. While the 
action of neuregulins in vivo is typically paracrine, 
being expressed in mesenchymal tissues adjacent to 
epithelia, epithelial tumors frequently show gain of 
expression, increased (sensitivity to) paracrine 
signaling and/or disruption of spatial control, all of 
which may contribute to the transformation process. 
This transformation is likely mediated by activation of 
a wide array of signaling events, leading to changes in 
gene expression, as well as rapid alterations in the 
actin cytoskeleton. Although relatively little is known 
about the mechanisms leading to increased HRG 
expression, the recent identification of the NRG1 
locus as a target of recurrent chromosome breakpoints 
in breast and gastric cancer cell lines offers an 
intriguing possible explanation. The characterization 
of HRG as a constitutive activator of HERs in a 
variety of tumors may offer opportunities for targeted 
therapies in these cancers. 
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The Heregulin/Human Epidermal Growth Factor Receptor as a
New Growth Factor System in Melanoma with MultipleWays of
Deregulation
Christophe Stove,Veronique Stove, Lara Derycke,Veerle Van Marck, Marc Mareel, and Marc Bracke
Laboratory of Experimental Cancerology, Department of Radiotherapy and Nuclear Medicine and the Department of Clinical Chemistry, Microbiology
and Immunology, Ghent University Hospital, Ghent, Belgium
In a screening for new growth factors released by mela-
noma cells, we found that the p185-phosphorylating ca-
pacity of a medium conditioned by a melanoma cell
line was due to the secretion of heregulin, a ligand for
the human epidermal growth factor receptor (HER)
family of receptor tyrosine kinases. Expression of
heregulin, including a new isoform, and secretion
of functionally active protein was found in several cell
lines. Receptor activation by heregulin, either autocrine
or paracrine, resulted in a potent growth stimulation
of both melanocytes and melanoma cells. Heregulin
receptor HER3 and coreceptor HER2 were the main
receptors expressed by these cells. Nevertheless, none
of the cell lines in our panel overexpressed HER2 or
HER3. In contrast, loss of HER3 was found in two cell
lines, whereas one cell line showed loss of functional
HER2, both types of deregulations resulting in unre-
sponsiveness to heregulin. This implies the heregulin/
HER system as a possible important physiologic growth
regulatory system in melanocytes in which multiple
deregulations may occur during progression toward
melanoma, all resulting in, or indicating, growth
factor independence. Key words: heregulin-neuregulin-1/
autocrine-paracrine communication/receptor tyrosine kinases.
J Invest Dermatol 121:802 ^812, 2003
G
rowth of melanocytes and their malignant counter-
parts is regulated by a variety of cytokines and other
polypeptides (LaŁ zaŁ r-MolnaŁ r et al, 2000; Payne and
Cornelius, 2002). Under physiologic conditions,
melanocytes depend for their survival on paracrine
stimulatory factors provided by the surrounding keratinocytes
(Meier et al, 1998). Transformed melanocytes have a decreased de-
pendence on paracrine stimulation, which facilitates their survival
outside their natural environment, the epidermis. Changes in sev-
eral growth factor systems contribute to this decreased depen-
dence. Whereas overexpression of receptor tyrosine kinases
(RTK) may lead to increased growth factor sensitivity and con-
stitutive signaling, loss of expression may result in insensitivity to
inhibitory factors or indicate growth factor independence (Easty
and Bennett, 2000). Also, the pro¢le of growth factors secreted
by melanoma cells is frequently altered, compared to melano-
cytes.Whereas de novo expression of some growth factors by mel-
anoma cells may stimulate proliferation of these cells in an
autocrine loop, these factors may act on the surrounding cells as
well, stimulating or inhibiting these cells in a paracrine way
(Halaban, 2000; LaŁ zaŁ r-MolnaŁ r et al, 2000; Ruiter et al, 2002).
The human epidermal growth factor receptor (HER) family
of RTK consists of four members, epidermal growth factor
receptor (EGFR)/erbB1/HER1, neu/erbB2/HER2, erbB3/HER3,
and erbB4/HER4 (Olayioye et al, 2000; Yarden and Sliwkowski,
2001). Although constitutive activation of these receptors, owing
to overexpression, frequently occurs in various types of cancers
(ReŁ villion et al, 1998), this does not seem to be common in mela-
noma (Natali et al, 1994; Korabiowska et al, 1996; Persons et al,
2000; Fink-Puches et al, 2001). Constitutive RTK signaling may
also be the result of truncation, mutation, association with other
cell-surface proteins, transactivation via other receptors, or the
presence of autocrine loops (Blume-Jensen and Hunter, 2001;
Gullick, 2001). The latter may result from the aberrant expression
of HER ligands.
Neuregulin-1 is the term for a family of proteins derived by
alternative splicing from a single gene, functioning as ligand for
HER3 and HER4 (Holmes et al, 1992; Yarden and Sliwkowski,
2001). At present, at least 24 splice variants have been identi¢ed
in di¡erent species, of which 10 were found in humans. Alterna-
tive splicing at the N-terminus results in three types of proteins:
heregulins (HRG, type I) (Holmes et al, 1992), glial growth factors
(type II) (Marchionni et al, 1993), and sensory- and motor-neu-
ron-derived factors (type III) (Ho et al, 1995). Further alternative
splicing of HRG at the EGF-like domain (a or b), the C-terminal
part of the EGF-like domain (1, 2, or 3) (Fig 1), and/or at the
intracellular tail (a, b, or c) gives rise to closely related proteins,
di¡ering in size and cellular localization and having distinct
receptor activation potentials and functions (Wen et al, 1994;
Pinkas-Kramarski et al, 1996; Meyer et al, 1997). Transmembrane
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HRG typically function as precursor molecules that are subject to
the action of metalloproteinases. This results in the release of the
extracellular domain that may subsequently bind to nearby re-
ceptors (autocrine/paracrine action) (Montero et al, 2000; Shira-
kabe et al, 2001). Necessary and su⁄cient for receptor binding is
the EGF-like domain; the roles of the various other domains have
not been fully elucidated yet. Some regulation may be exerted by
the cytoplasmic tail (Liu et al, 1998a, b; Han and Fischbach, 1999)
or by interaction of the N-terminal heparin-binding motif with
other molecules such as cell surface heparan sulfate proteoglycans
(Li and Loeb, 2001). A recently proposed model for ligand-
mediated HER activation proposes receptor conformational
changes as the driving force for receptor activation (Cho and Lea-
hy, 2002; Garrett et al, 2002; Ogiso et al, 2002). For HRG, this
would mean that binding of its EGF-like domain to HER3 or
HER4 leads to an altered receptor conformation, thus promoting
dimerization with another HER, preferentially HER2. Hetero- or
homodimerization of the receptors leads to trans- and autopho-
sphorylation, creating speci¢c docking sites for signal transduc-
tion molecules (Dankort et al, 2001; Hellyer et al, 2001) and
initiating further downstream signaling.When only HER2 and
HER3 are present, this model of HRG-induced receptor activa-
tion implies that HER3, which lacks catalytic activity (Guy et al,
1994; Sierke et al, 1997), can only become phosphorylated in trans
by heterodimerization with HER2 (Kim et al, 1998). Conversely,
HER2, for which no direct ligand has been identi¢ed yet, only
becomes activated after ligand binding to HER3.
Based on the initial observation that conditioned medium
(CM) from a melanoma cell line induced a strong phosphoryla-
tion of HERs in MCF-7 mammary cancer cells, we decided to
dissect the role of this putative ligand^receptor system in mela-
nocytes and a panel of melanoma cell lines. Here, in 4 of a panel
of 13 melanoma cell lines, we describe a number of deregulations
in the HRG/HER system. Production and release of functionally
active HRG in the medium were found in three cell lines and
resulted in an autocrine loop in one case. Whereas exogenous
HRG-stimulated growth of the majority of melanoma cell lines
and melanocytes, three cell lines did not respond to HRG, owing
to the absence of HER3 or owing to a functionally incompetent
HER2.
MATERIALS ANDMETHODS
Cell lines The cell lines were obtained as follows: 530 and BLM
melanoma cell lines from L. Van Kempen (University of Nijmegen, the
Netherlands); A375 melanoma cell line from J. Hilkens (NKI, the
Netherlands); Bowes melanoma from G. Opdenakker (Rega Institute,
Belgium); DX3 and DX3azaLT5.1 melanoma cell lines from J. Ormerod
(Imperial Cancer Research Fund, UK); FM3/D, FM3/p, FM45, and FM87
melanoma cell lines from J. Zeuthen (Danish Cancer Society, Denmark);
HMB2, MeWo, and MJM melanoma cell lines from D. Rutherford
(Rayne Institute, St Thomas Hospital, UK); MCF-7/6 mammary carci-
noma cell line (further called MCF-7) from H. Rochefort (University
of Montpellier, France); COLO-16 squamous skin carcinoma cell line and
SK-BR-3 mammary carcinoma cell line from C. De Potter (Ghent Univer-
sity Hospital, Belgium); and MDA-MB-231 breast cancer cell line from
American Type Culture Collection (Manassas, VA). Cell lines were
routinely maintained in the following media (Gibco BRL, Belgium):
RPMI 1640 (FM and COLO-16 cell lines), L15 (MDA-MB-231), 50% Dul-
becco’s modi¢ed Eagle’s medium/50% Ham’s F12 (MCF-7), or Dulbecco’s
modi¢ed Eagle’s medium (all other cell lines). All media for rou-
tine culture contained 10% heat-inactivated fetal bovine serum (Greiner
Bio-One, Belgium), 100 IU per mL penicillin, 100 mg per mL strepto-
mycin, and 2.5 mg per mL amphotericin B. Epidermal melanocyte primary
cultures were obtained from neonatal foreskins and established in M199
medium (Gibco BRL), supplemented with 2% fetal bovine serum, 10^9 M
cholera toxin, 10 ng per mL basic ¢broblast growth factor (bFGF), 10 mg
per mL insulin, 1.4 mM hydrocortisone, and 10 mg per mL transferrin (all
from Sigma, Belgium). Postprimary cultures were maintained in low-
calcium (0.03 mM) M199 medium, supplemented with the same factors
and 10% fetal bovine serum. The melanocytic origin of all melanoma cell
lines was checked by immunocytochemistry using two antibodies against
melanoma-speci¢c proteins, HMB45 (Enzo Diagnostics, Farmingdale,
NY) and NKI/C3 (Biogenex, San Ramon, CA). All melanoma cell lines
were positive for at least one of these markers (data not shown). Because
most of the experiments were carried out with Bowes melanoma cells,
which were only positive for NKI/C3, additional electron microscopy was
performed to con¢rm the presence of premelanosome-like structures in
this nonpigmented cell line (data not shown).
Antibodies and reagents Primary antibodies used were: rabbit
polyclonal anti-HER1, -2, -3, and -4 and anti-HRG precursor antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA), mouse monoclonal
antitubulin (Sigma), mouse antiphospho-mitogen-activated protein kinase
(MAPK; Westburg, the Netherlands), and antiphosphotyrosine antibody
RC20 conjugated to horseradish peroxidase (Transduction Laboratories,
Lexington, KY). Goat anti-HRG-a and recombinant HRG-b1, consisting
of the EGF-like domain of HRG (rHRG-b1, used at 10 ng/mL unless
indicated otherwise), was purchased from R & D Systems (Abingdon,
UK). Full-length recombinant HRG-b1 was obtained from Laboratory
Vision (Fremont, CA), whereas heparin, PD168393 (used at 2 mM, unless
indicated otherwise), and PD98059 were from Calbiochem (Darmstadt,
Germany).
Preparation of CM Subcon£uent monolayers were washed three times
with phosphate-bu¡ered saline (PBS), incubated for 24 h with serum-free
medium, and washed again three times with PBS, followed by a 48-h
incubation with serum-free medium. The latter medium was cleared from
cells by 5 min centrifugation at 250 g. The resulting supernatant was
centrifuged for an additional 20 min at 2000 g to remove cell debris,
¢ltered through a 0.2-mm ¢lter, and stored at ^201C until use. To isolate
the heparin-binding fraction from the CM, the latter was depleted from
heparin-binding factors by triple precipitations with heparin beads (Bio-
Rad, Hercules, CA). Elution of the heparin-binding fraction was done
with 1 M NaCl, followed by desalting and dilution in fresh serum-free
medium.
Figure1. Neuregulin-1 splicing variation in the EGF-like domain.
The scheme depicts the genomic organization of the exons encoding
the region surrounding the variable part of the EGF-like domain of the
NRG-1 gene. The locations of the sequences that are complementary to
the primers used for RT-PCR are indicated with S and AS for the sense
and antisense primers, respectively. The table indicates all possible splicing
variants within this domain with their expected ampli¢cation product
lengths in base pairs (bp), when using the indicated primer pair. NA, not
ampli¢ed; EGFc, sequence common in the EGF-like domain of all HRG;
hatched, coding sequence for the HRG transmembrane domain; asterisk, lo-
cation of the stop codon in case of the (a)^(b) combination; ?, putative
isoform not yet characterized.
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Western blotting and (immuno)precipitation All lysates were
made of cells of approximately 90% con£uence. For phosphorylation
experiments, cells were washed three times with PBS, serum-starved
overnight, washed again three times with PBS, and treated with serum-
free medium for the indicated times. Before making all lysates, the cells
were washed three times with PBS. Cells were lyzed with PBS containing
1% Triton X-100, 1% Nonidet P-40 (Sigma), and the following protease
inhibitors: aprotinin (10 mg/mL), leupeptin (10 mg/mL) (ICN Biomedicals,
Costa Mesa, CA), phenylmethylsulfonyl £uoride (1.72 mM), NaF (100 mM),
NaVO3 (500 mM), and Na4P2O7 (500 mg/mL) (Sigma). After clearing the
lysates, protein concentration was determined using Rc Dc protein assay
(Bio-Rad), and samples were prepared such that equal amounts of protein
were to be loaded. For immunoprecipitation, equal amounts of protein
were ¢rst incubated with protein A^Sepharose (Amersham Pharmacia
Biotech, UK) for 30 min. After discarding the beads, the supernatant was
incubated with primary antibody for 3 h at 41C, followed by incubation
with the added protein A^Sepharose beads for 1 h. For heparin and
streptavidin precipitations, cell lysates were incubated with heparin
beads (Bio-Rad) or streptavidin beads (Sigma). Sample bu¡er (Laemmli)
with 5% 2-mercaptoethanol and 0.012% bromophenol blue was added,
followed by boiling for 5 min and separation of proteins by gel
electrophoresis on a 8 or 12% polyacrylamide precast gel (Invitrogen, San
Diego, CA) and transfer onto a nitrocellulose membrane (Amersham
Pharmacia Biotech). Quenching and immunostaining of the blots were
done in 5% nonfat dry milk in PBS containing 0.5% Tween 20, except
for RC-20 and antiphospho-MAPK antibodies, where 4% bovine serum
albumin in PBS containing 0.2% Tween 20 was used instead. The
membranes were quenched for 1 h, incubated with primary antibody for 1
h, washed four times for 10 min, incubated with horseradish peroxidase-
conjugated secondary antibody for 45 min, and washed six times for 10
min. Detection was done using enhanced chemiluminescence reagent
(Amersham Pharmacia Biotech) as a substrate. To control for equal
loading of total lysates, immunostaining with antitubulin antibody was
performed routinely (not shown). Quanti¢cation of bands was done using
Quantity-One software (Bio-Rad).
RT-PCR, cloning, and sequencing Total RNA was extracted from
approximately 5106 cells using the Qiagen RNeasy kit (Qiagen,
Chatsworth, CA). One microgram of total RNA was reverse transcribed
with oligo(dT) primers using the Qiagen RT kit (Qiagen) according to
the manufacturer’s instructions. HRG cDNA encoding all transmembrane
isoforms was ampli¢ed using the sense primer 50 -CTGTGTGAATGGAG-
GGGAGTGC-30 (complementary to a sequence encoding a conserved
part of the EGF-like domain) and the antisense primer 50 -GACCACAAG-
GAGGGCGATGC (complementary to a sequence encoding part of the
transmembrane domain) (Fig 1). As a control (not shown), b2-microglobulin
cDNA was ampli¢ed using the sense primer 50 -CATCCAGCGTACTC-
CAAAGA-30 and the antisense primer 50 -GACAAGTCTGAATGCTC-
CAC-30 to generate a 165-bp product. PCR was performed on 250 ng
template cDNA using the QiagenTaq PCR kit (Qiagen) according to the
manufacturer’s instructions. Reactions were done in a Minicycler (Biozym,
the Netherlands) with an initial denaturation at 941C for 3 min, 35 cycles
of 941C for 50 s (denaturation), 611C for 50 s (annealing), and 721C for 1
min (elongation), followed by a ¢nal extension at 721C for 10 min. For
cloning of the HRG ampli¢cation products, the HRG sense and antisense
primers were extended at the 50 end with GCCGGATCCG, creating a
BamHI restriction site, and with TCCGAATTC, creating a EcoRI
restriction site, respectively. The resulting ampli¢cation products were
either separated by agarose gel electrophoresis, followed by gel extraction
using Qiagen gel extraction kit (Qiagen), or used directly for digestion
with BamHI and EcoRI restriction enzymes (Roche Diagnostics,
Germany). Digested products were ligated into dephosphorylated BamHI/
EcoRI-digested pIRES2-EGFP vector (Clontech, Palo Alto, CA). After
transformation of competent DH5a bacteria with the ligated product, the
kanamycin-resistant clones were screened by PCR using primers com-
plementary to sequences of the pIRES2-EGFP vector surrounding the
insert. This resulted in PCR products of di¡erent lengths, corresponding
to di¡erent HRG isoforms, which were subjected to sequencing (Applied
Biosystems, Foster City, CA). The sequence of the a4-isoform was
submitted to GenBank (Accession Number AY207002).
Scattering assay MCF-7 cells were seeded until small islands were
formed. The cells were washed three times with PBS and were serum-
starved overnight. The following day, the cells were washed again three
times with PBS, after which the treatments (all in serum-free medium)
were applied for 2 h. Pictures were taken with an Axiovert 200M
microscope (Carl Zeiss Vision, Germany) on living cultures or after the
cultures had been ¢xed with crystal violet (0.5% in 4% formaldehyde,
30% ethanol and 0.17% NaCl) for 15 min.
Cell proliferation assays A total of 12,500 melanocytes were seeded in
the wells of a 96-well plate in 100 mL of Dulbecco’s modi¢ed Eagle’s
medium/Ham’s F12 medium containing 10% fetal bovine serum. After
attachment, 100 mL of medium, supplemented with growth factors as
indicated, was added. After 5 days, metabolic activity was measured with
a colorimetric assay. Brie£y, 100 mL of medium was taken o¡, followed by
the addition of 20 mL of 5 mg per mL 3-(4,5-dimethyl-thiazol-2-yl)-2,5-
diphenyltetrazolium bromide (Sigma) in PBS. After a 2-h incubation and
removal of all £uid, the colored formazan formed was dissolved in 100 mL
of dimethyl sulfoxide and absorption was measured with an ELISA reader
at 490 nm. Proliferation of melanoma and MCF-7 cells was measured with
the sulforhodamine B colorimetric assay. A total of 5000 cells were seeded
in 96-well plates, allowed to attach, and treated as indicated. After 5 days,
50 mL of 50% trichloroacetic acid was added to the culture medium,
followed by an incubation of 1 h at 41C. The wells were rinsed with
water, dried, incubated with 100 mL of sulforhodamine B (0.4% in 1%
acetic acid) for 30 min, rinsed with 1% glacial acetic acid, and dried
again. Bound dye was dissolved in 200 mL of 10 mM Tris bu¡er, pH 10.5,
and absorption was measured with an ELISA reader at 490 nm.
Annexin V staining Melanocytes were seeded on a collagen type I
gel for 4 days. After taking photographs, adherent cells were detached
with a swab and brought together with £oating cells. Annexin V staining
was performed with Annexin V^PE (Becton Dickinson Biosciences,
Mountain View, CA), according to the manufacturer’s instructions.
The cells were analyzed on a FACSCalibur £ow cytometer (Becton
Dickinson) with an argon^ion laser tuned at 488 nm and a helium^neon
diode laser at 635 nm. Forward light scattering, orthogonal scattering, and
two £uorescence signals were stored in list-mode data ¢les. Data
acquisition and analysis were done using the CellQuest software (Becton
Dickinson). Additional propidium iodide (PI) staining was performed to
rule out cells that were necrotic (AnnexinVþ and PIþ ).
Statistics Di¡erences between means were considered signi¢cant when
the p value was less than 0.01, using Student’s t test.
RESULTS
Expression of HERs in a panel of melanoma cell
lines Expression of HERs by melanocytes and melanoma cell
lines was examined by Western blotting and immunostaining
with anti-HER1, -2, -3, and -4 antibodies. Neither melanocytes
nor any of the melanoma cell lines showed expression of full-
length HER1 or HER4, compared with the respective posi-
tive controls A431 and T47D (data not shown). Nevertheless,
this does not necessarily mean that these receptors are comple-
tely absent. All melanoma cell lines, as well as melanocytes,
expressed HER2 (Fig 2). HER2 levels in melanocytes and in all
Figure 2. Analysis of HER2/HER3 expression in melanocytes and
melanoma cell lines.Whole-cell lysates were analyzed by immunoblot-
ting (I.B.) with anti-HER2 and anti-HER3 antibodies, as described under
Materials and Methods. Quanti¢cation of the resulting bands was done re-
latively to the level of HERs in MCF-7 mammary carcinoma cells, set at 1.
Open and ¢lled bars, HER2 and HER3 expression, respectively.
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melanoma cell lines were far below the level found in the
HER2-overexpressing SK-BR-3 mammary carcinoma cell line
(Press et al, 1993). Moreover, quanti¢cation showed that none of
the melanoma cell lines had HER2 levels that were more than
two times higher than that seen in MCF-7 mammary carcinoma
cells, often used as a control for normal expression (Press et al,
1993; Aguilar et al, 1999). Comparable levels of HER3 were
expressed by melanocytes and 11 of the melanoma cell lines.
Two melanoma cell lines (BLM and FM45) did not show
expression of HER3 protein (Fig 2). The absence of HER3
protein was due to a strongly reduced level of HER3 mRNA
in these cell lines, compared with the other cell lines (data not
shown).
Expression of HRG by melanoma cell lines Western
blotting, followed by immunostaining of total lysates using an
anti-HRG antibody directed against a cytoplasmic sequence
conserved in all transmembrane HRG isoforms, revealed the
presence of a7105-kDa band in Bowes melanoma, BLM, and
MJM, the ¢rst two having the stronger expression (Fig 3A,
top panel). This band was also present in the positive controls
MDA-MB-231 (although very faint) and COLO-16, previously
described to secrete HRG (Holmes et al, 1992) or HRG-like
activity (De Corte et al, 1994), respectively, and was not found in
the MCF-7-negative control (Aguilar et al, 1999; Aguilar and
Slamon, 2001). The size of this band indicates that it corresponds
to the full-length HRG precursor (Burgess et al, 1995; Aguilar and
Slamon, 2001). The 50-kDa band, also seen by others using this
antibody (Aguilar and Slamon, 2001), probably represents an
artifact, because it could also be found in the MCF-7 HRG-
negative cells. Also two other bands (at785 and 75 kDa), seen
in some melanoma cell lines, are likely due to cross-reactivity of
the antibody with other proteins. Because these bands were not
consistently found in cell lines expressing HRG mRNA, and
CM of these cells had no HRG-like activity (see below), they
are unlikely to represent cleavage products of transmembrane
HRG. The localization of the 105-kDa immunoreactive band at
the plasma membrane was con¢rmed for Bowes melanoma
cells by biotinylation (Fig 3B, lane 4) and by precipitation us-
ing heparin beads (Fig 3B, lane 3), which is consistent with
the presence of a heparin-binding motif at the extracellular
N-terminus of HRG.
RT-PCR analysis was carried out to verify the results obtained
by western blotting and to detect which isoforms were expressed
by the HRG-positive melanoma cell lines. Because alternative
splicing of the HRG-encoding gene leads to multiple isoforms,
with most variation in the EGF-like domain, primers were
chosen so that di¡erent lengths of ampli¢cation products were
obtained, depending on the isoform expressed. The sense and
antisense primers chosen were complementary to the mRNA
encoding a conserved part of the EGF-like domain and a
sequence conserved in all transmembrane isoforms, respectively
(Fig 1). RT-PCR using this primer set, with MDA-MB-231 and
COLO-16 as positive controls and MCF-7 as a negative control,
con¢rmed the results obtained by western blotting for Bowes
melanoma, BLM, and MJM cells (Fig 3A, bottom panel). In
addition, lower levels of mRNA were found in some other
melanoma cell lines, possibly resulting in HRG protein levels
that were below the detection level in western blotting.
Melanocytes had amounts of mRNA that were comparable to
those found in MJM cells. Because we initially did not detect
HRG protein in these cells (Fig 3A), we loaded more protein
and overexposed the ¢lm, which eventually resulted in the
appearance of a weak band at 7105 kDa (Fig 3C). The pattern
of PCR ampli¢cation products that was obtained from Bowes
melanoma suggested the presence of multiple isoforms. Cloning
and sequencing of these products revealed that a2, b1, and b2
isoforms were the most abundant transmembrane isoforms in
this cell line (Fig 3D). In addition, a new isoform, designated
a4, was identi¢ed. This isoform combines the sequences from
both the exon leading to the a isoforms and the exons leading to
the b1 isoform (Figs 1, 3D). Two bands (indicated with an open
circle) did not correspond to a speci¢c isoform because they were
the result from cross-annealing of PCR products coming from
b1^b2 or a2^b2 isoforms, presumably resulting in an imperfect
double strand with slower migration on agarose gel (Fig 3D).
Melanoma cells release functionally active HRG in the
culture medium Following cleavage in the juxtamembrane
Figure 3. Presence of HRG protein and mRNA in melanocytes and
melanoma cell lines. (a, top panel; c) HRG precursor expression was ana-
lyzed by immunoblotting (I.B.) of whole-cell lysates with an anti-HRG
antibody. (b) Total lysates of MCF-7 and Bowes melanoma (T), a heparin
precipitate (H), streptavidin precipitate (S), or control protein G^Sepharose
precipitates of Bowes melanoma cells or biotinylated Bowes melanoma
cells (bio) were analyzed by immunoblotting with an anti-HRG antibody.
(c) Prolonged exposure after immunoblotting of total lysates of melano-
cytes and Bowes melanoma cells reveals a weak band in the former. Aster-
isk, the band of full-length HRG at 105 kDa. (a, bottom panel) RT-PCR
analysis of HRG mRNA in the indicated cell lines using the primer panel
indicated in the legend to Fig 1. (d) The ¢rst lane depicts HRG mRNA
expression in Bowes melanoma as assessed by RT-PCR, using the primer
panel indicated in the legend to Fig 1. Lanes 2^5, PCR analyses of clones
derived from Bowes melanoma, representing the indicated HRG isoforms.
Open circle, bands corresponding to PCR products formed by cross-anneal-
ing of two related isoforms and thus considered as aspeci¢c.
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extracellular region, HRG are released into the culture medium
as 40- to 45-kDa proteins, depending on the isoform and glyco-
sylation level (Holmes et al, 1992; Lu et al, 1995a, b).Western blotting
of 50 concentrated CM, using an antibody directed against the
HRG extracellular domain, revealed the presence of a broad band
at the expected molecular weight (Fig 4A, lane 1). This band was
absent upon depletion of the concentrated CM from heparin-
binding factors (Fig 4A, lane 2).
To test whether the released HRG was functional, we veri-
¢ed whether CM from the melanoma cell lines was capable
of activating HERs in MCF-7 cells. Prominent tyrosine
phosphorylation of a 185-kDa protein was evident upon
treatment with the positive controls recombinant HRG-b1
(rHRG-b1) and COLO-16 CM and was further restricted to
CM from HRG-positive melanoma cell lines (Fig 4B). This
phosphorylation could be blocked by pretreating the MCF-7
cells for 30 min with the HER-speci¢c irreversible inhibitor
PD168393 (Fry et al, 1998) or by adding heparin to the CM (Fig
4C,D). Heparin treatment did not interfere as such with the
capability of HERs in MCF-7 cells to become activated, because
the combination with rHRG-b1 (lacking a heparin-binding
domain) still resulted in full phosphorylation of HERs in these
cells (data not shown). To quantify the phosphorylating capacity
of the Bowes melanoma CM, we made a comparison with the
phosphorylation of MCF-7 cells that had been treated with
di¡erent concentrations of rHRG-b1. As also shown by others
(Aguilar and Slamon, 2001), phosphorylation of a 185-kDa
protein could readily be detected using 0.5 ng per mL rHRG-b1
(Fig 4E). Treatment with CM of Bowes melanoma cells resulted
in a phosphorylation at 185-kDa equivalent to 75 ng per mL
(700 pM) rHRG-b1, correlating with a concentration of 7100
pM 45-kDa HRG in the CM. Also the kinetics of this
phosphorylation were similar, with phosphorylation occurring
already after 1 min of treatment, suggesting a similar mechanism
of direct receptor activation (Fig 4F).
One of the well-described biologic e¡ects of HRG is the rapid
induction of spreading/scattering of epithelial islands (Spencer et
al, 2000), which led us to test the e¡ect of the CM of the HRG-
positive melanoma cell lines in this assay. We found that a 2-h
treatment of serum-starved MCF-7 islands with melanoma cell
line CM resulted in a disruption of epithelial islands similar to
that of treatment with rHRG-b1. This scattering was blocked by
pretreating the cells for 30 min with PD168393 (Fig 5A).
Based on the fact that HRG contains an extracellular heparin-
binding domain, we performed precipitations using heparin
beads on 50 concentrated CM. Three consecutive precipi-
tations completely abolished the ability of the CM to induce
phosphorylation (Fig 5B, lane 4) or spreading/scattering of
epithelial MCF-7 islands (Fig 5C). In contrast, after
eluting the heparin-binding factors from the heparin beads,
desalting, and dilution of these factors in serum-free medium,
used for treating MCF-7 cells, the phosphorylation of a 185-kDa
band (Fig 5B, lane 3) as well as the induction of spreading/
scattering (Fig 5C) were evident. Both e¡ects could be blocked
by pretreating the cells for 30 min with PD168393 (Fig 5C,B,
lane 6).
An autocrine loop in Bowes melanoma cells leads to
constitutive HER phosphorylation, MAPK activation, and
increased growth Total lysates from di¡erent melanoma cell
lines were immunostained for tyrosine-phosphorylated proteins.
This revealed the presence of a highly phosphorylated protein at
185 kDa, possibly re£ecting activated HER2 and HER3, in
Bowes melanoma cells, but not in the other melanoma cell lines
tested (Fig 6A). This band was also found in the HRG-positive
COLO-16 cells, but not in the weaker HRG-positive MDA-
MB-231 cells. By precipitating HER2 and HER3 from Bowes
melanoma cells and staining for tyrosine phosphorylated pro-
teins, we could show constitutive phosphorylation of HER2
and HER3 (Fig 6B, middle panel). Treating the cells for 30 min
with PD168393 resulted in a complete block of this phospho-
rylation (Fig 6B, left and middle panels). This was not due to
alterations in receptor levels, as immunostaining for HER2 and
HER3 showed no di¡erences between untreated cells and cells
treated with PD168393 (Fig 6B, right panel). In line with this,
when tested in a 5-day growth assay, PD168393 gave a signi¢-
cant (po0.01) and concentration-dependent growth inhibition
of Bowes melanoma cells (Fig 6C). This e¡ect was not due to
general cytotoxicity because virtually no growth inhibition was
seen of MCF-7 cells (HER2/3-positive and HRG-negative) or
BLM cells (HER2/HRG-positive and HER3-negative).
Figure 4. Melanoma cells release receptor activating HRG in the
medium. (a) Immunoblotting (I.B.), using an anti-HRG antibody directed
against the EGF-like domain, of concentrated CM of Bowes melanoma,
before (lane 1) and after (lane 2) depletion of heparin-binding factors reveals
the presence of a 45-kDa protein only in lane 1. Full-length recombinant
HRG-b1 (rHRG-b1), produced in Escherichia coli (lane 3)migrates at 33 kDa
owing to di¡erences in glycosylation. (b^e) Analysis of tyrosine-phos-
phorylated proteins in serum-starved MCF-7 cells. (b) Cells treated for 30
min with serum-free medium (Untr), with rHRG-b1, or with CM from
the indicated cell lines. (c) Cells pretreated or not for 30 min with 2 mM
PD168393 (PD) and treated for an additional 30 min with serum-free med-
ium or CM from the indicated cell lines. (d) Cells pretreated or not for 30
min with 2 mM PD168393 (PD) and treated with serum-free medium or
with CM of Bowes melanoma to which heparin was added in the indi-
cated concentrations. (e) Quanti¢cation of tyrosine phosphorylation, in-
duced by treating MCF-7 cells with Bowes melanoma CM or by treating
these cells with increasing concentrations of rHRG-b1. The arrow indicates
that, by extrapolation, the phosphorylating capacity of Bowes melanoma
CM is equivalent to that of 7 5 ng per mL rHRG-b1. (f) MCF-7 cells
treated with 5 ng per mL rHRG-b1 or CM Bowes melanoma for the in-
dicated periods of time. Arrowheads, 7185-kDa tyrosine-phosphorylated
bands.
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Constitutive receptor activation in Bowes melanoma cells
could be inhibited not only by directly blocking its kinase
activity, but also the interference with ligand binding resulted
in this e¡ect. This was evident from the rapid, concentration-
dependent inhibition of HER phosphorylation and the con-
sequent growth inhibition seen upon treatment with heparin
(Fig 6D,E). The MAPK pathway is a major pathway implicated
in uncontrolled growth of melanomas (Govindarajan et al, 2003;
Satyamoorthy et al, 2003). Because it is also a well known
signaling pathway activated by HRG (Pinkas-Kramarski et al,
1998), we checked its activation status in Bowes melanoma cells
by western blotting using a phospho-MAPK-speci¢c antibody.
Constitutive HER phosphorylation of Bowes melanoma cells
was accompanied by a constitutively active MAPK pathway (Fig
6F, lane 1). Blocking HER phosphorylation with PD168393
rapidly led to a block of MAPK activation (Fig 6F, lanes 2,3),
showing that continuous HER activation is the main cause of
the constitutively activated MAPK pathway in these cells. The
importance of the continuous activation of this pathway for the
growth of Bowes melanoma cells was shown in experiments in
which we used PD98059, a MAPK inhibitor. Bowes melanoma
cells were particularly sensitive to this inhibitor and showed
signi¢cant growth inhibition at concentrations that did not have
any e¡ect on growth of control BLM or MCF-7 cells (Fig 6G).
In conclusion, constitutive HER activation by autocrine HRG
supports growth of Bowes melanoma cells via continuous
MAPK activation.
Exogenous HRG stimulates growth of melanoma cells and
melanocytes but does not protect melanocytes against
apoptosis Melanocytes depend for their survival in vitro
strongly upon the addition of extracellular stimuli. A prominent
growth factor promoting growth and survival of these cells is
bFGF (Halaban, 2000). To test whether HRG could have similar
e¡ects, we treated melanocytes with di¡erent concentrations of
rHRG-b1, bFGF, or the combination of both. As is evident
from Fig 7A, rHRG-b1 stimulated HER phosphorylation of
melanocytes and a variety of melanoma cell lines. rHRG-b1
concentration-dependently stimulated growth of melanocytes
and could even provide an additive stimulus over bFGF (Fig
7B). A signi¢cant growth stimulation was also seen when, e.g.,
MCF-7, MeWo, and A375 cells were treated with rHRG-b1
(data not shown). Because bFGF is also a potent antiapoptotic
factor for melanocytes (Alanko et al, 1999), we next tested
whether HRG might have a similar e¡ect. Upon seeding of
melanocytes on a collagen gel, these cells undergo apoptosis,
round up, and become annexin V-positive owing to the
exposure of phosphatidylserine at the outer surface of the cells.
This can be inhibited by adding bFGF to the medium (Alanko
et al, 1999) (Fig 7C,D). Although a small decrease in the
percentage of apoptotic cells was reproducibly seen upon treat-
ment with rHRG-b1, this e¡ect was negligible compared to the
antiapoptotic e¡ect of bFGF (Fig 7C,D). Overall, the results
from these assays show that HRG potently stimulates growth
of melanoma cells and melanocytes, but does not protect
melanocytes against collagen-induced apoptosis.
Defective HRG/HER system in various melanoma cell
lines As shown in Fig 8A, phosphorylation in Bowes mela-
noma cells was already maximal, because treatment with
Figure 5. Scattering of MCF-7
epithelial islands by rHRG-b1 and
by CM of HRG-positive cell lines.
Serum-starved MCF-7 cells pretreated
or not for 30 min with 2 mM PD168393,
followed by an additional 30-min treat-
ment and preparation of lysates (b) or
followed by additional 2-h treatments
before taking pictures of living cultures
(a) or crystal-violet-¢xed cultures (c). (b)
Antiphosphotyrosine immunoblotting
(I.B.) of whole-cell lysates of MCF-7
cells that were treated for 30 min with
serum-free medium, CM of Bowes mel-
anoma (CM Bowes), the heparin-binding
fraction from CM Bowes (eluate) or CM
Bowes depleted from heparin-binding
factors. Arrowhead,7185-kDa phosphory-
lated band. (c) Indicated conditions as in
(b). Bars, 50 mm.
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rHRG-b1 did not result in an increase of phosphorylation.
Consistent with this, no additional growth stimulation could be
seen upon treatment with rHRG-b1 (data not shown). The
observation that the HRG-positive BLM cells lack constitutive
receptor activation (Fig 6A) and cannot be activated upon
addition of rHRG-b1 (Fig 8A) is in agreement with the absence
of the HRG-receptor HER3 (Fig 2A) in these cells. The lack
of HER3 also accounts for the unresponsiveness of FM45 cells
to rHRG-b1 (Fig 8A). MJM cells seem to have a defective
HER-system as well: although HER2 and HER3 were present
(Fig 2A), treatment with rHRG-b1 led only to a minor
phosphorylation, compared with treated MCF-7 cells (Fig 8A).
This minor phosphorylation was due to a small increase in
phosphorylation of HER3, but not of HER2 (Fig 8B, lane 2).
To check whether HER2 can be activated in MJM cells, we
treated them for 10 min with pervanadate, a phosphatase
inhibitor. This led to phosphorylation of multiple proteins,
including HER2 and HER3 (Fig 8B, lane 3). Cotreatment with
rHRG-b1 and pervanadate led to an additional increase in
phosphorylation of only HER3 (Fig 8B, lane 4), compared to
treatment with pervanadate only. To verify whether mutations
in HER2 could be responsible for the lack of activation in
response to signaling from outside the cell, we sequenced all
exons of the HER2 gene. Apart from described polymorphisms
in the sequences encoding the transmembrane domain (Ile655 to
Val655) (Ehsani et al, 1993) and the C-terminal tail (Pro to Ala),
no mutations were found. Furthermore, biotinylation revealed
that full-length HER2 was present at the plasma membrane of
MJM cells (data not shown). So, despite the lack of mutations
of HER2 and its localization at the plasma membrane in MJM
cells, this receptor lacks the potential to become activated via
stimulation with ligands.
DISCUSSION
In this report, we investigated the expression and function of the
HRG/HER ligand^receptor system in 13 melanoma cell lines,
compared to normal melanocytes. HER2 and HER3 were found
to be the main members of the EGFR family expressed in these
cells. Nevertheless, these receptors were not overexpressed, which
is consistent with the analysis of both nevi and melanoma tumor
material by others (Natali et al, 1994; Korabiowska et al, 1996;
Persons et al, 2000; Fink-Puches et al, 2001). Similar amounts of
HER3 protein were present in melanocytes and in 11 of the
13 cell lines. The fact that two melanoma cell lines (BLM and
FM45) showed only low HER3 mRNA levels and even no de-
tectable HER3 protein is a ¢rst example of how the HRG/HER
system may be deregulated in melanoma (Fig 9). Loss of HER3
may imply that transformed melanocytes no longer depend on
HRG, normally provided by the surrounding keratinocytes
(Schelfhout et al, 2000), for their survival. Downregulation or loss
of other melanocytic RTK (e.g., c-Kit, protein-tyrosine kinase 4,
ephrin receptor EphA4) during melanoma progression has been
Figure 6. Correlation between constitutive HER activation in
Bowes melanoma, continuous MAPK activation, and increased
growth. (a) Whole lysates from 48-h serum-starved cell lines analyzed
by immunoblotting (I.B.) using an antiphosphotyrosine antibody. (b,d)
Immunoblotting of tyrosine-phosphorylated proteins in serum-starved
Bowes melanoma cells, treated or not with 2 mM PD168393 for 30 min
(b) or with di¡erent concentrations of heparin for 10 min before making
cell lysates (d). (b) The left panel indicates whole-cell lysates. Middle and right
panels, equal amounts of protein were immunoprecipitated (I.p.) using anti-
HER2 or anti-HER3 antibodies, before immunoblotting with anti-phos-
photyrosine, anti-HER2, or anti-HER-3 antibodies. (f) Bowes melanoma
cells treated with 1 mM PD168393 for di¡erent periods of time.Whole-cell
lysates were analyzed by immunoblotting using antiphosphotyrosine (top
panel) or antiphospho-MAPK antibodies (bottom panel). Arrowheads, 7185-
kDa phosphorylated bands. (c,e,g) Growth, relative to vehicle-treated cells,
as measured by sulforhodamine B assay. Cells were treated for 5 days with
the indicated concentrations of PD168393 (c,e) or heparin (e) or with 5 mM
PD98059 (g). Asterisks, di¡ers signi¢cantly (po0.01) from controls.
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described before (Easty and Bennett, 2000). Their loss may un-
couple the melanocytes from certain physiologic regulatory me-
chanisms or may indicate an independence from the growth
factor system involved. In the latter case, other systems (auto-
crine/paracrine) and/or activating mutations of other (intracellu-
lar) proteins may have substituted for the loss. In this context, it
is noteworthy that we found a mutated N-ras allele in BLM, and
also in MJM cells (see further), resulting in a constitutively active
N-ras (data not shown), whereas FM45 cells have a mutation in
the tumor suppressor PTEN (Guldberg et al, 1997), resulting in
constitutive phosphoinositide 3-kinase signaling. We have evi-
dence (unpublished data) that the absence of HER3 in BLM
and FM45 cells is accompanied by the loss of microphtalmia
transcription factor M, a melanocyte-speci¢c transcription factor
necessary for melanocyte development. Interestingly, expression
of both HER3 and microphtalmia transcription factor M has
been described to be under the control of SOX-10, a transcription
factor necessary for melanocyte development, thus making this
protein a putative regulatory candidate (Verastegui et al, 2000;
Britsch et al, 2001).
The MJM cell line represents a second example of a deregu-
lated HRG/HER system in melanoma (Fig 9). Although it ex-
presses HRG, HER2, and HER3, surprisingly, it cannot use the
secreted HRG in an autocrine loop. Following treatment of
MJM cells with exogenous HRG, HER2 is not activated at all,
whereas HER3 becomes only weakly phosphorylated. The fact
that a minute phosphorylation of HER3 still occurs is surprising,
because HER3 lacks catalytic activity and needs HER2 for its
phosphorylation in the absence of other HERs. We cannot ex-
clude that HER1 or HER4, whose levels were below the detec-
tion limit of our western blotting experiments, account for this
e¡ect.We can exclude the possible (lack of) regulatory action of
heparan sulfate proteoglycans to be responsible for the impaired
response, because the used rHRG-b1 only consists of the EGF-
like domain. Also the interference by circulating soluble HER2
Figure 8. Deregulated HRG/HER system in several melanoma cell
lines. (a) Serum-starved cells, treated with rHRG-b1 or not before the
preparation of whole-cell lysates and analysis by immunoblotting (I.B.)
using an antiphosphotyrosine antibody. (b) Equal amounts of protein from
cell lysates of MJM cells that had been treated for 10 min with rHRG-b1
and/or pervanadate were subjected to immunoprecipitation (I.p.) with anti-
HER2 or anti-HER3 antibodies before immunoblotting using an anti-
phosphotyrosine antibody. Arrowhead,7185-kDa phosphorylated band.
Figure 7. Receptor-activating and growth-promoting, but no anti-
apoptotic e¡ects of exogenous HRG on melanoma cells and mela-
nocytes. (a) Immunoblotting (I.B.), using an antiphosphotyrosine
antibody, of lysates from serum-starved cells, treated or not with rHRG-
b1. Arrowhead, 7185-kDa phosphorylated band. (b) Growth, relative to
untreated cells, as measured by 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenylte-
trazolium bromide assay. Melanocytes were treated for 5 days with the
indicated concentrations of growth factors. Asterisks, di¡ers signi¢cantly (p
o 0.01) from control. (c) Phase contrast photographs of melanocytes cul-
tured on a collagen gel for 4 days with the treatments indicated. Arrows,
rounded cells in melanocyte cultures that were left untreated or were trea-
ted with rHRG-b1. These rounded cells were not found in bFGF-treated
cultures. Bar, 50 mm (d) Histogram, showing the pro¢le of annexinV posi-
tivity in melanocytes that were cultured on a collagen gel in the absence of
added growth factors (solid line) or in the presence of 5 ng per mL bFGF
(broken line) or 50 ng per mL rHRG-b1 (dotted line). The percentage of
annexinV-positive cells is indicated.
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or HER3 ectodomains (Doherty et al, 1999; Aigner et al, 2001;
Lee et al, 2001; Justman and Clinton, 2002) is unlikely, because
CM from the HRG-positive MJM cells still induced activation
of HERs in MCF-7 cells. Biotinylation experiments suggested a
transmembrane localization of HER2 in MJM cells, whereas ana-
lysis of functional sequences failed to show mutations. Neverthe-
less, sequencing did reveal two polymorphisms, one of which (Ile
toVal at position 655 in the HER2 transmembrane domain) was
predicted to favor the formation of stable HER2 homodimers
(Fleishman et al, 2002). Although it still needs to be shown
whether the proposed model also holds for HER2 activation by
heterodimerization (following ligand binding), it would mean
that HER2 in MJM cells would be more easily activated than
in, e.g., Bowes melanoma cells, which is in contrast to our ¢nd-
ings. It thus seems unlikely that this polymorphism may provide
an explanation for the observed lack of HER2 activation in MJM
cells treated with HRG. A possible role for the other polymorph-
ism we identi¢ed in MJM cells has not been established yet. Re-
maining explanations for the lack of HER2 activation following
stimulation with HRG are the interference with ligand binding
by sterical hindrance, the constitutive association or action of in-
tracellular negative regulatory proteins or receptor mislocaliza-
tion (although transmembrane).
Here, we have shown by western blotting, RT-PCR, cloning,
and using functional assays the presence and function of HRG as
new growth factors produced by human melanoma cells. In addi-
tion to three known HRG isoforms, we could identify a new iso-
form, designated a4. This isoform combines the sequences that
normally lead to either a- or b-isoforms. A similar combination
was already described for the a3-isoform, which di¡ers from the
a4 -isoform because the latter contains the coding sequence for
the transmembrane domain (Wen et al, 1994) (Fig 1). Neverthe-
less, the resulting protein is the same, because this a^b combina-
tion leads to a frameshift, resulting in the generation of a stop
codon upstream of the sequence encoding the transmembrane
domain. This truncated protein is most likely cytosolic because
the transmembrane domain functions as a signal peptide (Burgess
et al, 1995).The presence of HRG in melanomas ¢ts with the neu-
roectodermal origin of melanocytes and the fact that HRG are
molecules typically expressed in neuroectodermal tissues (March-
ionni et al, 1993; Meyer and Birchmeier, 1995). Although melano-
cytes showed HRG expression at the mRNA level, HRG could
barely be detected at the protein level, suggesting the presence of
(post)translational negative regulatory mechanisms in these cells.
Activating mutations in H-ras have been shown to result in upre-
gulation of HRG in mammary epithelial cells (Mincione et al,
1996). Although two of the HRG-producing cell lines (BLM
and MJM) have an activating mutation in N-ras, transient trans-
fections using dominant-negative and constitutively active N-ras
constructs learned that this was unlikely to be the underlying
cause of the increased HRG expression (data not shown). Thus,
the molecular basis for the high HRG expression in some mela-
noma cell lines is not clear, yet. Although exogenous HRG did
not exert a signi¢cant antiapoptotic e¡ect, it potently stimulated
growth of cultured melanocytes and melanoma cells and could
even provide an additive growth stimulation over bFGF. Upregu-
lation of HRG expression in melanomas may result in the gen-
eration of an autocrine loop and in the independence from HRG
normally provided by the keratinocytes (Schelfhout et al, 2000).
This decreased dependence from paracrine growth factors is one
of the hallmarks of melanoma progression (LaŁ zaŁ r-MolnaŁ r et al,
2000). Our data clearly show that in the Bowes melanoma cell
line, in the absence of receptor overexpression, HER2 and
HER3 are permanently activated, leading to continuous MAPK
activation and stimulation of growth. This activation is due to
continuous ligand^receptor interactions and not to, e.g., activat-
ing mutations. Arguments hereto are that the phosphorylation
could be abolished by adding heparin to the culture medium
and that refreshing of the culture medium led to a transient, gra-
dual decrease in receptor phosphorylation, followed by a gradual
recovery to the initial levels (data not shown). Thus, the Bowes
melanoma cell line, with its autocrine loop, represents a third ex-
ample of how the HRG/HER system may be deregulated in
melanoma (Fig 9). Expression of the HRG/HER systemwas also
described in various other types of cancers (e.g., breast, lung, en-
dometrium, thyroid, head and neck, colon, ovarium) (Ethier et al,
1996; Fernandes et al, 1999; Srinivasan et al, 1999; Fluge et al, 2000;
O-Charoenrat et al, 2000; Gilmour et al, 2002;Venkateswarlu et al,
2002). Although in only some of these studies constitutive recep-
tor activation, owing to an autocrine loop, was looked at, it may
play a role in the other cases as well, rendering it a possible target
for future therapies. In line with this is the increased attention
that is being given toward receptor activation status in certain
cancers, rather than only taking into account receptor levels as a
criterium of malignancy (Thor et al, 2000).
Overall, it is striking that two of the three HRG-positive cell
lines, BLM and MJM, cannot use the secreted HRG in an auto-
crine loop, because of the absence of HER3 or because of an im-
paired HER2 activation, respectively. Still, in a physiologic
situation, the HRG secreted by such cells may have prominent
e¡ects on the surrounding cells, directly or indirectly contribut-
ing to malignant progression. Direct e¡ects may include an in-
creased motility of the surrounding keratinocytes (Schelfhout et
al, 2002), possibly rendering the environment in which the mela-
nocytes reside less tight. Indirect e¡ects may be the stimulation of
angiogenesis owing to a HRG-mediated upregulation of vascular
endothelial growth factor or increased expression of other
growth factors by the target cells (O-Charoenrat et al, 2000;
Talukder et al, 2000;Yen et al, 2000; Ruiter et al, 2002).
Figure 9. Schematic representation of the several deregulations of
the HRG/HER system found in human melanoma cells. In melano-
cytes and the majority of melanoma cell lines, HERs can be activated by
exogenous HRG. The absence of HER3 in BLM and FM45 cells or the
presence of functionally inactive HER2 in MJM hampers HRG respon-
siveness. Bowes melanoma cells show constitutive HER activation, owing
to the presence of an autocrine loop.
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In summary, we have shown the presence of HRG, including
one new isoform, as new factors produced and secreted by hu-
man melanoma cell lines. The HRG/HER system is functional
in melanocytes and in the majority of melanoma cell lines, lead-
ing to growth stimulation. Nevertheless, multiple deregulations
in this growth factor system may release the melanocytes from
their natural dependence on keratinocyte-derived factors and thus
represent a step toward melanoma progression. Lack of stimula-
tion by HRG in some melanoma cell lines is due to the loss of
expression of HER3 protein or to a severely impaired HER2 ac-
tivation. In contrast, the aberrant expression and secretion of
HRG by melanoma cells may serve as an autocrine and/or para-
crine signal, promoting cell growth and/or migration. These dis-
tinct types of deregulation of the HRG/HER system may
contribute to the malignant phenotype of melanoma cells. In
the future, it will be important to verify whether these deregula-
tions are present in tumor samples of melanoma patients and may
become a therapeutic target for this disease with ever increasing
incidence.
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Melanoma cells secrete follistatin, an antagonist of activin-mediated growth
inhibition
Christophe Stove1,3, Frank Vanrobaeys2, Bart Devreese2, Jozef Van Beeumen2, Marc Mareel1
and Marc Bracke*,1
1Laboratory of Experimental Cancerology, Department of Radiotherapy and Nuclear Medicine, Ghent University Hospital, De
Pintelaan 185, 9000 Ghent, Belgium; 2Laboratory of Protein Biochemistry and Protein Engineering, Ghent University, KL
Ledeganckstraat 35, 9000 Ghent, Belgium
Using a proteomic approach to screen for new growth
factors released by melanoma cells, we identiﬁed follista-
tin as a major heparin-binding factor in medium condi-
tioned by the Bowes melanoma cell line. Since follistatin is
primarily studied in relation to its neutralization of
activin, a member of the transforming growth factor-b
family of ligands, the expression and function of this
receptor system was investigated in a panel of melanoma
cell lines and melanocytes. All cell lines expressed activin
receptors and showed phosphorylation of Smad signal
transduction molecules upon treatment with activin.
Secretion of follistatin, either native or after retroviral
transduction, efﬁciently prevented Smad activation or
activation of an activin-responsive luciferase reporter
construct. In melanocytes, activin treatment led to growth
inhibition and induction of apoptosis. These effects were
counteracted by cotreatment with follistatin. In summary,
we characterized the activin–activin receptor system in
melanocytes and melanoma cell lines and found that
secretion of follistatin by melanoma cells may represent
an effective way to circumvent activin’s negative regula-
tory effects.
Oncogene advance online publication, 5 April 2004;
doi:10.1038/sj.onc.1207699
Keywords: follistatin; activin; Smad; melanoma;
growth; apoptosis
Introduction
Melanocytes, the pigment-forming cells of the skin, are a
quiescent cell population located in the basal layer of the
epidermis. Their growth is controlled by an interplay
with the surrounding keratinocytes (Meier et al., 1998;
La´za´r-Molna´r et al., 2000). Disturbance of this tight
control may result in an imbalance of stimulatory versus
inhibitory factors and may represent a ﬁrst step towards
malignant transformation. The transforming growth
factor-b (TGF-b) family of growth factors has been
described as an important growth-regulatory system in
melanocytes. Whereas TGF-b acts as a potent inhibitor
of growth and inducer of apoptosis in normal melano-
cytes, these effects are often much less pronounced,
absent or even inversed in melanoma cells (Rodeck et al.,
1994, 1999; Alanko and Saksela, 2000).
Activins are TGF-b-like dimeric molecules that were
initially isolated as stimulators of follicle-stimulating
hormone secretion (hence the name) (Ling et al., 1986;
Vale et al., 1986). They consist of two disulﬁde-linked b
subunits, translated from one of three known (A, B or
C) human inhibin b gene transcripts, the main activin
proteins being the homodimeric activins A and B and
the heterodimeric activin AB (Knight, 1996). They exert
their biological effects by interacting with two types of
transmembrane serine/threonine kinase receptors (types
I and II). Following binding of the dimeric ligand to two
type II receptors (II or IIB), two type I activin-like
receptor kinases (ALK4¼ activin receptor IB) are
recruited and activated by phosphorylation in trans.
On their turn, the type I receptors will phosphorylate
cytoplasmic Smad proteins (Smad2 and 3) which, after
forming a complex with Smad4, will translocate to the
nucleus to regulate transcription of activin-responsive
genes (Shi and Massague´, 2003). Activins have been
implicated in the control of diverse cellular processes,
ranging from tissue patterning during embryogenesis to
the control of homeostasis, cell growth and differentia-
tion in multiple adult tissues (Ball and Risbridger, 2001;
Luisi et al., 2001; Risbridger et al., 2001; Chen et al.,
2002; Welt et al., 2002). The effects of activin are cell-
type speciﬁc: in some tissues or cell types, it stimulates
proliferation, while in others it induces differentiation,
growth inhibition and/or apoptosis. Disruption or
deregulation of activin signaling is associated with
multiple pathological states, including inﬂammation,
reproductive disorders and carcinogenesis (Risbridger
et al., 2001; Chen et al., 2002; Cho et al., 2003). Cells
may escape from the growth inhibitory effects of activin
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in several ways: by mutation or downregulation of
activin responsive genes or inhibition of their actions or
alternatively, by alterations interfering with the activin
signal transduction pathway. The latter may occur both
by mutations or inhibitory interactions at the receptor
level as well as at the level of the Smad signal
transduction molecules (Chen et al., 2002). Alterna-
tively, several factors (inhibins, cripto, follistatin) may
interfere with the ability of activin to gain access to and/
or assemble its signaling receptors (Gumienny and
Padgett, 2002; Gray et al., 2003).
Follistatin (FS), a monomeric secreted glycoprotein
that binds activin with high afﬁnity, blocks the ability of
activin to bind its cell-surface receptors (de Winter et al.,
1996). FS was ﬁrst isolated from ovarian follicular ﬂuid
on the basis of its ability to suppress the secretion of
follicle-stimulating hormone from pituitary cells
(Robertson et al., 1987; Ueno et al., 1987), an activity
that later was found to be due to the sequestering of
activin secreted by these cells (Nakamura et al., 1990).
Up to now, almost all known biological effects of FS are
due to its high afﬁnity, nearly irreversible, binding to
activin (Nakamura et al., 1990; Schneyer et al., 1994).
Alternative splicing at the 30 end of the follistatin gene
results in two isoforms, FS-288 and FS-315, the latter
having a 27 amino-acid extension at its C-terminus
(Shimasaki et al., 1988). Both contain an N-terminal
activin-binding domain and three consecutive 10-cysteine
follistatin domains, the ﬁrst of these containing a lysine-
rich heparin-binding motif (Wang et al., 2000; Sidis et al.,
2001; Innis and Hyvo¨nen, 2003). FS-288 is primarily
bound to cell surface heparan-sulfate proteoglycans,
presumably creating a barrier that prevents activin from
accessing its receptors (Delbaere et al., 1999; Sidis et al.,
2002) and leading to endocytosis and degradation of
surface-bound activin (Hashimoto et al., 1997). FS-315
contains an additional acidic C-terminal tail which
interferes to some extent with heparin binding, rendering
this the major isoform in solution (Schneyer et al., 1996).
This feature may explain the different potencies of both
isoforms in inhibiting the actions of endogenous versus
exogenous activin. It is not fully clear what the relative
importance of the different isoforms is. Although FS-315
transcripts, in general, are more abundant than FS-288
transcripts, the biologically active form of FS-315 in vivo
may be a processed shorter form with properties similar
to those of FS-288 (Inouye et al., 1991).
Based on the identiﬁcation of FS as a newmajor heparin-
binding factor released by melanoma cells, we characterized
the activin/activin receptor system as a new growth factor
system in melanoma and melanocytes and investigated the
potential role of FS in controlling this system.
Results
Identification of follistatin as a factor secreted by
melanoma cell lines
In a screening for new growth factors secreted by
melanoma cell lines, conditioned medium (CM) from
the Bowes melanoma cell line was prepared, concen-
trated 50 times, and subjected to a triple precipitation
procedure using heparin beads in order to deplete it
from heparin-binding factors. The initial and depleted
concentrated CM and the resulting heparin-binding
fraction were subjected to gel electrophoresis, followed
by protein silver staining of the gel. This resulted in a
very similar pattern of proteins in the concentrated CM
and in the depleted concentrated CM, indicating that
the vast majority of secreted proteins did not bind to the
heparin beads (Figure 1a, lanes 1 and 2). However, a
band at 745 kDa (indicated with an asterisk) was not
present in the depleted CM. This band corresponded
with the major band found in the heparin-binding
fraction (Figure 1a, lanes 3 and 4). N-terminal sequen-
cing identiﬁed this band as FS. The sequence obtained,
GN(C)WLRQA, represents the N-terminus of mature
FS after cleavage of its precursor form (Esch et al., 1987;
Robertson et al., 1987; Ueno et al., 1987; Nakamura
et al., 1990) (Figure 1b). To ascertain that this major
band is due to FS and does not represent a major other,
N-terminally blocked protein, we performed an in-gel
digestion of this band, using trypsin. The resulting
peptides were extracted and then submitted to mass
spectrometric analysis. This conﬁrmed that the major
heparin-binding factor released by Bowes melanoma
cells was indeed FS (Figure 1b). Western blotting and
immunostaining with an anti-FS antibody conﬁrmed the
presence of FS in concentrated Bowes melanoma CM,
but not in concentrated CM depleted of heparin-binding
factors (Figure 1c). To verify whether the different
molecular weight forms recognized by the antibody
represent different FS isoforms or result from differ-
ential post-translational modiﬁcations (glycosylation, C-
terminal processing), the Bowes melanoma cell line was
treated for 24 h with the glycosylation inhibitor tunica-
mycin before harvesting the CM. Subsequent immunos-
taining of this concentrated CM with an anti-FS
antibody revealed only one, faster migrating band
(Figure 1d), meaning that the different bands seen in
CM from the Bowes melanoma cell line represent
differentially glycosylated forms of one FS isoform. As
the tryptic peptides that had been identiﬁed by mass
spectrometry did not allow us to conclude which
isoform (FS-288 or FS-315) was produced by these
cells, we focused further on the tryptic fragment that
would be obtained from the C-terminus. However,
although we screened speciﬁcally for masses of potential
C-terminal peptides by mass spectrometry, we could not
identify this peptide. This may be due to the highly
hydrophilic nature of the C-terminus or, alternatively,
may mean that the C-terminus of mature FS is close to
the last trypsin cleavage site, and would thus give rise to
a peptide that is too small to be detected.
As an alternative approach to identify which FS
isoform was produced, RT–polymerase chain reaction
(PCR) was performed. A primer set was designed such
that different lengths of ampliﬁcation products were
obtained, depending on the isoform present. This primer
set was used to amplify cDNA from Bowes melanoma
cells, melanocytes and melanocytes that had been
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cultured in the presence of the phorbolester PMA, a
known upregulator of FS (Tano et al., 1995). As
compared to nonstimulated melanocytes, high FS-315
mRNA levels were found in Bowes melanoma cells and
in melanocytes cultured in the presence of PMA. In all
cases, only an ampliﬁcation product derived from the
FS-315-encoding mRNA was obtained (Figure 1e). This
isoform has been described to be the major FS isoform
in solution (in contrast to FS-288, which is primarily cell
surface bound), consistent with our isolation of FS as a
factor secreted in the medium.
To verify whether FS production was also seen in
other melanoma cell lines, we analysed concentrated
CM from a panel of melanoma cell lines by Western
blotting (Figure 1f). This revealed that, albeit lower than
was found for the Bowes melanoma cell line, FS
secretion was easily detectable in several cell lines (530,
A375, DX3), whereas lower (FM45, FM87, HMB2) to
faint signals were obtained in others (e.g. FM3/P,
MeWo). None of the cell lines accumulated higher FS
levels than those found for the Bowes melanoma cell
line. Also here, RT–PCR analysis learned that FS-315
was the only isoform produced by melanoma cells (data
not shown). In conclusion, several melanoma cell lines
release FS-315, either as a full-length or a C-terminal-
truncated form, in their medium.
Expression of activin and activin receptors in melanoma
cell lines
Since nearly all known effects of FS are mediated via its
binding to and neutralization of activin, we ﬁrst
characterized whether activin can act on melanoma
cells. Therefore, we performed RT–PCR for activin
receptors I, IB, II and IIB. Of these, activin receptors IB
and IIB were highly expressed in all melanoma cell lines
and melanocytes (Figure 2). To verify whether activin
and inhibin were produced by melanocytes and the
melanoma cells, we performed RT–PCR for the inhibin
a-subunit and the bA, bB and bC subunits (Figure 2).
This revealed a high expression of the bA subunit in the
majority of the melanoma cell lines, suggesting that
activin A, a homodimer of two bA subunits, is the major
activin expressed in this type of cells. Melanocytes
cultured in the presence of PMA had higher mRNA
levels of inhibin-a, -bA and -bB, consistent with the
PMA-induced upregulation of activin expression and
secretion in a variety of cells (Cho et al., 2003). To
quantify activin A secretion by the melanoma cells, we
set up an ELISA, which allowed us to detect activin A
levels as low as 0.25 ng/100 ml. When 25-fold concen-
trated CM of the melanoma cell lines was tested in this
ELISA, no speciﬁc signal could be obtained, meaning
that activin A levels in the melanoma cell lines do not
exceed 0.1 ng/ml (data not shown). Using a similar
ELISA to detect FS, a signal was easily obtained using
crude CM from the Bowes melanoma and FS-trans-
duced FM3/P cell lines, whereas vector-transduced
FM3/P cells were completely negative (data not shown).
These data suggest that activin A is secreted in only very
low amounts by the melanoma cells, or may remain cell-
surface associated, leading to residual levels in the
medium, or may, in contrast to FS, be subject to fast
proteolytical breakdown.
Figure 1 Follistatin secretion by melanoma cell lines. (a) Protein silver staining and (c) immunoblotting (I.B.) with an anti-FS
antibody of 50 concentrated CM of Bowes melanoma cells (lane 1), CM depleted from heparin-binding factors (lane 2), the heparin-
binding fraction of the CM (lane 3) or a more concentrated heparin-binding fraction (lane 4). (b) Sequence of FS precursor with the
sequences identiﬁed by mass spectrometry (underlined). 4 Indicates the N-terminus of mature FS that was identiﬁed by N-terminal
sequencing. 1 Indicates the C-terminus of FS-288. (d) Immunoblotting with anti-FS antibody of 50 concentrated CM of Bowes
melanoma cells, left untreated (U) or treated for 24 h with 10 mg/ml tunicamycin (Tun). (e) RT–PCR analysis of FS mRNA in the
indicated cells. (f) Immunoblotting with anti-FS antibody of 50 concentrated CM of the indicated cell lines. The asterisk indicates
the band(s) corresponding to FS
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Activin-induced Smad-phosphorylation in melanoma cell
lines
Receptor activation by members of the TGF-b family of
growth factors is typically followed by activation
(phosphorylation) of receptor Smads (Shi and Massa-
gue´, 2003). Using a phospho-Smad-speciﬁc antibody, we
determined whether the addition of activin indeed
resulted in activation of Smads in the cells. We therefore
added activin to serum-free medium or to medium
conditioned for 48 h by the melanoma cell lines. Positive
and negative controls, respectively, were the human
breast cancer cell line MCF-7 (Liu et al., 1996) and the
human colon cancer cell line HCT-8, the latter having a
nonsense mutation in activin receptor II (Hempen et al.,
2003) (Figure 3, upper panel). Note that basal Smad
activation levels seen in Figure 3 should not be
compared between cell lines, since differences in band
intensities between blots may be the result of different
ﬁlm exposure times. When activin was added in fresh
serum-free medium, Smad phosphorylation increased in
all melanoma cell lines tested, meaning that the ﬁrst
steps of the activin signal transduction (receptor binding
and activation of signal transduction molecules) re-
mained intact (Figure 3, middle panel, last two lanes).
Of note, the Smad activation observed was much more
pronounced than that seen in treated MCF-7 breast
cancer cells, possibly due to the higher receptor levels in
all of the melanoma cell lines (Figure 2). Smad
phosphorylation following activin treatment in fresh,
serum-containing medium was also seen in melanocytes
(Figure 3, lower panel, last two lanes). Here, serum
starvation was omitted, since the majority of melano-
cytes does not survive, or goes into apoptosis, after a
48-h serum depletion (unpublished observations). To
verify whether the presence of secreted factors inﬂuences
the response of the cells, activin was added to medium
conditioned by the cells. In several melanoma cell lines,
this resulted in a lower (e.g. A375, DX3) or even
completely absent (Bowes) Smad activation, when
compared to activin treatment in fresh medium
(Figure 3, ﬁrst two lanes). This means that, although
these cell lines have retained the intrinsic capacity to
respond to activin in terms of Smad activation, the
secretion of (an) inhibitory factor(s) prevents this
activation. Since the prevention of Smad activation
following activin treatment in the CM correlated well
with the presence of FS in this CM (Figure 1f), the
action of FS, secreted by melanoma cells, was further
investigated.
Follistatin-315 secretion by melanoma cell lines inhibits
activin-induced Smad activation
In the Bowes melanoma cell line, secreting the highest
amounts of FS (Figure 1f), Smad phosphorylation was
not altered upon addition of activin to the CM (Figure 3
and 4a). We therefore chose this cell line to provide
further evidence that activin’s stimulatory effects are
indeed blocked by secretion of FS into the medium.
Bowes melanoma cells were ﬁrst washed extensively
before the addition of activin to CM or to fresh medium.
When administered in the CM, activin treatment did not
lead to an increase in Smad phosphorylation, irrespec-
tive of whether (Figure 4a, lanes 3 and 4) or not (lanes 1
and 2) the cells had been washed before the treatment.
Addition of activin to serum-free medium that was
added to washed cells did result in increased Smad
Figure 3 Activin treatment of melanoma cells and melanocytes
induces Smad activation. Immunoblotting (I.B.), using an anti-
phospho-Smad antibody of whole-cell lysates of the indicated cells.
All cell lines were serum starved for 48 h before a 30-min treatment
with activin (10 ng/ml) in their medium (CM) or in fresh serum-free
medium that was added to cells that had been washed three times
with PBS (Fresh Med). In the case of melanocytes, CM and Fresh
Med indicate serum-containing medium
Figure 2 Expression of the activin–activin receptor system in
melanoma cell lines and melanocytes. RT–PCR analysis of activin
receptors and activin/inhibin subunits in the indicated cell lines. b2-
microglobulin (b2-MG) was used as a control
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activation (lanes 7 and 8). Taken together, this shows
that Bowes melanoma cells release a factor in their
medium that prevents activin-induced Smad activation.
Since FS is a heparin-binding factor, we next depleted
Bowes melanoma CM from heparin-binding factors
(CMdep). Interestingly, treatment with CMdep already
leads to an increase in Smad activation (Figure 4a,
lane5), and addition of activin to this medium does not
result in an increase in Smad phosphorylation
(Figure 4a, lane 6). This raises the possibility that, by
depleting Bowes melanoma CM from FS, the balance
between endogenous activin and FS is disrupted, readily
leading to Smad activation. Finally, to provide proof
that the production and secretion of the FS-315 isoform
by melanoma cell lines can indeed fully prevent Smad
activation by activin, two FS-negative cell lines, FM3/P
and MeWo, were infected with the retroviral vector
pLZRS-FS315-internal ribosomal entry site (IRES)-
enhanced green ﬂuorescent protein (EGFP). An IRES
allows both FS315 and EGFP to be translated
separately from the same mRNA transcript, with
expression levels of FS315 and EGFP being directly
proportional. As a control, retroviral transduction with
pLZRS-IRES-EGFP, encoding only EGFP, was per-
formed. As shown in Figure 4b, transduction with
retrovirus containing either an empty vector (pLZRS-
IRES-EGFP, LIE) or FS (pLZRS-FS315-IRES-EGFP,
FS) resulted in an efﬁciency of around 50% for both
melanoma cell lines. As evidenced by Western blotting,
FS-transduced, but not empty-vector-transduced cells,
secreted FS into their medium (Figure 4c). Owing to this
secretion, we reasoned that further sorting of these
cell lines would not be necessary to investigate its
effects: FS produced by the transduced cell lines was
likely to protect nontransduced cells as well. No
differences in morphology or growth could be observed
between the two transduced populations, either in the
presence or absence of activin (data not shown). When
tested for Smad activation, both the empty-vector- and
FS-transduced FM3/P and MeWo cell lines were
responsive to activin, when added in serum-free medium
(Figure 4d, lanes 5 and 6). However, similar to what was
observed in the Bowes melanoma cell line, no increase
in Smad activation occurred when activin was added
immediately to FS-transduced cells (lanes 1 and 2) or,
alternatively, was added to 48-h conditioned medium
that was added to washed cells (lanes 3 and 4). T
his contrasts with the empty-vector-transduced cells,
which were still fully responsive to activin (lanes 1, 2
and 3, 4). In agreement with this, treatment of
washed Bowes melanoma cells with activin in CM from
FM3/P FS did not lead to increased Smad activation
(Figure 4e, lanes 5 and 6), in contrast to its addition in
fresh serum-free medium or in CM from FM3/P LIE
(lanes 1, 2 and 3, 4). In conclusion, FS secretion by
melanoma cells is an effective way to prevent Smad
activation by activin.
Follistatin secretion by melanoma cell lines inhibits their
response to an activin-responsive reporter gene construct
Since the activation of receptor-Smads does not
necessarily mean that the signal will lead to alterations
in gene transcription, we performed luciferase-reporter
assays using the TGF-b- and activin-responsive CAGA
promoter construct (Dennler et al., 1998). Activin
treatment of FM3/P cells resulted in a twofold increase
Figure 4 Follistatin secretion prevents activin-mediated Smad
activation. (a) Immunoblotting (I.B.), using an anti-phospho-Smad
antibody of total lysates of Bowes melanoma cells. The 48-h serum-
starved cells were washed three times with PBS (washed), or were
not, and treated with activin (10 ng/ml) for 30min in their CM
(CM), in this CM depleted from heparin-binding factors (CMdep)
or in fresh serum-free medium (Fresh Med). (b) Dot plot analysis of
EGFP expression by the indicated retrovirally transduced cell lines.
Percent positivity is indicated in the upper right panel. (c)
Immunoblotting, using an anti-FS antibody, of 50 concentrated
CM of the indicated retrovirally transduced cell lines. The asterisk
indicates the band corresponding to FS. (d) and (e) Immunoblot-
ting (I.B.), using an anti-phospho-Smad antibody of total lysates of
the indicated cell lines. The 48-h serum-starved cells were washed
three times with PBS (washed), or were not, and treated with
activin (10 ng/ml) for 30min in their CM (CM) or in fresh serum-
free medium (Fresh Med). LIE indicates cells transduced with
empty vector, FS indicates cells transduced with FS-315. In (e), also
non-self serum-free CM was used
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of luciferase activity that could be completely inhibited
by the addition of exogenous FS (Figure 5a). When the
transduced cells were tested, a similar increase was seen
in empty-vector-transduced cells, whereas the FS-
transduced FM3/P cells did not show any increase in
promoter activity (Figure 5b). This conﬁrms the results
of Smad activation and, again, shows that the secretion
of FS by melanoma cells is an effective mechanism to
neutralize the effects of activin.
Activin inhibits melanocyte growth and induces apoptosis
Since TGF-b has been described as a proapoptotic
and growth-inhibitory factor for melanocytes, we
addressed the question whether activin may have
similar effects. Melanocytes cultured in the presence of
activin showed a marked decrease in growth, as
measured by mitochondrial activity using the MTT
assay (Figure 6a). This decrease could be counteracted
in a dose-dependent way by cotreatment with FS,
which, when administered alone, did not have an effect
on the growth of melanocytes. To verify whether an
increase in apoptosis can provide an explanation for the
observed decrease in growth, we performed Annexin V
labeling of serum-starved melanocytes that were treated
or not with activin. Annexin V has a high afﬁnity for
phosphatidylserine, which is exposed at the outer
surface of the cells in early apoptosis. Deprivation of
melanocytes from growth factors readily renders them
susceptible to apoptosis. As is evident from Figure 6b, a
20-h treatment with activin results in a signiﬁcant
increase in apoptosis, thus providing a likely explana-
tion for the decreased ‘growth’ observed, as measured
by mitochondrial activity. Again, this effect could
be counteracted by coadministering FS. In conclusion,
FS protects melanocytes against growth inhibition
by activin, at least partly, by counteracting its proa-
poptotic effects.
Discussion
Although TGF-b-like molecules have been studied
for more than a decade in melanocytes and their
malignant derivatives, surprisingly, only the roles of
TGF-b itself have been looked at (Rodeck et al., 1994,
1999; Alanko and Saksela, 2000). In the present paper,
based on the identiﬁcation of FS as a major heparin-
binding growth factor released by melanoma cells, we
studied the activin/FS system as a new regulatory
growth factor system in melanocytes and melanoma
cell lines.
Melanocytes are neural crest-derived cells that mi-
grate to the skin during an early stage of development.
They form a quiescent population in the basal layer of
the epidermis, making extensive contacts with the
surrounding keratinocytes, to which they deliver mela-
nin. Conversely, keratinocytes are crucial in controlling
normal proliferation of melanocytes. They do so in a
contact-dependent manner by the formation of E-
cadherin-mediated adherens junctions with the melano-
cytes, necessary for and leading to the formation of gap
junctions (Meier et al., 1998). A delicate balance exists
between stimulatory and inhibitory factors, released
either by the melanocytes themselves or by the
keratinocytes. Loss of control of keratinocytes over
melanocytes may thus be the result of altered cell–cell
adhesion and/or alterations in growth factor systems in
either of both partners. A shift in the balance between
positive (basic ﬁbroblast growth factor, insulin-like
growth factor-I, heregulin, etc.) and negative (TGF-b,
interleukin-6, etc.) regulators of melanocyte growth may
represent a ﬁrst step towards uncontrolled proliferation
(La´za´r-Molna´r et al., 2000; Stove et al., 2003a). Here, we
have shown that activin may serve as a novel negative
regulatory factor controlling melanocyte proliferation.
Exogenous activin is able to inhibit proliferation and
induce apoptosis in primary melanocytes. These effects
resemble those of TGF-b (Alanko and Saksela, 2000). In
vivo, activin may be provided by the keratinocytes,
Figure 6 Follistatin counteracts activin-mediated growth inhibi-
tion and apoptosis in melanocytes. (a) Growth, relative to
untreated cells, as measured by MTT assay. Melanocytes were
treated for 4 days with activin (25 ng/ml) and the indicated
concentration of follistatin. (b) % Annexin V positivity of serum-
starved melanocytes that have been treated for 20 h with activin
(25 ng/ml) and/or follistatin (400 ng/ml). Asterisks indicate means
that differ signiﬁcantly (Po0.05) from control
Figure 5 Follistatin prevents activin-mediated induction of a
luciferase reporter construct. Activin (25 ng/ml) and/or follistatin
(100 ng/ml) was added for 30min to the indicated melanoma cell
lines that had been transiently transfected with a b-galactosidase
reporter construct and a luciferase-reporter construct with an
activin-responsive promoter (open bars), without a promoter
(black bars) or with a constitutively active promoter (gray bars).
Bars represent normalized luciferase activities, relative to untreated
cells. In (a), a representative experiment is shown, in (b), the
asterisk indicates that the mean is signiﬁcantly larger than the
control (Po0.05)
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which are known producers of this molecule (Beer et al.,
2000). Using transgenic mice, a role for keratinocyte-
derived activin in the skin has been shown to exist in
wound healing processes and in the regulation of cell
matrix deposition (Munz et al., 1999; Wankell et al.,
2001b). Although, in vitro, keratinocyte proliferation
was shown to be decreased by activin, no decreased
keratinocyte proliferation was observed in vivo, possibly
because of the induction by activin of other factors that
may act as prosurvival factors for the keratinocytes
(Beer et al., 2000). Here, we found that both melano-
cytes and melanoma cells express mRNA for inhibin b
subunits, primarily the bA subunit, presumably leading
to the formation of the homodimeric activin A.
Expression of this bA subunit was markedly higher in
melanocytes cultured in PMA-containing medium,
consistent with the fact that PMA is a known inducer
of activin (Cho et al., 2003). However, surprisingly,
measurement of activin A levels in melanoma CM
revealed that activin A levels in none of the melanoma
cell lines exceeded 0.1 ng/ml. Although it is possible that
melanoma cells indeed secrete only residual amounts of
activin A, we cannot exclude that it is rapidly degraded,
or alternatively, remains associated with the cell surface,
prohibiting measurement in the CM. Therefore,
although several of the melanoma cell lines had higher
expression of the bA subunit, when compared to the
levels found in non-PMA treated melanocytes, a role for
activin in melanomagenesis, as has been proposed for
TGF-b (Shellman et al., 2000; Berking et al., 2001),
remains speculative. Further in vitro and in vivo
experiments, using activin-transduced cells, are needed
to clarify this issue.
Early in malignant transformation, it is crucial for the
survival of transformed cells to proﬁt optimally from
mitogenic stimuli, while escaping from inhibitory
signals. Overexpression or mutation of receptor systems,
or the gain of autocrine loops, may contribute to the
ﬁrst, while downregulation of inhibitory receptors or the
secretion of ligand traps have been shown to contribute
to the latter (Massague´ and Chen, 2000; Blume-Jensen
and Hunter, 2001; Gullick, 2001). Since activin acts as
an inhibitory molecule for melanocytes, neutralization
of its effects implies the release from a negative
regulatory factor. As shown here, one way to do so is
the production and secretion of FS. By binding to
activin, FS sequesters it in the medium and prevents it
from accessing its cell surface receptors. As a result,
although these cell lines have an intact signaling
machinery, no signaling occurs when activin is added
to medium in which these cells have released FS
previously. A similar activin-inhibitory effect has been
described for the more recently described follistatin-
related protein FLRG/FSTL3 (Sidis et al., 2002). Using
RT–PCR, we found transcripts of the latter in
melanocytes and in all melanoma cells (data not shown).
However, we consider it unlikely that follistatin-related
protein would play a major role in our system, since (1)
no correlation could be found between its expression
and the activin responsiveness of the cells, with FLRG/
FSTL3-expressing cells still being fully responsive when
activin was administered in their CM and (2) FLRG/
FSTL3 lacks a heparin-binding site, while the activin-
neutralizing effect of our CM can be abolished by
depleting it from heparin-binding factors. FS is a known
target gene of the canonical Wnt signaling pathway, in
which b-catenin translocation to the nucleus results in
transcriptional activation of target genes (Willert et al.,
2002). In cancer, including melanoma, b-catenin muta-
tions may lead to constitutive activation of this path-
way, resulting in aberrant activation of these target
genes (Rubinfeld et al., 1997). However, examination of
b-catenin localization in our panel of melanoma cell
lines did not reveal obvious nuclear b-catenin localiza-
tion in any cell line (data not shown). Other factors
capable of regulating FS secretion include retinoic acid,
prostaglandin E2, activators of protein kinase A and C,
as well as growth factors such as keratinocyte growth
factor and epidermal growth factor (Michel and Farn-
worth, 1992; Wankell et al., 2001a). Interesting in this
respect is our recent identiﬁcation of a potent autocrine
loop of heregulin, an epidermal growth factor-like
ligand, in the Bowes melanoma cell line, which secretes
the highest amounts of FS (Stove et al., 2003a). Whether
there is a crosstalk between receptor tyrosine kinase
pathways and regulation of FS expression in melanoma
cell lines is currently being investigated. We could not
ﬁnd a clear correlation between FS expression and the
differentiation status of the cell lines in our panel: FS
secretion was both present in cell lines that had lost
several melanocytic markers (e.g. Bowes melanoma,
A375 and DX3) as in cell lines that retained, at least
partly, markers of differentiation (e.g. the pigmented
530 and FM87).
Surprisingly, although the ﬁrst steps in the activin
signaling pathway were intact in all cell lines tested,
none of the melanoma cell lines showed signiﬁcant
growth inhibition following activin treatment, in con-
trast to what was seen for melanocytes. Several
explanations may account for this. Important for
activin’s growth-inhibitory effects is the modulation of
genes involved in cell-cycle regulation (Chen et al.,
2002). These genes are frequently mutated in melanoma
(Bartkova et al., 1996). Alternatively, activation of the
MAPK pathway, either by mutation of signaling
molecules (N-ras and B-raf) (Davies et al., 2002;
Tuveson et al., 2003) or by autocrine loops (La´za´r-
Molna´r et al., 2000; Stove et al., 2003a) was shown to be
of major importance in many melanomas. Constitutive
activation of this pathway was shown to result in
insensitivity to growth inhibition by TGF-b, while still
allowing other effects of these molecules to occur
(Shellman et al., 2000).
In conclusion, the effects of the activin–follistatin
system in melanoma may be dual: while early in
progression the secretion of FS may be crucial as a
protection against activin’s inhibitory effects, cells in a
later stage may use activin – either autocrine or
paracrine – to maintain a state of dedifferentiation and
to create a supportive microenvironment. It will be
important to determine the presence of this growth
factor system in tumor samples from melanoma patients
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in different stages of progression, in order to evaluate
whether it may become a therapeutic target.
Materials and methods
Cell lines
The cell lines were obtained and cultured as described before
(Stove et al., 2003a). Epidermal melanocyte primary cultures
were obtained from neonatal foreskins and established in
M199 medium (Gibco BRL, Merelbeke, Belgium), supplemen-
ted with 2% fetal bovine serum, 109 M cholera toxin, 10 ng/ml
basic ﬁbroblast growth factor, 10mg/ml insulin, 1.4mM
hydrocortisone and 10mg/ml transferrin (all from Sigma,
Bornem, Belgium). Postprimary cultures were maintained in
low-calcium (0.03mM) M199 medium, supplemented with the
same factors and 10% fetal bovine serum. The melanocytic
origin of all melanoma cell lines was checked by immunocy-
tochemistry using two melanoma-speciﬁc antibodies, HMB45
(Enzo Diagnostics, Farmingdale, NY, USA) and NKI/C3
(Biogenex, San Ramon, CA, USA). All melanoma cell lines
were positive for at least one of these markers (data not
shown). As most of the experiments were carried out with
Bowes melanoma cells, which were only positive for NKI/C3,
additional electron microscopy was performed to conﬁrm the
presence of premelanosome-like structures in this nonpigmen-
ted cell line (data not shown).
Antibodies and reagents
Primary antibodies used were mouse monoclonal anti-follista-
tin (R&D Systems, Abingdon, UK) and rabbit polyclonal
anti-phospho-Smad 2 (Cell Signaling Technology, Beverly,
MA, USA). Recombinant activin and follistatin were pur-
chased from R&D Systems, tunicamycin was obtained from
Sigma.
Preparation of CM
Subconﬂuent monolayers were washed three times with
phosphate-buffered saline (PBS), incubated for 24 h with
serum-free medium, washed again three times with PBS,
followed by a 48 h incubation with serum-free medium. The
latter was cleared from cells by a 5-min centrifugation step at
250 g. The resulting supernatant was centrifuged for an
additional 20min at 2000 g to remove cell debris, ﬁltered
through a 0.2mm ﬁlter, and stored at 201C until use. To
isolate the heparin-binding fraction from the CM, the latter
was depleted from heparin-binding factors by triple precipita-
tions with heparin beads (Bio-Rad, Hercules, CA, USA).
Elution of the heparin-binding fraction was carried out with
1M NaCl, followed by desalting using Microcon ﬁlters.
Western blotting
All lysates were made from cell cultures of approximately 90%
conﬂuence. For phosphorylation experiments, cells were
washed three times with PBS and serum starved for 48 h.
Then, the cells were treated without washing or, alternatively,
after washing three times with PBS. Immediately after the
treatments, the cells were washed three times with PBS before
lysis with PBS containing 1% Triton X-100, 1% Nonidet P-40
(Sigma) and the following protease inhibitors: aprotinin
(10mg/ml), leupeptin (10 mg/ml) (ICN Biomedicals, Costa
Mesa, CA, USA), phenylmethylsulfonyl ﬂuoride (1.72mM),
NaF (100 mM), NaVO3 (500mM) and Na4P2O7 (500mg/ml)
(Sigma). After clearing the lysates, protein concentration was
determined using the Rc Dc Protein Assay (Bio-Rad), and
samples were prepared such that equal amounts of protein
were to be loaded. Sample buffer (Laemmli) with 5% 2-
mercaptoethanol and 0.012% bromophenol blue was added,
followed by boiling for 5min and separation of the proteins by
gel electrophoresis on 8 or 12% polyacrylamide gels and
transfer onto a nitrocellulose membrane (Amersham Pharma-
cia Biotech, UK). Quenching and immunostaining of the blots
was performed in 5% nonfat dry milk in PBS containing 0.5%
Tween-20. The membranes were quenched for 30min,
incubated with primary antibody for 2 h, washed four times
for 5min, incubated with horseradish peroxidase-conjugated
secondary antibody for 30min, and washed ﬁve times for
5min. Detection was carried out using enhanced chemilumi-
nescence reagent (Amersham Pharmacia Biotech) as a
substrate. To control for equal loading of total lysates,
immunostaining with anti-tubulin antibody was performed
routinely (not shown).
N-terminal sequencing and mass spectrometry
N-terminal sequence analysis of a PVDF electroblotted sample
was performed on a 476A Protein sequencer. For mass
spectrometric analysis, the gel slice containing the band of
interest was excised and washed twice with 200mM ammonium
bicarbonate in 50% acetonitrile/water (20min, at 301C),
and allowed to dry at room temperature. The tube was then
chilled on ice and 8 ml of digestion buffer (50mM ammonium
bicarbonate, pH 7.8) containing 150 ng of modiﬁed trypsin
was added. The sample was kept on ice for 45min, after
which 15 ml of digestion buffer was added, followed by
overnight incubation at 371C. The supernatant was recovered,
and the peptides were extracted from the gel piece by
washing twice with 60% acetonitrile/0.1% formic acid in
water. The extracts were then combined, followed by drying
in a Speedvac centrifuge. The sample was dissolved in
0.1% formic acid and injected in an automated nano-HPLC
system (Dionex) (Devreese et al., 2002). The separated
peptides were detected on-line by an ESI-Q-TRAP mass
spectrometer (Applied Biosystems/MDS Sciex, Concord, ON,
Canada) (Hager, 2002), equipped with a nanospray ion
source (Protana, Odense, Denmark). In this method, an
automated MS to MS/MS switching protocol was used for
LC-MS/MS analysis of the peptides (Sandra et al., 2004).
Brieﬂy, ﬁrst an enhanced MS scan as survey scan (m/z
400–1500), followed by an enhanced resolution scan of the two
most intense ions was performed. If their charge state was þ 2
or þ 3, an enhanced product ion scan (MS/MS) of these ions
was performed. The total cycle time of this set-up was
approximately 4.5 s.
RT–PCR
Total RNA was extracted from approximately 5 106 cells
using the Qiagen RNEASY kit (Qiagen, Chatsworth, CA,
USA). In total, 1 mg of total RNA was reverse-transcribed with
oligo-dT primers using the Qiagen RT kit (Qiagen) according
to the manufacturer’s instructions. PCR was performed on
250 ng template cDNA using the Qiagen Taq PCR kit (Qiagen)
according to the manufacturer’s instructions. Reactions were
carried out in a Minicycler (Biozym, The Netherlands) with an
initial denaturation at 941C for 3min, 35 cycles of 941C for 50 s
(denaturation), 611C for 50 s (annealing), and 721C for 1min
(elongation), followed by a ﬁnal extension at 721C for 10min.
Table 1 lists the primers that were used.
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Retroviral transduction
FS315 was Tsp509I digested from the FS315 plasmid
construct, pSV2HF-315 (Inouye et al., 1991), and EcoRI
subcloned into the retroviral vector LZRS-IRES-EGFP. This
control vector expresses only EGFP from an IRES. The
production of retroviral supernatant was carried out as
described before (Stove et al., 2003b). Brieﬂy, the Phoenix-
Amphotropic packaging cell line (a kind gift from Dr GP
Nolan, Stanford University School of Medicine, Stanford, CA,
USA) was transfected with the LZRS-IRES-EGFP control
vector, or with LZRS-FS315-IRES-EGFP, by using calcium-
phosphate precipitation (Invitrogen, San Diego, CA, USA) to
generate the retrovirus. The retroviral supernatant was spun
(10min for 350 g) and aliquots were stored at 701C until use.
For transduction of cell lines, cells were mixed with retroviral
supernatant that was incubated for 10min with Dotap (Roche
Molecular Biochemicals, Mannheim, Germany). To increase
transduction efﬁciency, cells were spun (90min, 950 g, 321C).
Transduction efﬁciency was evaluated by ﬂow cytometry.
Cell proliferation assay
A total of 12 500 melanocytes were seeded into the wells of a 96-
well plate in 100ml DMEM medium containing 10% fetal
bovine serum. After 24 h, the cells were washed twice with
serum-free DMEM and then treated with 200ml serum-free
medium, supplemented with growth factors as indicated. After 4
days, metabolic activity was measured with a colorimetric assay,
using 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) (Sigma), as described before (Stove et al., 2003a).
Annexin V staining
150 000 melanocytes were seeded in the wells of a 24-well plate
in 1ml DMEM medium containing 10% fetal bovine serum.
After 24 h, the cells were washed twice with serum-free DMEM
and then treated for 20 h with 500ml serum-free medium,
supplemented with growth factors as indicated. After detach-
ing the cells, Annexin V staining and ﬂow cytometric analysis
were performed as described before (Stove et al., 2003a).
Luciferase reporter assay
A total of 100 000 cells were seeded per well of a 24-well plate.
After 24 h, cells were transfected with 300 ng of pGL3basic,
pGL3 control (Promega) or the CAGA luciferase reporter
construct (Dennler et al., 1998), together with 100 ng pUT
b-galactosidase reporter construct to normalize for transfec-
tion efﬁciencies. Some 24 h after transfection, cells were
treated, or left untreated, for 20 h, after which they were lysed.
After freezing the lysates for 1 h at 801C and thawing, they
were cleared from debris by centrifugation and used for
measuring luciferase- and b-galactosidase activities.
Statistics
Differences between means were considered as signiﬁcant
when the P-value was o0.05, using Student’s t-test.
Abbreviations
CM, conditioned medium; EGFP, enhanced green ﬂuores-
cence protein; FS, follistatin; IRES, internal ribosomal entry
site; LIE, LZRS-IRES-EGFP; PMA, phorbol 12-myristate 13-
acetate; TGF-b, transforming growth factor-b.
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Part II: New aspects of the role of cadherins in cancer 
 
II.1. Introduction: The cadherin/catenin system 
 
Adhesion of cells to their neighbors determines 
cellular and tissue morphogenesis and regulates major 
cellular processes including motility, growth, 
differentiation and cell survival (Conacci-Sorrell et 
al., 2002). Cadherins (Ca2+-dependent adherent 
proteins) are a superfamily of single-pass 
transmembrane glycoproteins responsible for 
calcium-dependent cell-cell adhesion in a variety of 
tissues (Gumbiner, 1996). They are characterized by 
the presence of distinctive cadherin repeat sequences 
of ± 110 amino acids in their extracellular domains. 
Cadherins typically have several of these repeats 
tandemly organized in their extracellular domain, the 
connections between these repeats being rigidified by 
the specific binding of three Ca2+ ions (Figure II.1).  
They can be classified into several subfamilies: the 
type I (classical) and type II cadherins, linked to the 
actin cytoskeleton; desmosomal cadherins 
(desmocollins and desmogleins), which are linked to 
intermediate filaments; protocadherins, expressed 
primarily in the nervous system; and several ‘atypical’ 
cadherins, containing one or more cadherin repeats, 
but bearing no other hallmarks of cadherins. Type I 
‘classical’ cadherins, which will be the main subject 
of the following discussions, include E-, N-, P- and R-
cadherin (cadherins 1-4, respectively). They have 5 
repeats (extracellular repeats EC1-5) in their 
extracellular domain, the first containing an HAV 
(histidine alanine valine) sequence in EC1. Via these 
extracellular domains, they mediate (primarily) 
homophilic protein-protein interactions. In 2002, 
Boggon et al. elucidated the crystal structure of the 
type I C(C. elegans)-cadherin ectodomain. The 
structure shows an adhesive interface involving the N-
terminal cadherin repeats of opposing cadherin 
molecules, supporting the strand-dimer model of the 
 
             
            Figure II.1. Sequence of human E-cadherin with the known functional domains. 
                  New regulatory molecules in growth and invasion of melanoma and breast cancer: cadherins, heregulin and follistatin     
 
 
70 
binding interaction between cadherin molecules (see 
Figure II.2.). In this model, the interaction interface is 
mediated by the exchange of the N-terminal β-strands 
between the partner EC1 repeats, with as a central 
feature the docking of the conserved Trp2 side chain 
from one molecule into a hydrophobic pocket (with at 
its bottom the conserved HAV sequence) of the other.  
 
Cell adhesion by cadherins is modulated by 
their conserved juxtamembrane (JMD) and catenin-
binding (CBD) cytoplasmic domains, linking them to 
the actin cytoskeleton and cell-signaling pathways. 
Catenins, namely the β-, γ-, p120- and α-catenins are 
the best-documented interaction partners (Yap et al., 
1997). β-catenin (βctn) (and perhaps also γ-catenin) 
serves as an important signaling molecule, playing a 
critical role in both tissue patterning during 
development and maintaining the normal cellular 
phenotype. Its signaling functions are regulated by its 
specific binding to the CBD of cadherins, and by 
interactions with receptor tyrosine kinases and 
transcription factors of the lymphocyte enhancer 
factor/T-cell factor family (Morin, 1999). P120-
catenin (p120ctn) is also a member of the 
Armadillo/βctn gene family and is emerging as an 
important factor regulating cadherin function. 
Originally identified as a substrate for Src (Reynolds 
et al., 1992) and various receptor tyrosine kinases 
(Downing and Reynolds, 1991), p120ctn has 
subsequently been shown to interact directly with the 
JMD of cadherins (Reynolds et al., 1994, 1996) and 
has been implicated in cadherin clustering and cell 
motility, depending on the cell type and 
phosphorylation state (Daniel and Reynolds, 1997). 
The cadherin/catenin junctional complex is linked to 
the actin cytoskeleton via α-catenin (Rimm et al., 
1995), thus strengthening its adhesive force. In 
general, differential expression of cadherins has been 
implicated in several aspects of embryonic 
development, including cell sorting during 
gastrulation and tissue morphogenesis (Gumbiner, 
1996; Tepass et al., 2000), as well as the 
establishment of a differentiated cell identity. In 
addition, cadherins have been studied extensively 
with respect to their role in carcinogenesis (Conacci-
Sorrell et al., 2002). 
 
The best-characterized cadherin, E-cadherin 
(E-cad), has been studied as a prototype molecule for 
the whole cadherin superfamily. In many different 
cancers, including breast cancer, a relationship has 
been suggested between its reduced expression and 
neoplastic progression and metastasis (Berx and Van 
Roy, 2001; Strumane et al., 2003). Bi-allelic 
inactivation of the E-cadherin gene by any 
combination of inactivating mutations in the coding 
region, loss of heterozygosity for 16q22.1, promoter 
hypermethylation and expression of trans-repressors 
(Snail, Slug, Twist, SIP1) have been demonstrated in 
various tumor types, including breast, diffuse gastric 
and hepatocellular carcinomas. Also mutation of other 
components of the cadherin/catenin system (e.g. 
mutation of α-catenin) may result in inactivation of 
the complex. Furthermore, posttranslational 
modifications of components of the cadherin/catenin 
system, including phosphorylation, glycosylation and 
proteolytical processing, may affect the functionality 
of the complex as well (reviewed by Strumane et al., 
2003). Finally, even when E-cadherin remains present 
in tumors, its function of an invasion suppressor may 
be overcome by the aberrant expression or 
upregulation of other cadherins, as has been shown 
for N-cadherin (N-cad) (Hazan et al., 2000) and 
cadherin-11 (Feltes et al., 2002). These cadherins 
have been associated with development or 
progression of breast carcinoma and are thought to 
interfere with E-cad mediated cell-cell adhesion, 
hamper its signaling and/or lead to activation of 
alternative signaling pathways (Yap and Kovacs, 
2003). 
 
The four manuscripts in this chapter describe 
novel features of the cadherin/catenin system in breast 
cancer and melanoma. A first manuscript, linking the 
previous chapter with the present, describes the pro-
aggregating and anti-invasive effects of conditioned 
medium from a melanoma cell line on MCF-7/6 cells, 
harboring a functionally deficient E-cadherin/catenin 
complex. These effects could, at least partly, be 
attributed to the secretion of heregulin by the 
 
Figure II.2. Schematic representation of the strand 
dimer model, based on the model proposed by 
Boggon et al (2002). Represented are the trans 
interactions between cadherin molecules of opposing 
cells (EC1-EC1) and the cis interactions between 
cadherin molecules on the same cell (EC1-EC2) 
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melanoma cells. In a second manuscript, we studied 
the functional role of a classical cadherin, P-cadherin, 
in aggregation and invasion of melanoma cells. The 
last two manuscripts describe two novel ways of 
interference with the invasion-suppressor function of 
E-cadherin. In the first of these we studied the 
upregulation of P-cadherin in breast cancer cells in the 
absence of estrogen signaling and the subsequent 
promotion of invasion, mediated by the P-cadherin 
juxtamembrane domain. The last manuscript 
describes the action of a proteolytically generated E-
cadherin ectodomain fragment, which is capable of 
counteracting cell-cell adhesion and inducing 
invasion.  
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SUMMARY 
 
Invasiveness, the ability of cancer cells to migrate 
beyond the normal tissue boundaries, often leads 
to metastasis and thereby usually turns cancer 
into a fatal disease. At the molecular level, the E-
cadherin/catenin complex is an example of a 
powerful invasion suppressor in epithelial cells. 
Since the absence of melanocytes has been 
associated with disturbances in epithelial 
organization, we decided to investigate the 
influence of molecules secreted by melanocytes on 
the function of the E-cadherin/catenin complex. 
We used the Bowes melanoma cell line as a source 
of such molecules. The conditioned medium of 
Bowes melanoma stimulated aggregation of 
human MCF-7/6 mammary adenocarcinoma cells 
at short (30 min) and at long (24 to 72 h) notice. 
This effect could be inhibited by MB2, an 
antibody against human E-cadherin. Conditioned 
medium of Bowes melanoma also inhibited 
invasion of MCF-7/6 cells into precultured chick 
heart fragments. Candidate molecules, such as 
insulin, insulin-like growth factor I, follistatin and 
interleukins were ruled out to be responsible for 
the effects, but heregulin mimicked some of the 
effects of the conditioned medium. Our data 
indicate that heregulin stimulates aggregation and 
inhibits invasion of MCF-7/6 cells via activation of 
the E-cadherin/catenin complex.  
 
 
 
INTRODUCTION  
 
The acquisition of invasive and metastatic 
behavior is the hallmark of cancer malignancy. 
Previous experiments have shown a key role for the 
                                                 
Abbreviations used are: CM, conditioned medium; HER, human 
epidermal growth factor-like receptor; HRG, heregulin; IGF-I, 
insulin-like growth factor-I; IGFBP, IGF-binding protein 
 
E-cadherin/catenin complex in epithelial organization 
during normal development and in the regulation of 
the invasive behavior of cancer cells1-3. The cell-cell 
adhesion molecule E-cadherin is a 120 kD 
transmembrane glycoprotein linked to the actin 
cytoskeleton via β-catenin or plakoglobin and α-
catenin4. β-Catenin is an intracellular 94-kDa 
molecule with 13 armadillo repeats5. These repeats 
are also present in plakoglobin. α-Catenin is an 
intracellular 102-kDa molecule with strong homology 
to vinculin6. Downregulation of the E-
cadherin/catenin complex or of its function has 
proven to be a key element in the acquisition of the 
invasive phenotype in experimental and clinical 
cancer7. Up- and downregulation of the E-
cadherin/catenin complex is sensitive to external 
factors and has been described previously8. 
Intercellular junctions may also be disturbed in non-
cancerous epithelia, e.g. in Waardenburg’s syndrome. 
This is an autosomal-dominant disorder characterized 
by sensorineural hearing loss, displacement of the 
inner canthus of the eyes and pigmentary 
disturbances due to absence of melanocytes9. The 
absence of melanocytes seems to interfere with the 
cochlear morphogenesis: in a mouse model 
ultrastructural cell-cell contact specializations in the 
epithelium are lacking and this absence is responsible 
for auditory dysfunctions10. We, therefore, wondered 
if melanocytes could produce factors that promote the 
epithelial organization. We also wanted to investigate 
if this effect on epithelia was E-cadherin/catenin-
mediated and might, by consequence, also have 
implications for the invasive behavior of cancer cells. 
Since the culture of melanocytes requires the 
presence of insulin, a molecule already known to 
activate the E-cadherin/catenin complex11, we chose 
an insulin-independent melanoma cell line, coined 
Bowes, as a possible source of such factors. As a 
target for the study of the effects on cell-cell adhesion 
and invasion, we used the human MCF-7/6 mammary 
adenocarcinoma cell line. This is a variant of the 
MCF-7 family that is invasive in the chick heart 
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invasion assay, and displays poor cell-cell adhesion 
in aggregation assays in suspension, due to a 
defective function of the E-cadherin/catenin 
complex12. In this study, we present evidence that 
Bowes melanoma cells produce a factor that 
stimulates E-cadherin-dependent aggregation of 
MCF-7/6 cells, and abrogates the invasive potential 
of those cells. Different candidate molecules were 
considered, among which heregulin appeared to be 
one of the responsible factors. 
 
 
 
MATERIALS AND METHODS 
 
Cell lines and culture media 
Human Bowes melanoma cells13, a gift from G. Opdenakker 
(Department of Molecular Immunology, Rega Institute for Medical 
Research, Leuven, Belgium) and human MCF-7/6 breast 
adenocarcinoma cells (provided by H. Rochefort, Unité d' 
Endocrinologie Cellulaire et Moléculaire, Montpellier, France) 
were cultured in a 50:50 mixture of D-MEM and HAMF12 
(Invitrogen, Merelbeke, Belgium) supplemented with 10 % fetal 
bovine serum (Invitrogen), 100 IU/mL penicillin (Invitrogen), 100 
µg/mL streptomycin (Invitrogen) and 2.5 µg/mL amphotericin B 
(Bristol-Meyers Squibb, Brussels, Belgium) in an atmosphere of 
10 % CO2 in air. For subcultivation, Bowes melanoma cells were 
brought into suspension by vigorous shaking. All cells were tested 
for mycoplasma contamination by staining with 4',6-diamidino-2-
phenylindole (DAPI) and found to be negative.  
Conditioned medium from Bowes melanoma 
(CM Bowes melanoma) was obtained as follows. Cells were grown 
to confluence in 75 cm2 tissue culture plastic vessels (Becton 
Dickinson, New Jersey). The medium was removed, and 10 mL of 
fresh D-MEM/HAM F12 culture medium was added. When 
serum-free CM was needed, the cells were first washed three times 
with phosphate buffered saline (containing calcium and 
magnesium) for 5 min. Cells were kept in culture for two 
additional days, and then the medium was harvested, centrifuged at 
2,000 x g for 30 min and filtered through a 0.22 µm filter to 
eliminate any possible cell particles. This medium was used 
directly, or frozen at -20°C for later use.  
 
Antibodies and other products 
HECD-I (Takara, San Diego) and affinity purified MB211 are both 
murine monoclonal anti-E-cadherin antibodies. PY20 (ICN, Costa 
Mesa, California) is a murine monoclonal anti-phosphotyrosine 
antibody. αIR3 (Calbiochem, San Diego, California) is a murine 
monoclonal antibody against the insulin-like growth factor-(IGF)-
I-receptor β-subunit. Secondary antibodies for immunoblotting 
were alkaline phosphatase-labeled rabbit polyclonal anti-mouse-
IgG and goat polyclonal anti-rabbit-IgG (both from Sigma, St.-
Louis, Missouri). IGF-I was obtained from Boehringer 
Bioproducts (Verviers, Belgium). A mixture of human interleukins 
and chemokines (a gift from Dr J. Van Damme, Department of 
Molecular Immunology, Rega Institute for Medical Research, 
Leuven, Belgium) was prepared by stimulation of Malavu cells 
with 12-O-tetradecanoylphorbol-13-acetate (TPA) (100 ng/mL) 
and interleukin (IL)-1 (10 ng/mL). This resulted in secretion of IL-
6 (25,000 U/mL) and IL-8 (1,300 ng/mL). Recombinant heregulin-
β1, consisting of the epidermal growth factor-like domain of 
heregulin, was purchased from R&D Systems (Abingdon, U.K.). 
Polyclonal antibodies against chick heart were used as described 
earlier14. 5D10 is a murine monoclonal antibody against MCF-7 
cells15. PD168393 was obtained from Calbiochem.  
 
Aggregation Assays 
Slow Aggregation Assay 
In suspension: 100,000 cells per mL were added to 50 mL-
Erlenmeyer flasks in 6 mL medium containing the test agents16. 
The flasks were incubated on a Gyrotory shaker (New Brunswick 
Scientific Co., New Brunswick, NJ) at 72 rpm, and continuously 
gassed with humidified CO2 (10 %) in air. Aggregate formation 
was evaluated under a Macroscope (Wild, Heerbrugg, Switzerland) 
at a magnification 25x after 4 days. On photographs the larger (a) 
and the smaller (b) diameter of 12 aggregates were measured, and 
apparent volumes (v) were calculated in accordance with the 
formula of Attia and Weiss17: v = 0.4 x a x b2. Statistical analysis 
was performed with StatView 4.1 for Macintosh software (Abacus 
Concepts, Inc., Berkeley, California).  
On semi-solid substratum: 20,000 MCF-7/6 cells in 200 µL 
medium were seeded on solidified agar in a 96-well-plate, and 
treated with the test agents18. Aggregate formation was evaluated 
under an inverted microscope after 24 and 48 h. 
 
Fast Aggregation Assay 
A fast aggregation assay was used as described earlier18. Cells 
were pretreated with CM Bowes melanoma for 24 h and detached 
in accordance with an “E-cadherin-saving” procedure19. The cell 
suspension was then treated further with CM Bowes melanoma for 
30 min at 4°C and incubated in BSA-coated wells at 37°C for 30 
min under shaking. Untreated cells were incubated in fresh 
medium. Cells were fixed and the particle size distribution was 
measured with a Coulter Particle Size Counter LS 200 (Coulter 
Company, Miami, FL). The diameter of the particles can be 
considered as a measure for aggregate formation. Statistical 
analysis of differences between the particle size distribution curves 
was done with the Kolmogorov-Smirnov method.  
In all aggregation assays, E-cadherin specificity of the aggregation 
was demonstrated with a functionally blocking antibody against E-
cadherin (MB2 at 2 µg/mL)20. 
 
Chick heart invasion assay in vitro 
The chick heart invasion assay was used as described earlier16,21. 
Briefly, heart fragments of 9-day old chick embryo's were 
precultured for 4 days (PHF) and then confronted with tumor cells 
under continuous Gyrotory shaking. Tumor cells were applied as 
monolayer fragments (Bowes melanoma) or as aggregates (MCF-
7/6). For double confronting cultures, Bowes melanoma and MCF-
7/6 cells were simultaneously confronted with the chick heart 
fragments. The individual confrontations were fixed in Bouin-
Hollande’s solution after 4, 7 or 11 days of incubation. They were 
afterwards embedded in paraffin, serially sectioned and stained 
with hematoxylin-eosin. Immunohistochemistry with antibodies 
against the chick heart and the MCF-7/6 cells was performed as 
described earlier14.  
 
Measurements of insulin and IGF-I 
Insulin in CM Bowes melanoma was measured with the 
radioimmunoassay kit INS-RIA-100 (Medgenix Diagnostics, 
Brussels, Belgium). The minimal detectable concentration of 
insulin is 3.6 µU/mL. IGF-I in CM Bowes melanoma was 
determined with the IRMA kit Active™ IGF-I (Diagnostic 
Systems Laboratories, Webster, Texas). The minimal detectable 
concentration of IGF-I is 4 ng/mL.  
 
Phosphorylation of the IGF-I receptor and analysis of total 
tyrosine phosphorylation 
Phosphorylation of the IGF-I receptor was determined as described 
earlier22. Briefly, cells were labeled with 500 µCi/mL HCl-free 32P-
orthophosphate (ICN) and incubated with the test agents during 10 
min up to 24 h. After washing in PBS, cells were treated with lysis 
buffer containing 1 % Triton X-100 and 1 % Nonidet P40 in PBS, 
with the protease inhibitors leupeptin (ICN), aprotinin (ICN) and 
phenylmethylsulfonyl fluoride (PMSF) (Sigma) and the 
phosphatase inhibitors NaVO3, Na4P2O7 and NaF (all from 
Sigma). Equal amounts of trichloroacetic acid (TCA)-precipitable 
radioactive protein material were precleared with Protein G 
Sepharose CL-4B beads (Pharmacia Biotech AB, Uppsala, 
Sweden) and antiphosphotyrosin antibody PY-20 was added, 
followed by Protein G Sepharose beads. After elution of tyrosine-
phosphorylated proteins with excess phospho-L-tyrosine, αIR3 
antibody was added to the elutes, followed by Protein G Sepharose 
CL-4B beads. After washing, the immune complexes were 
extracted with Laemmli buffer and boiled for 5 min. The 
centrifuged supernatants were analyzed by SDS-polyacrylamide 
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(7.5 %) gel electrophoresis under reducing (mercapto-ethanol) 
conditions. After electroblotting, Hyperfilm MP (Amersham, 
Buckinghamshire, UK) was exposed to the membranes and 
developed. Blot membranes were immunostained afterwards to 
confirm the identity of the bands appearing on the film. 
For analysis of total tyrosine phosphorylation, Western Blotting 
and immunostaining was performed as described before23. 
 
Ligand blot assay for IGF-binding proteins 
IGF-binding proteins (IGFBP) were evaluated by ligand blotting as 
described earlier22. Briefly, cells were washed 5 times with serum-
free medium followed by incubation in serum-free medium for 48 
h. The conditioned medium was dialyzed against 1.5 mM Tris, and 
concentrated 100 times by lyophilisation. Lyophilized proteins 
were denatured with sodium dodecyl sulphate under non-reducing 
conditions, separated on a 12 % polyacrylamide gel and 
electroblotted. IGFBP were visualized by autofluorography after 
binding of [125I]-IGF-I (Amersham).  
 
 
 
RESULTS 
 
Effect of CM Bowes melanoma on aggregation 
In slow aggregation assays in suspension or on 
semi-solid substratum, untreated MCF-7/6 cells 
formed small and irregular aggregates. This limited 
aggregate formation could be inhibited by MB2, an 
antibody against E-cadherin. Treatment of MCF-7/6 
cells with CM Bowes melanoma stimulated 
aggregate formation in both types of assays. The 
diameter of the aggregates was larger in comparison 
with the untreated MCF-7/6 cells, and their aspect 
was more compact. In suspension, after 4 days, 
untreated MCF-7/6 cells formed aggregates with a 
mean apparent volume of 79.0 mm3 (standard 
deviation = 23.6 mm3). Cells treated with 20 % CM 
Bowes melanoma formed aggregates with a mean 
apparent volume of 827.5 mm3 (standard deviation = 
372.1 mm3). Treatment with 50 % CM Bowes 
melanoma resulted in a mean apparent aggregate 
volume of 1553.4 mm3 (standard deviation = 653.6 
mm3). Differences between all three groups were 
statistically significant (P < .0001, except for the 
comparison 20 % versus 50 % CM Bowes melanoma 
where P = .0038, Student’s t-test). In presence of CM 
Bowes melanoma plus MB2, aggregate formation 
was abrogated and the cells remained single. Similar 
results were obtained in cultures on semi-solid 
substratum after 24 h (Figure 1). CM Bowes 
melanoma did not stimulate the aggregation of MDA-
MB-231, an E-cadherin-negative cell line24. In line 
with this, the aggregation of the human colon 
carcinoma cell line HCT-8/E11, expressing the 
complete E-cadherin/catenin complex, was 
stimulated, whereas no effect was seen on the 
aggregation of HCT-8/E11R1, an α-catenin-negative 
variant of this cell line (data not shown)25. 
In a fast aggregation assay, the particle size 
distribution profiles showed limited spontaneous 
aggregation of MCF-7/6 cells after 30 min incubation 
in suspension. This aggregation was calcium-
dependent and could be prevented by the monoclonal 
anti-E-cadherin antibody MB2. CM Bowes 
melanoma, diluted 1:3, stimulated aggregate 
formation of MCF-7/6 cells within 30 min. This was 
observed as a shift of the particle size distribution 
curve towards the larger particle diameters (Figure 
 
 
Figure 1. Phase contrast micrographs of MCF-7/6 aggregates on 
soft agar (after 24 h), untreated (a), treated with 20 % CM 
Bowes melanoma (b), treated with 50 % CM Bowes Melanoma 
(c) and treated with 50 % Bowes Melanoma plus MB2 diluted 
1:20 (d). Scale bar = 200 µm 
 
 
 
Figure 2. Volume percentage distribution plotted against the diameter 
of MCF-7/6 aggregates. Measurements were done after 0 min 
(broken line, ---) and after 30 min (full lines, —), either untreated 
(without symbol), treated with CM Bowes melanoma (open circles) 
or treated with CM Bowes melanoma and MB2 (filled circles). The 
curve of the cells treated with CM Bowes melanoma at 0 min 
coincided with the curve of the untreated cells at 0 min (not shown).
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2). The mean particle diameter of the untreated MCF-
7/6 cells was 41.8 µm (standard deviation = 29.9 
µm), while the mean particle diameter of the MCF-
7/6 cells treated with CM Bowes melanoma was 
110.4 µm (standard deviation = 63.8 µm). 
Kolmogorov-Smirnov statistics were applied to prove 
the statistical significance of this shift (P < .001). In 
presence of MB2, the effect of CM Bowes melanoma 
was absent. The rapid pro-aggregating effect of the 
CM (occurring within 30 minutes) suggested that 
protein synthesis did not play a role in the observed 
response. To confirm this, MCF-7/6 cells were 
pretreated for 1 hour with the translational inhibitor 
cycloheximide at 20 µg/ml, a concentration known to 
inhibit protein synthesis. Addition of Bowes 
melanoma CM to these cycloheximide-pretreated 
cells in the aggregation assay still resulted in an 
increase in cell-cell adhesion, suggesting that CM 
Bowes melanoma activates the E-cadherin/catenin 
complex in a post-translational way (Figure 3). 
 
 
Effect of Bowes melanoma and CM Bowes 
melanoma on invasion of MCF-7/6 cells in chick 
heart fragments 
In untreated confronting cultures, MCF-7/6 
cells had invaded the PHF after 8 days of incubation 
(Figure 4a). Histological sections stained with 
haematoxylin-eosin showed MCF-7/6 cells 
occupying and replacing the PHF. 
Immunohistochemical staining with antibodies 
against the chick heart tissue and the MCF-7/6 cells 
(5D10) confirmed this observation. Treatment of the 
confrontations with CM Bowes melanoma in a 
dilution 1:3 resulted in absence of invasion by the 
MCF-7/6 cells. The MCF-7/6 cells formed a regular 
epithelioid layer around the PHF and no MCF-7/6 
cells were found inside the heart tissue (Figure 4b). 
Bowes melanoma cells confronted separately with 
the chick heart fragments invaded spontaneously. 
When MCF-7/6 and Bowes melanoma cells were 
simultaneously confronted with the chick heart 
fragments, in equal numbers, MCF-7/6 cells formed 
an epithelioid layer around the chick heart and did 
not invade, while Bowes melanoma were found 
inside the chick heart fragments (Figure 4c, d and e).  
 
 
Responsible factors 
We analyzed CM Bowes melanoma for the 
presence of factors that were proven to upregulate the 
function of the E-cadherin/catenin complex in MCF-
7/6 cells in previous experiments8. With a 
Radioimmunoassay kit, having a detection limit of 
3.6 µU/mL, no insulin was found in CM Bowes 
melanoma. With an IRMA-test we found small 
concentrations (around 10 ng/mL) of insulin-like 
growth factor I (IGF-I). These concentrations are 
slightly above the detection limit of the assay (4 
ng/mL). To investigate if the IGF-I receptor could be 
activated at this concentration, we treated MCF-7/6 
cells with CM Bowes melanoma or 10 ng/ml of pure 
IGF-I and checked the phosphorylation status of the 
IGF-I receptor after 24 or 48 hours. As a positive 
control, MCF-7/6 cells were treated for 10 minutes 
with 500 ng/mL of IGF-I22. Whereas phosphorylation 
was evident after both 24h and 48h treatment with 10 
 
 
 
Figure 3. Volume percentage distribution plotted against the 
diameter of MCF-7/6 aggregates. Measurements were done after 0 
min (0)  and after 30 min (30) of MCF-7/6 aggregates pretreated 
(c) or not (-) with cycloheximide, and then treated either with 
serum free medium (s) or with CM Bowes melanoma (b) 
 
 
Figure 4. Light micrographs of sections from 8-day old 
confronting cultures between PHF and MCF-7/6 cells. An 
untreated confrontation (a) is compared with a confrontation 
treated with CM Bowes melanoma (diluted 1:3) (b) or 
simultaneous confrontations with Bowes melanoma cells (c, d and 
e). The sections were stained with hematoxylin-eosin (c), anti-
chick heart antibody (d) or 5D10 against MCF-7/6 cells (a, b and 
e). Panel e shows the MCF-7/6 cells that are not invading the PHF 
which is totally destroyed (panel d) by the Bowes melanoma cells 
visible on the hematoxylin-eosin staining in panel c. Scale bar = 50 
µm.  
New regulatory molecules in growth and invasion of melanoma and breast cancer: cadherins, heregulin and follistatin 
79 
ng/ml IGF-I, treatment with CM Bowes melanoma 
for 10 min, 24 or 48 h, did not result in 
phosphorylation of the IGF-IR in MCF-7/6 cells 
(Figure 5A). In a parallel experiment, this CM was 
found to be biologically active, since it stimulated 
aggregate formation of MCF-7/6 cells. The lack of 
IGF-I receptor phosphorylation by CM Bowes 
melanoma may be explained by the secretion of IGF-
binding proteins (IGFBP) by these cells. Binding of 
IGF-I to IGFBP’s usually results in prevention of 
IGF-I binding to its receptor and hence inhibition of 
receptor activation. We therefore checked IGFBP 
secretion by Bowes melanoma cells using a ligand 
blot assay with [125I]-IGF-I. As a control, medium 
conditioned by MCF-7/6 cells was used. Based on 
molecular weight, MCF-7/6 cells were found to 
produce IGFBP-2 (34 kD), IGFBP-5 (29-32 kD) and 
IGFBP-4 (24 kD) (Figure 5B, lane 2), in accordance 
with findings by others26,27. In CM Bowes melanoma, 
IGFBP-4 could not be detected, there was a stronger 
band for IGFBP-5 and a less prominent band for 
IGFBP-2 than in CM MCF-7/6 (Figure 5B, lane 3). 
Fetal bovine serum showed a faint band representing 
IGFBP-5 (not shown) and no band was detected in 
fresh D-MEM/HAM F12. Thus, the lack of IGF-IR 
phosphorylation by CM Bowes melanoma may be 
attributed to the inactivation of IGF-I by the 
concomitant secretion of (mainly) IGFBP-5 by these 
cells. To exclude that certain interleukins were 
responsible for the effect, we added an interleukin-
mix (containing interleukin-1, -6, -8) to MCF-7/6 
cells in a slow aggregation assay. No stimulation of 
aggregation could be observed (data not shown). 
Recently, we reported the secretion of 
heregulin by Bowes and other melanoma cell lines. 
Heregulin in CM Bowes melanoma was able to 
phosphorylate the 185 kD human epidermal growth 
factor-like receptor 2 and 3 (HER2 and 3) in MCF-
7/6 cells (Figure 6A)23. Human recombinant 
heregulin-β1 (rHRG-β1) could mimic the effect of 
CM Bowes on invasion: treatment with 50 ng/ml 
rHRG-β1 inhibited invasion of MCF-7/6 cells into 
PHF, and yielded histological images similar to those 
obtained with CM Bowes (Figure 6B). Moreover, this 
heregulin concentration also stimulated cell 
aggregation of MCF-7/6 cells in the slow aggregation 
assay (Figure 7A and 7C, left panels), despite the fact 
that on solid substratum both rHRG-β1 and Bowes 
melanoma CM induced scattering of epithelial MCF-
7/6 islands (Figure 7B). Since transfection of Bowes 
melanoma with an antisense HRG construct yielded 
no colonies and since none of the anti-HRG 
antibodies we tested could fully block HRG-induced 
phosphorylation (data not shown), we used a specific, 
irreversible HER inhibitor, PD16839328, to evaluate 
whether heregulin was the only factor responsible for 
increased aggregation of MCF-7/6 cells. PD168393 
fully prevented the rHRG-β1-mediated increase in 
aggregation of MCF-7/6 cells, without affecting 
control aggregation (Figure 7C, right panels). 
However, this inhibitor could nut fully prevent the 
increase in aggregation by CM Bowes melanoma, 
suggesting that additional pro-aggregating factors 
A 
            Untr           CM 
 
Figure 6. (A) Antiphosphotyrosine immunoblotting of total lysates
of MCF-7/6 cells, left untreated (Untr) or treated for 30’ with CM
Bowes melanoma (CM). A prominent tyrosine-phosphorylated
band appears at 185kD. (B) Light micrographs of hematoxyline-
eosine stainings of sections from 8-day old confronting cultures
between PHF and MCF-7/6 cells, left untreated (Untr) or treated 
with 50ng/ml HRG-β1. Scale bar = 50µm 
 
B 
 
A 
 
 
B 
 
 
Figure 5. 
(A) Fluorographs of a sequential immunoprecipitation with PY20 
and _IR3 antibodies of the beta subunit of the IGF-IR in MCF-7/6 
cells labelled with 32P and treated with IGF-I or CM Bowes 
melanoma. Lanes a are from cells treated with CM Bowes 
melanoma, lanes b are from cells treated with IGF-I. Treatment 
periods were 10 min (lanes 1), 24 h (lanes 2) and 48 h (lanes 3). 
The IGF-I concentration was 500 ng/mL for lane 1b and 10 
ng/mL for lanes 2b and 3b. Figures indicate molecular weight in 
kDa. 
(B) Fluorographs of a ligand blot of IGFBPs detected with [125I]-
IGF-I. Examined samples are CM MCF-7/6 (lane 1), CM Bowes 
Melanoma (lane 2) and fresh D-MEM/HAM F12 medium (lane 
3). Figures indicate molecular weight in kDa.   
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may be present in the CM. In agreement with the 
presumption that HRG secretion by Bowes 
melanoma is not sufficient to explain all of its effects, 
is the inability of rHRG-β1 to promote cell 
aggregation of MCF-7/6 in the fast aggregation assay 
(Figure 8). In conclusion, although for some of the 
observed effects on MCF-7/6 cells the cooperation 
with a synergizing factor may be necessary, HRG 
secretion by Bowes melanoma cells is sufficient for 
its anti-invasive and pro-aggregating effects on long 
term.  
 
 
DISCUSSION 
 
Our data show that Bowes melanoma cells 
produce a factor that stimulates aggregation and 
abrogates invasion of human MCF-7/6 mammary 
cancer cells in vitro. Our experiments were inspired 
by the finding that melanocytes play a role in the 
normal development of the mammalian inner ear. In 
mutant mice, with a primary neural crest defect 
leading to absence of recognizable melanocytes, 
transmission electron microscopy revealed cell-cell-
contact defects between the cells of the stria 
vascularis10. A similar syndrome has been found in 
humans and is known as Waardenburg’s syndrome. 
There also, the absence of human melanocytes seems 
to be the key event. We chose Bowes melanoma cells 
as candidate-producers of factors that might modulate 
epithelial cell-cell interactions in vitro. In a number 
of aggregation assays we observed that CM Bowes 
melanoma was able to increase the aggregation of 
MCF-7/6 cells. These human mammary carcinoma 
cells are a variant of the MCF-7 family and express 
all the elements of the E-cadherin/catenin complex, 
but the function of the complex is impaired 
depending on the culture conditions12. When cultured 
on solid substratum, the epithelial organization of the 
cells is intact and the complex is evidently active. 
However, when the cells are detached from their 
substratum, they display poor aggregate formation 
 
Figure 7. Phase contrast micrographs of MCF-7/6 aggregates (A) in suspension (after 3 days) or (C) on soft agar (after 48 h), left untreated 
(untr), treated with CM Bowes melanoma (CM), or treated with 50ng/ml rHRG-β1 (HRG), in combination or not with 2µM PD168393.  
(B) Phase contrast micrographs of serum-starved MCF-7/6 cells, treated for 2 hours with serum free medium (untr), with CM Bowes 
Melanoma (CM) or with 50ng/ml rHRG-β1. Scale bars = 100 µm. 
 
 
Figure 8. Volume percentage distribution plotted against the diameter 
of MCF-7/6 aggregates. Measurements were done after 0 min (0) and 
after 30 min (30) of MCF-7/6 aggregates treated either with serum free 
medium (Untr), with 50ng/ml rHRG-β1 in serum free medium (HRG) 
or with CM Bowes melanoma (CM). 
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and clear cut invasive behavior in various in vitro 
invasion systems11,12. Interestingly, the complex is 
still active to some extent, since the remaining 
aggregation can be abrogated completely by MB2, a 
monoclonal antibody against E-cadherin. Treatment 
of MCF-7/6 with CM Bowes melanoma resulted in 
increased aggregate formation in the three types of 
aggregation assays mentioned. The effects on 
stimulation of aggregation were E-cadherin-
mediated, as proven by inhibition experiments with 
MB2. These data show that CM Bowes melanoma 
increases aggregation of MCF-7/6 cells and that this 
effect is due to functional upregulation of the E-
cadherin/catenin complex. By calculating apparent 
volumes, we were able to quantify and statistically 
prove this effect. The E-cadherin/catenin complex is 
not only implicated in cell-cell adhesion, but also has 
a powerful invasion-suppressor function in epithelial 
cells2. Our results demonstrate that upregulation of 
the complex with CM Bowes melanoma leads to 
inhibition of invasion, as evidenced in the chick heart 
assay. MCF-7/6 cells do no longer invade into the 
chick heart when they are treated with CM Bowes 
melanoma. Another explanation could be that CM 
Bowes melanoma enhances the resistance of the 
chick heart towards invading cells. However, the 
double confrontation cultures (with MCF-7/6 and 
Bowes melanoma cells used at the same time) render 
this possibility unlikely: the melanoma cells still 
invade the chick heart while the MCF-7/6 cells form 
an epithelioid layer around the chick heart, without 
any sign of invasion. This shows that the anti-
invasive effect of CM Bowes melanoma is exerted by 
influencing the MCF-7/6 cells, and not the chick 
heart.  
As far as the responsible factor is concerned, we can 
consider the implication of certain molecules as 
improbable. The effects presented resemble those that 
have been described for a number of molecules that 
are able to functionally up-regulate the E-
cadherin/catenin complex. Examples are: 
tamoxifen29, insulin and IGF-I11, retinoic acid22 and 
tangeretin30. However, the presence of any of those 
compounds was either unlikely (tamoxifen, 
tangeretin and retinoic acid) or undetectable (insulin). 
Although small amounts of IGF-I, or a molecule 
immunologically recognized as such, may be secreted 
by Bowes melanoma cells, no detectable 
phosphorylation of the IGF-I-receptor occurred 
following treatment with the CM. Most likely, this is 
due to the concomitant secretion of IGF binding 
proteins (IGFBP-5) by the melanoma cells, since an 
equivalent concentration of pure IGF-I did lead to 
receptor activation. Since phosphorylation of the 
receptor was previously found to be indispensable for 
the activation of the signal transduction pathway 
towards the E-cadherin/catenin complex11, it is 
unlikely that IGF-I or IGF-I-like molecules are 
implicated. Previous studies31 have described that 
melanomas can produce cytokines, like interleukins, 
tumor necrosis factor-alpha, transforming growth 
factor-beta, granulocyte-macrophage-colony 
stimulating factor and stem cell factor. However, 
most of these molecules do not alter the function of 
the E-cadherin/catenin complex in MCF-7 cells32. 
Furthermore, as treatment with an interleukin mixture 
did not result in stimulated aggregation of the cells, 
we further could exclude interleukin-1, -6 and -8 as 
responsible factors. 
Heregulin (HRG) fits into the profile of the candidate 
factor in CM Bowes. Bowes melanoma cells 
synthesize at least 4 heregulin isoforms, heregulin 
was detected in their CM23, and addition of rHRG-β1 
to MCF-7/6 cells activated the E-cadherin/catenin 
complex, resulting in promotion of slow cell 
aggregation and inhibition of invasion in the chick 
heart assay. An aggregation-promoting effect of HRG 
has already been described by Tan et al33. However, 
since there the improved aggregation could take place 
at 4°C and was also seen in E-cadherin-negative 
breast cancer cells, it was independent of E-cadherin. 
Some data indicate that heregulin may not be the only 
anti-invasive factor in CM Bowes: in contrast to CM 
Bowes, recombinant heregulin failed to promote fast 
aggregation of MCF-7/6 cells, and a selective 
heregulin receptor tyrosine kinase inhibitor 
(PD168393)24 was unable to fully block slow cell 
aggregation after treatment with CM Bowes, but did 
so upon heregulin treatment. Moreover, recent data 
indicate that E-cadherin can exert its anti-invasive 
effect without promotion of cell-cell adhesion34.  We 
cannot exclude that other factors in CM Bowes act 
synergistically with heregulin, as it was recently 
shown for retinoids in a model for branching 
morphogenesis of breast cancer cells in collagen 
gels35. It should be noted that retinoic acid on itself is 
an anti-invasive agent for MCF-7/6 cells in the chick 
heart assay12, although no evidence could be found 
that the activating effect on the E-cadherin/catenin 
complex was responsible for the inhibition of 
invasion22. 
As for a number of other molecules such as 
estradiol36,37 and IGF-I38, it is not evident to reconcile 
the established motogenic effect of heregulin with its 
anti-invasive effect. In particular, the inactivating and 
downregulating effects of heregulin on the E-
cadherin/catenin complex leading to cell scattering 
appear to be in contradiction with its effect on 
aggregation and invasion. However, two points 
should be considered here. First, the effects are 
clearly dependent on the models used, since for 
MCF-7/6 cells heregulin induces scattering on a 
tissue culture plastic substratum (Figure 7B, 23) and 
promotion of aggregation in suspension culture. 
Second, triggering of the E-cadherin/catenin complex 
can activate the small GTPase rac, and hence induce 
the formation of lamellipodia, a kind of motility 
meant to achieve additional cell-cell contacts that 
eventually result in the formation of compact 
epithelia39. 
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In conclusion, the human melanoma cell line Bowes 
secretes one or more factors that can upregulate the 
function of the E-cadherin/catenin complex and 
inhibit invasion of the human breast carcinoma cells 
MCF-7/6. Most probably heregulin is responsible for 
these activities, although additional factors cannot be 
excluded. 
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II.3. The role of cadherins in melanocyte physiology and in human 
melanoma 
 
II.3.1. Cell adhesion molecules in 
human melanoma 
Cell adhesion molecules belonging to the 
integrin, immunoglobulin and cadherin superfamilies 
have been implicated in cutaneous melanoma. Altered 
expression of many of these cell-cell or cell-matrix 
adhesion molecules is frequently observed during 
tumor progression. 
Integrins are heterodimeric cell surface 
receptors formed by non-covalent association of an α 
chain with a β chain. At least 20 different α and 9 
different β chains have been identified to date. These 
mediate cation dependent adhesion to extracellular 
matrix molecules and to cell surface ligands. Aberrant 
expression of integrins has been associated with 
cancer progression in multiple malignancies, 
including melanoma (Keely et al., 1998; Seftor et al., 
1999; Hood and Cheresh, 2002). As compared to 
benign melanocytic lesions, malignant melanomas 
demonstrate a loss of expression of the laminin 
receptor α6β1 (Natali et al., 1991). Increased 
expression of α4β1 (also known as CD49d/CD29 and 
VLA-4), which may mediate interaction of the tumor 
cells with VCAM-1 (vascular cell adhesion molecule-
1) on vascular endothelium, has been associated with 
metastatic properties of melanoma cells Martin-
Padura et al., 1991; Schadendorf et al., 1995). 
Upregulation of the β3 chain, leading to high levels of 
the vitronectin receptor αvβ3 integrin is another 
frequent event in melanoma progression (Albelda et 
al., 1990). The β3 integrin chain is exclusively 
expressed in vertical growth phase and metastatic 
melanomas and correlates with proliferation (Felding-
Habermann et al., 1992), invasion (Seftor et al., 1992; 
Van Belle et al., 1999), recurrence and mortality 
(Hieken et al., 1996). Expression of the β3 integrin 
allows the cells to interact with denatured collagen, 
improving survival and proliferation (Montgomery et 
al., 1994; Petitclerc et al., 1999), and leads to 
enhanced matrix metalloproteinase (MMP) expression 
(Hofmann et al., 2000). Moreover, an important role 
for αvβ3 integrin in angiogenesis has been suggested 
(Friedlander et al., 1995). Despite this extensively 
described role for β3 integrin, it cannot, when 
overexpressed alone, promote the progression of 
melanocytes to melanoma (Meier et al., 2003). 
Immunoglobulin superfamily cell adhesion 
molecules mediate cation independent adhesion with 
themselves or other members of this superfamily, but 
can act as receptors for integrins and extracellular 
matrix proteins as well. Two molecules, capable of 
mediating homophilic adhesion of melanoma cells, 
which are upregulated in melanoma cells include 
ALCAM (activated leukocyte cell adhesion molecule, 
also known as CD166, BEN/DM-GRASP, SC1) and 
Mel-CAM/MCAM (Melanoma cell adhesion 
molecule, also known as CD146 or MUC18)(Degen et 
al., 1998; Shih et al., 1994). More specifically, high 
MCAM expression has been shown to confer 
metastatic properties to cells in experimental 
metastasis assays and is frequently found in 
metastases of melanoma patients (Van Kempen et al., 
2000). MCAM expression leads to upregulation of 
matrix metalloproteinase (MMP) activity and appears 
to be involved in melanoma-endothelial cell 
interactions, suggesting a role in tumor cell migration, 
invasion, extravasation and angiogenesis (Johnson et 
al., 1999). ICAM-1 (CD54) expression is stronger on 
malignant than on benign melanocytic lesions and has 
been correlated with significantly shorter disease free 
and overall survival of melanoma patients (Johnson et 
al., 1989). However, the exact role of this molecule in 
progression of melanoma is not well known. 
The role of cadherins, a large family of Ca2+-
dependent cell-cell adhesion molecules will be 
discussed into detail below. 
II.3.2. Cadherins in normal 
melanocyte physiology 
Cell-cell adhesion, migration and invasion 
are not only crucial events in cancer, they also fulfill a 
central role in normal melanocyte biology. 
Melanocytes are derived from the neural crest. Neural 
crest cells can be defined as a pluripotent population 
of cells that originate at the time of neural tube 
closure at its dorsal site. Neural crest cell precursors 
are located at the border of the neural ectoderm 
(neural plate) and the non-neural ectoderm. Neural 
crest cells emerge after an epithelial-mesenchymal 
transition, with disruption of the tight cell-cell 
contacts with other neuro-epithelial cells, a 
reorganization of the cytoskeletal network and the 
activation of specific genes (Knecht and Bronner-
Fraser, 2002). Two related transcription factors, Snail 
and Slug (both known transcriptional repressors of the 
E-cadherin gene, see further) seem to play a key role 
in this process. At the trunk, neural crest cells 
proliferate extensively, and follow two main 
migration pathways: dorso-ventral or dorso-lateral. 
Cells migrating dorsolaterally, between the somites 
and the ectoderm, give rise to melanocytes. 
Differential expression of cadherins has been 
suggested as a requirement for the correct migratory 
pathway to be followed (Furukawa et al., 1997; 
Nishimura et al., 1999; Jouneau et al., 2000, Pla et al., 
2001). Table II.1 summarizes the current knowledge 
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of cadherin expression in murine neural crest cell 
formation, migration and differentiation into 
melanocytes. Before migrating, the founder 
melanoblasts start to proliferate, producing precursor 
melanoblasts, on their turn giving rise to 
melanoblasts, a population of actively proliferating 
and migrating cells. In melanoblasts that have 
completed their migration in mesenchymal tissues, 
expression of P-, and particularly E-cadherin, is 
strongly elevated upon crossing the basement 
membrane, which separates the dermis from the 
epidermis (Nishimura et al., 1999). During this 
‘invasion’ of the epidermis, the melanocytes retain 
contact with the basement membrane on the 
epidermal side, eventually becoming interspersed 
among basal keratinocytes. In the end, skin 
melanocytes are found at three locations: at the basal 
side of the epidermis, dermal and in the hair follicles. 
In hair follicles, melanocytes have high levels of P-
cadherin and little or no E-cadherin. The importance 
of P-cadherin expression in melanocytes is evident in 
juvenile hypotrichosis with macular dystrophy 
(JHMD, a syndrome found in humans with bi-allelic 
inactivation of P-cadherin that is characterized by 
early hair loss and progressive degeneration of the 
retina, culminating in blindness (Sprecher et al., 2001; 
Indelman et al., 2002, 2003). Although N-cadherin 
expression is absent or very weak in epidermal 
melanocytes in vivo, it is strongly expressed by 
dermal melanocytes. N-cadherin expression in the 
skin is further confined to the fibroblasts and 
endothelial cells in the dermis. Expression of N-
cadherin in epidermal melanocytes is elevated upon in 
vitro culture of these cells and further increases with 
the number of passages (Hsu et al., 1996). 
In normal human skin, all epidermal cells, 
including melanocytes, keratinocytes (both basal and 
differentiated) and Langerhans cells, express E-
cadherin, whereas P-cadherin expression is further 
only found in the basal keratinocytes. The latter are 
the dominant cellular partner of melanocytes and are 
able to control the growth, morphology and antigenic 
phenotype of melanocytes. Neither soluble factors nor 
extracellular matrix derived from the keratinocytes are 
able to recapitulate this control (Valyi-Nagy et al., 
1990, 1993). Instead, specific heterotypic gap-
junctional communication was shown to play a crucial 
role in conserving epidermal homeostasis (Hsu et al., 
Stage - species Event/localization Cadherins present Cadherins absent 
 Ectoderm E  
 Neurulation: formation of 
the neural plate 
E↓ 
N↑ 
 
 Neural crest cell precursors 
are located at the border of 
the ectoderm and neural 
plate 
E? (ectoderm),  
N? (neural plate) 
 
 Formation of the neural 
fold, leading to neural tube 
formation 
N 
6 (low) 
 
 Closure of neural tube N (low) 
6 (high) 
 
 Epithelial-mesenchymal 
transition, start of 
migration 
N ↓ 
6 (6B↓in chick) 
(7↑ in chick) 
 
E10.5 mouse embryonic skin 
 
Dorsolateral migration of 
melanoblasts in dermis 
6 (7 in chick) 
11 
E, N, P 
Desmoplakin 1/2 
E12.5 mouse embryonic skin Dermal melanoblasts E (low) N, P 
Desmoplakin 1/2 
Dermal (melanoblasts are 
migrating to epidermis) 
E N, P 
Desmoplakin 1/2 
E14.5 mouse embryonic skin 
 
Epidermal (melanoblasts 
migrated from the dermis) 
E, P N 
Desmoplakin 1/2 
Newborn skin Dermal melanocytes and 
melanoblasts (rare in 
regions covered with hair, 
but abundant in regions 
lacking hair, e.g. pinna) 
N E, P 
Desmoplakin 1/2 
 Epidermal E, P 
Desmoplakin 1/2 
N 
 Hair follicles E, P (higher P than in 
epidermis) 
N 
Desmoplakin 1/2 
Table II.1. Expression of cadherins during melanocyte expansion and migration in development. 
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2000a). Gap junctions are composed of radially 
arranged integral membrane proteins, connexins, 
forming hemi-channels (connexons). Alignment of 
these half-channels between adjacent cells results in 
communication channels which allow the direct 
transport of small molecules between cells (reviewed 
by Segretain and Falk, 2004). The specificity of this 
gap-junctional communication is dependent on 
cadherin-driven cell sorting (Prowse et al., 1997).  
II.3.3. Cadherin switches in 
melanoma 
In contrast to melanocytes, melanoma cells 
are often refractory to the normal contact-mediated 
phenotypic control of keratinocytes (Shih et al., 
1994). Normal melanocytes are positive for E- and P-
cadherin (N-cadherin is absent or only very weak). 
During melanoma progression a shift in cadherin 
profile frequently occurs. This shift may confer new 
adhesive properties to the cells: while a progressive 
reduction or loss of E-and P-cadherin abolishes 
heterotypic contact formation with E- and P-cadherin 
positive basal keratinocytes, upregulation of N-
cadherin allows a better homotypic communication 
among melanoma cells, as well as heterotypic 
communication with fibroblasts and endothelial cells 
(Tang et al., 1994; Seline et al., 1996; Hsu et al., 
1996, Danen et al., 1996; Seline et al., 1996; Silye et 
al., 1998; Sanders et al., 1999; Li et al., 2001a,b; 
Krengel et al., 2004). The important biological 
consequences of these interactions are evident from 
several observations:  
1) restoration of E-cadherin expression in melanoma 
cells restored their ability to associate with 
keratinocytes, allowing the formation of gap junctions 
and resulting in growth retardation, inhibition of 
invasion and induction of apoptotic cell death in a 
three-dimensional skin reconstruct, and decreased 
tumorigenicity in mice (Hsu et al., 2000a, 2000b); 
2) N-cadherin-mediated cell adhesion promotes 
survival of melanoma cells via activation of the anti-
apoptotic protein Akt/PKB (Li et al., 2001a) 
3) N-cadherin promotes adhesion of and stimulates 
migration of melanoma cells over dermal fibroblasts 
and vascular endothelial cells, which may improve 
their ability to migrate over the stroma and enter the 
vasculature (Li et al., 2001a,b); 
4) anti-N-cadherin antibodies can delay the 
transendothelial migration of melanoma cells (Sandig 
et al., 1997; Voura et al., 1998); 
5) N-cadherin expression in a murine model of 
melanoma development is only found in melanocytic 
fractions isolated from deeper parts of the skin 
(dermis and basement membrane), implying that the 
cadherin shift occurred in the cells invading the skin 
(Berking et al., 2004); 
6) in vivo, invading melanoma cells show pagetoid 
distribution or nest formation, suggesting the 
existence of tight cell-cell adhesion in these cells 
(Berking et al., 2004). 
In conclusion, the E-to-N cadherin switching in 
melanoma cells not only frees melanocytic cells from 
the control of keratinocytes, but also provides growth 
and metastatic advantages to the melanoma cells. 
Thus, E- and N-cadherin seem to act in opposite ways 
in the melanoma system, as a tumor suppressor and 
tumor promoter, respectively. Several explanations 
may account for the striking different functional roles 
of these two highly related molecules. One plausible 
possibility is that the differences are a matter of the 
differential action of the partner cells: while ‘good 
neighbors’ (keratinocytes) serve as E-cadherin 
dependent master controllers of melanocytes, ‘bad 
neighbors’ (fibroblasts), via N-cadherin dependent 
contacts, may serve as positive stimulators for cancer 
cells by promoting proliferation, survival and 
migration. In this view, the initial cadherin-mediated 
contact selects the partner cell and represents a first 
step in the reciprocal communication between the 
partners. Alternatively, E- and N-cadherin, apart from 
functioning as ‘glue keeping cells together’, also 
participate in signal transduction pathways. As is 
known from other cancer types, the panel of 
molecules recruited by E- and N-cadherin may differ, 
resulting in quantitative and qualitative differences in 
the signaling pathways in which these molecules are 
involved. These differences may actively confer 
growth and motility advantages to N-cadherin positive 
cells (Suyama et al., 2002; Fedor-Chaiken et al., 
2003). 
 
The molecular basis for the decreased 
expression of E-cadherin does not seem to involve 
mutations in the E-cadherin gene or promoter 
methylation (Poser et al., 2001; Li et al., 2001b). 
Instead, upregulation of the zinc finger transcription 
factor Snail plays an important role in transcriptional 
repression of E-cadherin expression in melanoma 
(Poser et al., 2001; Li et al., 2003). No inverse 
correlation was found between the expression of E-
cadherin and Slug, another Snail family member (Li 
et al., 2003). Controversy exists about the role of 
another transcription factor, AP-2, in regulation of E-
cadherin expression in melanoma. Although loss of  
expression of the transcription factor AP-2 during 
melanoma progression was proposed as one of the 
mechanisms leading to loss of E-cadherin (Nyormoi 
and Bar-Eli, 2003), others did not support this view 
(Poser et al., 2001). Also the continuous exposure of 
melanocytic cells to HGF (hepatocyte growth factor) 
results in downregulation of E-cadherin and the 
desmosomal cadherin desmoglein (Li et al., 2001b). 
In contrast to melanocytes, which only express the 
hepatocyte growth factor (HGF) receptor c-Met, many 
melanoma cell lines express HGF as well, which may 
act in an autocrine loop, leading to constitutive 
receptor activation. The presence of this autocrine 
loop may explain the reduced expression of these 
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cadherins in several melanoma cell lines (Li et al., 
2001b). Although c-Met, E-cadherin and desmoglein 
were all part of a multi-protein complex in these cells, 
and downregulation could be (partially) prevented by 
blocking PI3K and MAPK pathways, the exact 
mechanisms leading to downregulation of these 
cadherins was not elucidated. Downregulation of E-
cadherin following HGF treatment has been shown in 
various epithelial cell types and may result from its 
internalization, driven by the ubiquitin ligase Hakai 
(Fujita et al., 2001). However, no data are available 
concerning the expression or action of this protein in 
melanoma. Moreover, Hakai-mediated down-
regulation is known as a relatively fast process, 
occurring within several hours (Fujita et al., 2001), 
which contrasts with the prolonged exposure required 
in melanocytic cells (Li et al., 2001b). These findings 
were confirmed in a transgenic mouse model, where 
keratin 14 promoter-driven HGF expression by 
keratinocytes resulted in dermal melanocytosis, 
accompanied by reduced E-cadherin expression 
(Kunisada et al., 2000). Among other growth factors 
that have been reported to downregulate E-cadherin 
expression in melanocytic cells is endothelin-1, which 
is produced by keratinocytes upon UV induction and 
can downregulate E-cadherin in a caspase-8 
dependent manner (Jamal and Schneider, 2002). 
Relatively few studies have studied the 
expression of other cadherins in melanoma. For 
instance, although Tang et al. (1994) proposed that E-
cadherin mediated cell adhesion dominated a possible 
role of P-cadherin, studies examining the function of 
the latter in melanoma are lacking. Also the 
mechanisms underlying the increased N-cadherin 
expression in melanoma cells remain unknown. Apart 
from N-cadherin, de novo expression of other 
cadherins, such as VE-cadherin and protocadherins, is 
found in melanoma cells (Hendrix et al., 2001; 
Matsuyoshi et al., 1997). Expression of VE-cadherin 
has been shown to play an important role in the ability 
of malignant melanoma cells to form tubular 
structures and patterned networks in 3D cultures, 
mimicking the embryonic vasculogenic networks 
formed by differentiating endothelial cells (so-called 
‘vasculogenic mimicry’) (Maniotis et al., 1999; 
Hendrix et al., 2001). Although it is not clear what 
role proto-cadherins play, they may possibly 
contribute to the communication between melanoma 
cells themselves and/or with the micro-environment. 
II.3.4. β-catenin: a player in 
melanoma? 
Apart from shifts in the expression of 
cadherins in melanoma, other events involving this 
system may take place as well. A molecule whose 
localization is frequently affected in melanoma is β-
catenin (Rimm et al., 1999). Loss of membranous 
expression of β-catenin in melanomas has been 
associated with tumor progression (Kageshita et al., 
2001; Demunter et al., 2002; Maelandsmo et al., 
2003). Apart from its role in cell-cell adhesion, β-
catenin is also involved in signaling and gene 
transcription. More specifically, it has a central role in 
what is known as the ‘canonical Wnt signaling 
pathway’. In this pathway, binding of a ligand, Wnt, 
to its receptor, Frizzled, leads to phosphorylation and 
inhibition of glycogen-synthase-kinase-3β (GSK-3β). 
This enzyme is part of a multi-protein complex, also 
containing APC (adenomatous polyposis coli) and 
axin, that drives non-cadherin-bound β-catenin via 
subsequent phosphorylation and ubiquitination 
towards proteasomal degradation. A blockage of β-
catenin degradation may thus be the result from Wnt 
signaling, but may also arise from mutations in 
proteins involved in its degradation (e.g. axin or APC) 
or in β-catenin itself. As a result, β-catenin may 
accumulate, translocate to the nucleus and associate 
with Lef/Tcf (lymphocyte enhancer factor/T-cell 
factor) transcription factors to influence gene 
transcription (Lustig and Behrens, 2003). 
Mutations in APC have been described in two 
melanoma cell lines (Rubinfeld et al., 1997), but its 
relevance for the in vivo situation is unclear. In a 
small series of cutaneous melanoma samples, no loss 
of heterozygosity (LOH) of the APC gene could be 
detected (Ichihashi and Kitajima, 2000). β-catenin 
mutations, affecting GSK-3β phosphorylation sites, 
have been found both in melanoma cell lines and in a 
limited number of melanoma cases (See table II.2.). 
However, as is evident from table II.2, these only 
account for a small part of the melanoma cases where 
nuclear β-catenin staining is observed. Consequently, 
additional mechanisms must be present in melanoma 
cells, leading to nuclear β-catenin localization. These 
include a reduction of cadherin expression 
(resulting in a reduction of membranous β-catenin), as 
well as mutations in other components of the β-
catenin degradation machinery. Among possible 
candidate molecules is the APC modifier 
phospholipase A2-activating protein (PLAP), a 
gene localized at 9p21, a chromosomal region that is 
frequently affected by LOH in cutaneous melanoma 
(Ruiz et al., 1999). Aberrant expression of Wnt 
ligands, which may act in an autocrine way on the 
melanoma cells, may represent an alternative way 
leading to nuclear β-catenin. In this context, based 
upon gene expression analysis of cutaneous 
melanoma samples, expression of Wnt5a has been 
proposed as a robust marker of aggressive behavior 
(Bittner et al., 2000)[5028]. However, subsequent 
functional analysis showed that, although Wnt5a 
expression could indeed increase melanoma cell 
motility and invasion, these effects were not 
accompanied by increased β-catenin nuclear 
localization and signaling, but required PKC 
activation instead (Weeratna et al., 2002). 
Overall, although from these studies it is 
evident that in a significant amount of melanoma 
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samples cytoplasmic and/or nuclear β-catenin staining 
is present, no clear role for this protein has been 
established in melanoma development and/or 
progression, yet. 
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ABSTRACT 
 
Malignant transformation of melanocytes 
frequently coincides with a loss of E- and P-
cadherin expression.  Using retroviral transduction 
of several melanoma cell lines with P-cadherin, we 
show here that ectopic expression of P-cadherin in 
P-cadherin negative cell lines (BLM and HMB2) 
promotes the formation of cell-cell contacts, both 
in two- and three-dimensional cultures, and 
counteracts invasion. These effects were not 
observed following introduction of P-cadherin in a 
cell line (MeWo) which already had P-cad 
expression. The pro-adhesive and anti-invasive 
effects of P-cadherin were abolished upon 
mutation of its intracellular juxtamembrane 
domain and by mimicking a known missense 
mutation in its extracellular domain which gives 
rise to hypotrichosis with juvenile macular 
dystrophy. In conclusion, this study establishes a 
potent pro-adhesive and anti-invasive effect of P-
cadherin in melanoma cell lines.  
 
 
 
INTRODUCTION 
 
The development of metastatic disease is a complex 
process in which tumor cells separate from the 
primary tumor mass, migrate through the extracellular 
matrix, enter and survive in the vascular system, 
extravasate into a foreign environment and establish 
new foci of growth. This process often involves 
changes in adhesive preferences of the tumor cells, 
which dictate their interactions with the surrounding 
extracellular matrix and neighboring cells. A better 
understanding of these adhesive changes may help to 
identify key molecules involved in the various steps 
of tumor progression.  
Human skin is a multi-layered, cohesive tissue with a 
unique functional architecture affording the primary 
barrier to the outside environment. In the epidermis, 
melanocytes reside at the dermal-epidermal border, 
lying on the basement membrane. There, they are 
surrounded by basal keratinocytes, to whom they 
deliver pigment as a protection against the deleterious 
effects of UV. Under normal circumstances, 
melanocytes form a very quiescent population, 
undergoing controlled self-replication, resulting in a 
stable, life-long ratio with basal keratinocytes of 1:5-
6. During melanoma development and progression, 
profound changes take place. These include 
uncontrolled proliferation and derangement of cellular 
and morphological differentiation (dysplasia), 
resulting in a radial growth phase, which, following 
additional genetic changes, results in profound 
invasion (vertical growth phase) and colonization of 
distant organs (metastasis) (Clark, 1991). Heterotypic 
cell-cell adhesion between melanocytes and 
keratinocytes is crucial for their intercellular 
communication. Important molecules involved in 
these contacts are cadherins, which are capable of 
establishing Ca2+-dependent cell-cell adhesion (Tang 
et al., 1994). Via association with their cytoplasmic 
binding partners, the catenins, cadherins are coupled 
to the actin cytoskeleton and to several signaling 
pathways (Yap et al., 1997; Peifer, 2003). β-catenin 
(βctn)2 binds to the cadherin C-terminal intracellular 
tail, via α-catenin providing a stabilizing link with the 
actin cytoskeleton. P120 catenin (p120ctn), another 
member of this family, binds to the cadherin 
juxtamembrane domain and is involved in regulating 
cadherin intracellular trafficking, stability, adhesive 
capacity, as well as cadherin-controlled migration 
(Anastasiadis et al., 2000, Davis et al., 2003; Chen et 
al., 2003). Epidermal melanocytes express two types 
of classical cadherins, E- and P-cadherin (cad). Both 
are expressed by the basal keratinocytes as well, 
whereas keratinocytes in the upper layers of the 
epidermis are only E-cadherin positive. The ratio 
between E- and P-cad in both keratinocytes and 
melanocytes depends on their localization: E-cadhigh, 
P-cadlow cells are primarily found in the epidermis, 
whereas E-cadlow, P-cadhigh cells reside at the hair 
follicles (Nishimura et al., 1999). During melanoma 
progression, a shift in cadherin expression has been 
described: while cells lose both E- and P-cad 
expression, N-cad is elevated (Hsu et al., 1996; Seline 
et al., 1996; Furukawa et al., 1997; Silye et al., 1998; 
Sanders et al., 1999; Krengel et al., 2004). Whereas a 
role for both E- and N-cad has been shown in 
melanoma, respectively counteracting and promoting 
invasive growth (Hsu et al., 2000, Li et al., 2001a), 
studies addressing a possible role for P-cad are 
lacking. We therefore set out to investigate the 
function of P-cad in in vitro cell-cell adhesion and 
                                                 
2 Abbreviations used are: βctn β-catenin; cad, 
cadherin; p120ctn, p120 catenin; wt, wild-type. 
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invasion assays and found that P-cadherin could 
counteract invasion and promote adhesion of P-cad 
negative melanoma cell lines. 
 
 
 
RESULTS 
 
Cadherin expression in melanoma cell lines  
 To investigate the role of P-cadherin in malignant 
melanoma, the expression of the major classical 
cadherins, E-, N- and P-cad was determined by 
Western Blotting in a panel of melanoma cell lines. 
This revealed three types of expression: cell lines that 
did not contain any classical cadherin (as measured 
with cadherin-specific antibodies and a pan-cadherin 
antibody), cell lines that only expressed N-cadherin, 
and cell lines that were E-, P- and N-cadherin 
positive. For our evaluation of P-cadherin expression, 
we selected a representative cell line from each of 
these three groups: BLM, HMB2 and MeWo (Table 
1). 
Ectopic de novo expression of P-cadherin induces an 
epithelioid morphology in melanoma cells 
Since BLM did not express any of the classical 
cadherins examined, this cell line was of first choice 
to explore the functional effects of P-cad expression. 
For this purpose, BLM cells were infected with the 
retroviral vector pLZRS-P-cad-internal ribosomal 
entry site (IRES)-enhanced green fluorescent protein 
(EGFP). An IRES allows both P-cad and EGFP to be 
translated separately from the same mRNA transcript, 
with expression levels of P-cad and EGFP being 
directly proportional. As a control, retroviral 
transduction with pLZRS-IRES-EGFP, encoding only 
EGFP, was performed. As shown in Figure 1, 
transduction with retrovirus containing either an 
empty vector (pLZRS-IRES-EGFP, LIE) or P-cad 
(pLZRS-P-cad-IRES-EGFP, P-cad), followed by 
sorting of the cells, resulted in a population that was 
more than 90% positive for EGFP (Figure 1). 
P-cad expression was verified in the BLM cell lines 
by Western blotting. Unlike in the total lysates of 
parental BLM and BLM LIE, a band of the expected 
118kD size, reactive with a monoclonal anti-P-cad 
antibody was revealed in BLM P-cad (Figure 2, upper 
panel, first 3 lanes). Biotinylation experiments 
confirmed the presence of P-cad at the cell surface in 
P-cadherin transduced cells (Fig 2, middle panel, third 
lane). 
 
As is evident from figure 3 (pictures 1-3), a striking 
change in morphology was seen in P-cad transduced 
BLM cells, as compared to non-transduced or vector-
transduced cells. Parental and vector-transduced cells 
are polygonal or spindle-shaped, with only minimal 
cell-cell contacts. In contrast, BLM P-cad cells adopt 
a more flattened, epithelioid morphology and arranged 
in cell rows with extensive cell-cell contacts. These 
changes were particularly evident in sub-confluent 
cultures and got less pronounced when cultures 
reached higher grades of confluency. In order to 
examine whether this feature was specific for BLM 
cells, or could be extended to other melanoma cell 
lines, we transduced and sorted HMB2 and MeWo 
cells, similarly as described above for BLM. 
Evaluation of the morphology of these transduced 
cells revealed that P-cad expression in HMB2 cells 
also promoted an epithelioid phenotype, although less 
pronounced than seen in BLM cells, whereas no 
Cell line E-cad P-cad N-cad 
BLM - - - 
HMB2 - - + 
MeWo +/- + + 
 
Table 1. Expression of classical cadherins in melanoma cell lines 
used in this study. 
 
     Figure 1. Flow cytometric evaluation of EGFP expression of transduced BLM cells. 
 
 
Figure 2. Western Blotting of total lysates (TL), streptavidin 
immunoprecipitates of lysates from biotinylated cells (str), or of 
the non-biotinylated fraction (sup) of BLM cells transduced with 
the indicated constructs 
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differences were observed in MeWo cells (data not 
shown). None of the transduced cell lines showed 
changes in growth, as measured by a colorimetric 
assay (data not shown). Upon testing in a wound 
healing migration assay, no differences could be 
observed in the speed of wound closure. However, the 
migration of P-cad transduced HMB2 and BLM cells 
differed from that of controls in that P-cad transduced 
cells migrated as sheets, whereas control cells 
migrated as single cells (data not shown). 
In conclusion, these results suggest that P-cad may 
contribute to an increased epithelioid phenotype in 
melanoma cells that do not express this protein 
natively. 
 
 
Ectopic de novo expression of P-cadherin stimulates 
cell-cell aggregation 
In a slow aggregation assay on soft agar, parental and 
vector-transduced BLM cells are forming no (24 h) or 
loose aggregates (72h), while in BLM P-cad, cell 
aggregation is promoted leading to the formation of 
compact aggregates already after 24h (Figure 4, upper 
two panels). Similar to our observations in BLM cells, 
P-cad could confer increased aggregation to HMB2 
cells. However, in the latter these changes were less 
evident at 24h, in which both parental, vector- and P-
cad transduced cells formed small cell clusters (not 
shown), but became increasingly clear upon 
prolonged incubation times (Figure 4, second lower 
panel). In MeWo cells, which already express P-cad, 
no changes in cell-cell adhesion could be observed, 
neither at early (not shown) nor at late time points 
(Figure 4, lower panel). These cells already showed 
relatively high levels of aggregation, presumably 
mediated by their native N-, P- or E- cad. To verify 
these data, we used another aggregation assay, in 
which the different cell lines were incubated in 
suspension under continuous shaking. As is evident 
from a shift to the right of the particle size distribution 
curves, larger aggregates were formed by P-cad 
transduced BLM and HMB2 cells, while no 
 
Figure 3. Phase-contrast micrographs of BLM cells transduced with the indicated constructs. Scalebar = 50µm 
 
 
Figure 4. Slow aggregation assay on soft agar of the indicated cell 
lines, photographed after the indicated time points. Scalebar = 
500µm 
 
 
Figure 5. Particle size distribution of aggregates of the indicated cell 
lines. Aggregation times were 24h for BLM cells and 48h for 
HMB2 and MeWo cells. Curves without symbols indicate parental 
cell lines, for the transduced cell lines + indicates LIE, # indicates 
P-cad, x indicates P-cad∆p120, and o indicates P-cadR503H. 
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differences were observed in MeWo cells (Figure 5). 
Because the aggregates formed by BLM P-cad cells 
were too large to be measured at the 48h time point, 
the assay was stopped after 24h for these cells, while 
HMB2 and MeWo cells were allowed to form 
aggregates for 48h. 
 
  
P-cadherin counteracts invasion of BLM and HMB2 
To test the role of P-cadherin in the invasive 
phenotype of melanomas, the chick heart invasion 
assay was performed. As illustrated in Figure 6A, 
confrontation of BLM and BLM LIE cells (indicated 
with “T”) with a precultured chick heart fragment 
(indicated with “N”) for 4 (left panels) or 8 (right 
panels) days resulted in a marked invasion of tumor 
cells into the chick heart already after 4 days of 
coculture. In contrast, BLM P-cad cells only showed 
minimal invasion, rather surrounding (4d), and 
eventually compressing (8d) the chick heart fragment. 
This anti-invasive effect was also obvious after blind-
coded acquisition of the invasion scores of 
independent confrontation cultures (Figure 6C). The 
counteraction of invasion by P-cad was also 
pronounced in HMB2 cells (Figure 6B, 6C). Whereas 
parental and vector-transduced HMB2 cells strongly 
invaded the chick heart, P-cad transduced cells nicely 
surrounded it. However, also in the confrontation 
cultures with P-cad transduced cells, one or some 
Figure 6. (A,B) Hematoxylin-eosin staining of chick heart confrontation cultures with the indicated BLM (A) or HMB2 (B) cell lines for the 
indicated time points. N stands for (remnants) of normal chick heart tissue, T stands for tumor cells. Scalebar = 100µm. (C) Invasion scores, 
obtained by scoring blindly independent confrontation cultures of the indicated cell lines for the indicated time points. 
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single cells could be found within the chick heart. 
Since our EGFP-based cell sorting resulted in 
population purities between 90 and 100%, we 
consider it very likely that these few single invasive 
cells represent non-transduced cells. The invasive 
behavior of MeWo cells was not affected by P-cad 
(Figure 6C). In conclusion, P-cad expression could 
counteract invasion of P-cad negative cells, 
paralleling its stimulating effects on aggregation. 
 
 
Generation of BLM P-cad mutants 
In order to identify which domains in P-cadherin were 
important for its pro-adhesive and anti-invasive 
activities, we constructed two P-cadherin mutants. We 
therefore targeted two different domains that can be 
expected to alter P-cad function. A first construct, P-
cad∆p120, lacks 5 amino acids (EEGGG) in the 
presumed p120ctn binding site in the juxtamembrane 
domain of P-cadherin. The corresponding domain in 
E- and N-cadherin has been shown to be implicated in 
modulation of cell-cell adhesion and motility 
(Thoreson et al., 2000, Fedor-Chaiken et al., 2003). 
For the second construct, P-cadR503H, we targeted an 
arginine residue in the fourth extracellular domain 
(EC4) of P-cad. This R503H mutation represents the 
only known missense mutation of P-cad, which, in 
patients carrying this mutation, results in 
hypotrichosis with juvenile macular dystrophy 
(Indelman et al., 2002, 2003). Since this mutation 
targets a conserved LDRE motif, which, on basis of 
sequence homology with E-cad, is likely implicated in 
Ca2+-binding (Troyanovsky, 1999), it is expected to 
affect P-cad-mediated adhesion. BLM cells were 
transduced with these P-cad mutants and sorted to 
more than 90% purity (Figure 1). Integrity and 
localization of the constructs at the plasma membrane 
was confirmed by Western Blotting of total lysates 
(Figure 2, upper panel, last two lanes). As expected, 
P-cad∆p120ctn migrated slightly faster in SDS-PAGE 
than the other P-cad constructs. Cell surface 
expression of the P-cad mutants was verified by 
biotinylation. As compared to BLM P-cad, cell 
surface levels of both P-cad mutants were lower 
(Figure 2, middle panel), possibly reflecting decreased 
stability, which may be inherent, or may be the 
consequence of their altered capacity to form stable 
cell-cell contacts (see further). Overall, although 
significant amounts of cytoplasmic P-cad were found 
in all P-cad transduced cells, these were apparently 
not higher in cells expressing P-cad mutants (Figure 
2, lower panel). 
 
Influence of mutation of the p120 catenin binding 
domain or the extracellular domain on β- and p120ctn 
To verify whether introduction of P-cad or P-cad 
mutants into BLM cells affected levels of β- and 
p120ctn, we performed Western Blotting of total 
lysates. As shown in figure 7, p120ctn levels 
remained unchanged upon expression of wild-type 
(wt) or mutated P-cad. In contrast, total levels of β-ctn 
were increased by all P-cad constructs, suggesting its 
stabilization by recruitment to the P-cad constructs. 
This was somewhat less pronounced in BLM P-
cad∆p120 cells. Examination of the association of 
these proteins with the P-cad constructs showed that, 
whereas all constructs co-immunoprecipitated with 
βctn (Figure 8, upper panel), the P-cad∆p120 mutant 
failed to co-immunoprecipitate with p120ctn, thus 
confirming that this construct cannot efficiently 
couple to p120ctn (Figure 8, lower panel). In order to 
evaluate the localisation of β- and p120ctn, which are 
both typically localized at sites of cell-cell contact in 
cadherin expressing cells, we performed 
immunocytochemistry for these molecules in nearly 
confluent cultures, in which, also in the control and P-
cad mutant cells, cell-cell contact formation is forced. 
As expected from their epithelioid morphology, BLM 
P-cad cells showed a nice honeycomb-like 
membranous staining pattern for both β- and p120ctn 
(Figure 9). In contrast, stainings in BLM (not shown) 
and BLM LIE were diffuse. Examination of the BLM 
P-cad mutants revealed striking differences with BLM 
P-cad. Whereas the staining pattern in BLM P-
cadR503H did reveal membranous localisation (albeit 
to a much lower extent than in wt P-cad transduced 
cells), recruitment of β-catenin to the plasma 
membrane was absent in BLM P-cad∆p120ctn. In the 
latter, βctn staining was present in discrete puncta 
instead. Concerning p120ctn, recruitment to the 
plasma membrane was not seen in P-cad∆p120ctn 
transduced cells, as expected. As observed for βctn, P-
cadR503H cells showed membranous p120ctn 
immunostaining, which was considerably weaker than 
in wt P-cad transduced cells. 
 
 
 
 
Figure 7. Analysis of the expression of P-cadherin, p120ctn and 
βctn in BLM-derived cell lines. Whole cell lysates of the indicated 
BLM-derived cell lines were analyzed by Western Blotting and 
immunostaining (I.S.) for the indicated proteins. 
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Mutation of the p120 catenin binding domain or the 
extracellular domain of P-cadherin interferes with its 
pro-adhesive effects 
Examination of subconfluent cultures revealed that 
the morphology of both BLM P-cadR503H and BLM 
P-cad∆p120 was indistinguishable from that of 
controls, meaning that in both instances, the 
promotion of cell-cell contact formation as seen with 
wt P-cad was completely abolished (Figure 3). 
When tested in a 24h slow aggregation assay in 
suspension, both mutants could promote cell 
aggregation to some extent, although significantly less 
than P-cad (Figure 5). As is evident from Figure 10A, 
taken after 48h in suspension, these differences 
became even more pronounced upon prolonged 
culture (the same magnification is used for all 
pictures). A similar effect was seen in a slow 
aggregation assay on soft agar (Figure 10B). 
However, here the changes induced by the mutations 
were less drastic than in suspension, likely because in 
the latter, due to the continuous shaking, a more 
stringent condition is created in which weak cell-cell 
contacts are less easily maintained. The reduced 
aggregation on soft agar was clearly visible in BLM 
PCAD∆p120 cells. The BLM P-cadR503H cells, on 
the other hand, showed significant aggregation, with 
the formation of a single aggregate, at first sight 
resembling the aggregate formed by the P-cad 
transduced cells. However, as indicated in the right 
panels of Figure 10B, this association remained loose. 
While the P-cad transduced BLM cells formed a very 
tight, compact aggregate, characterized by a smooth 
surface (indicated by arrowheads), this smooth surface 
(‘compaction’) was lacking in the aggregate formed 
by BLM P-cadR503H cells. 
 
In conclusion, disruption of the extracellular domain 
or the p120ctn binding domain of P-cad interferes 
with its ability to establish tight, stable cell-cell 
contacts. 
 
 
 
 
 
Figure 9. Immunocytochemistry for βctn and p120ctn in the 
indicated BLM cell lines. Nearly confluent cultures of the 
indicated BLM-derived cell lines were fixed and stained using 
anti-βctn (upper panel) or anti-p120ctn (lower panel) antibodies. 
Scalebar = 50µm. 
 
 
Figure 8. Association of βctn and p120ctn with P-cad and P-cad 
mutants. Equal amounts of whole cell lysates of the indicated cell 
lines were subjected to immunoprecipitation (I.P.), using anti-βctn 
antibody (upper 2 panels) or anti-p120ctn antibody (lower 2 
panels), followed by immunostaining (I.S.) as indicated. 
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Mutation of the p120 catenin binding domain or the 
extracellular domain of P-cadherin interferes with its 
anti-invasive  effects 
In order to determine the involvement of the p120ctn 
binding domain and the EC4 domain in the anti-
invasive function of P-cadherin, the BLM P-cad 
mutants were examined in the chick heart invasion 
assay. As shown in the lower panels of Figure 6A, and 
as evaluated in Figure 6C, both mutations completely 
abrogated the anti-invasive activity of P-cad. The 
mutant cell lines showed invasion of the chick heart 
tissue at both time points and to the same extent as the 
BLM LIE control cells. These results indicate that 
both the p120ctn binding domain and an intact EC4 
domain are implicated in the cell-cell adhesive and 
anti-invasive function of P-cadherin. 
 
 
 
DISCUSSION 
 
Altered expression of cell-cell adhesion molecules is a 
frequent event during malignant transformation of 
melanocytic cells (Johnson, 1999). Downregulation of 
two members of the cadherin family, E- and P-
cadherin, has been observed during melanoma 
progression (Hsu et al., 1996; Seline et al., 1996; 
Furukawa et al., 1997; Silye et al., 1998; Sanders et 
al., 1999; Li et al., 2001b; Krengel et al., 2004). The 
present study is the first to evaluate the possible role 
P-cadherin may play in cell-cell adhesion and 
invasion of melanoma cells, two processes involved in 
melanoma progression. 
We found that ectopic expression of P-cadherin in P-
cad negative melanoma cell lines promoted cell-cell 
contact formation and suppressed invasion. 
Importantly, these effects were not limited to cells 
lacking endogenous cadherin expression. Also the 
behavior of the HMB2 cell line, expressing N-
cadherin endogenously, was redirected towards 
increased aggregation and reduced invasion. Ectopic 
expression of P-cad in MeWo cells, which already 
expresses endogenous P-cad, in addition to N-cad and 
minute amounts of E-cad, could not alter the adhesive 
and invasive behavior of these cells. We hypothesize 
that this cell line has acquired additional genetic 
changes, rendering it resistant to the protective effects 
of P-cad. 
In order to evaluate the role selected domains in P-cad 
may play in the observed effects, we created two P-
cad mutants. A first mutant we tested, P-cadR503H, 
was chosen based on its occurrence in a human 
syndrome, hypotrichosis with juvenile macular 
dystrophy. This is a rare autosomal recessive disorder 
characterized by early hair loss and severe macular 
degeneration, eventually leading to blindness in most 
patients (Souied et al., 1995). This syndrome has 
recently been shown to result from mutations in 
CDH3 (the gene encoding P-cadherin) on 16q21 
(Sprecher et al., 2001; Indelman et al., 2002, 2003). 
Apart from deleterious frameshift mutations, 
disrupting the CDH3 open reading frame, a more 
subtle mutation, resulting in the substitution of a 
single amino acid, was found as well (Indelman et al., 
2002, 2003). The crystal structure of the C-cadherin 
ectodomain (Boggon et al., 2002) shows the 
involvement of the corresponding C-cad arginine 
residue, embedded in a highly conserved LDRE 
motif, in Ca2+-binding. Thus, although not tested 
experimentally, it was suggested that this mutation 
may affect P-cad function by disrupting the P-cad 
conformation. Here we have mimicked the R503H 
mutation in a melanoma cell line and analyzed its 
A 
 
 
 
B 
 
 
Figure 10. (A) Slow aggregation assay in suspension of the 
indicated BLM-derived cell lines, photographed after 48h. 
Scalebar = 100µm. (B) Slow aggregation assay on soft agar of the 
indicated BLM-derived cell lines, photographed after the 
indicated time points. Scalebar = 500µm in the left panels, 100µm 
in the right panel. Arrowheads indicate the smooth, compacted 
surface of the BLM P-cad aggregate. 
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influence on P-cad function. The second domain we 
targeted in P-cadherin was its juxtamembrane domain. 
This domain, which contains the p120 ctn binding 
sequence, is highly similar to the corresponding 
domain in E- and N-cadherin, where it has been 
involved in regulation of cell-cell adhesion and 
motility (Thoreson et al., 2000; Fedor-Chaiken et al., 
2003). The resulting mutant, P-cad∆p120, lacked 
p120ctn binding, as evidenced by co-
immunoprecipitation and immunocytochemistry. 
Evaluation of the function of PCADR503H and 
PCAD∆p120 in BLM cells, lacking expression of any 
other classical cadherin, learned that both have a 
severely impaired ability to suppress invasion and 
support cell-cell adhesion. The latter effect was more 
pronounced for PCAD∆p120. Although P-cadR503H, 
in non-stringent conditions, could support cell-cell 
adhesion in BLM cells, it failed in generating the 
compact aggregates that were formed in P-cad 
transduced cells. In contrast to wt P-cad, both mutants 
failed to form well-organized cell-cell contacts. In 
subconfluent cultures this was evident from the 
absence of cell islands, as seen in wt P-cad transduced 
cells. In more confluent cultures, in which cell-cell 
contacts are forced, the lack of organization was 
witnessed by the impaired recruitment of βctn to 
adherens junctions. Parallel with the effect of the 
mutations on aggregation, this impaired recruitment 
of βctn was less severe in P-cadR503H than in P-
cad∆p120, in which it was almost completely absent. 
In the latter, βctn staining was confined to discrete 
cytoplasmic puncta. Contrasting with the failure of the 
P-cad mutants to recruit βctn to the cell membrane as 
wt P-cad did, βctn co-immunoprecipitated with all P-
cad constructs. Moreover, expression of all mutants 
resulted in increased levels of βctn, suggesting 
stabilization of the latter. Of note, this increase was 
particularly seen in a band migrating slightly faster 
than the band corresponding to βctn in control or 
vector-transduced cells. This might represent a 
difference in phosphorylation status of βctn. Overall, 
these results suggest that P-cad mutants can still 
recruit and stabilize βctn, they largely fail to stabilize 
it at the membrane. In contrast to the increase of total 
βctn, p120ctn levels remained unchanged upon 
expression of P-cad. Recruitment of p120ctn to the 
plasma membrane was absent in BLM P-cad∆p120 
(as expected) and was largely decreased in BLM P-
cadR503H. The decreased ability of the mutants to 
counteract invasion, stabilize cell adhesion and recruit 
βctn and p120ctn to cell-cell contacts is likely due to 
their decreased cell surface expression. This was 
evident from biotinylation experiments, in which 
lower levels of the P-cad mutants were found at the 
cell surface, despite similar overall levels of P-cad. 
Consistent with this is our observation that P-cadherin 
shows the same subcellular distribution as βctn in 
transduced BLM cells: mainly membranous for wt P-
cad; membranous (at sites of cell-cell contacts) and 
cytoplasmic for P-cadR503H; and in discrete puncta, 
with some membranous staining at cell-cell contacts 
for P-cad∆p120 (data not shown). Whether this 
increased cytoplasmic staining is the cause or the 
consequence of defective adhesion is not clear, yet. 
The recent involvement of p120ctn in kinesin-
mediated transport of cadherin-catenin complexes to 
intercellular junctions (Chen et al., 2003) may provide 
an explanation for the impaired functions of P-
cad∆p120. However, using p120ctn-uncoupled N-
cadherin, these authors reported a delay, rather than a 
general incapability in reaching cell-cell contacts.  A 
more detailed study of the discrete areas where βctn 
and P-cad∆p120ctn were found may help to resolve 
this question. 
In conclusion, we have demonstrated that P-cad may 
promote strong aggregation and counteract invasion 
of melanoma cells. Our functional analysis of two P-
cad mutants, one lacking binding to p120ctn and the 
other representing the only known missense mutation 
of P-cad, revealed that both have a strongly impaired 
capacity to support cell-cell adhesion. This coincides 
with a decreased cell surface localization and likely 
explains the failure of these mutants to counteract 
invasion. 
 
 
 
MATERIALS AND METHODS 
 
Plasmids and cDNA Constructs, Retroviral Transduction and 
cell sorting. The hP-cad/pBR322-23-b expression vector, 
containing the 3.2kb cDNA encoding full-length human P-cad (13), 
was kindly provided by Prof. Keith R. Johnson (Department of Oral 
Biology, College of Dentistry and the Eppley Cancer Center, 
Nebraska Medical Center, Omaha, NE), with the permission from 
Prof. Yukata Shimoyama (Department of Surgery, International 
Catholic Hospital, Nakaochiai, Shinjuku, Tokyo, Japan). To create 
P-cad∆p120, P-cad was EcoRI subcloned into pIRES2-EGFP 
(Clontech, Palo Alto, CA), generating pP-cad-IRES2-EGFP. This 
was XhoI/SmaI digested and the removed fragment was cut with 
EarI, recognizing two nearby sites in the P-cad sequence. The small 
fragment between the two EarI restriction sites (encoding EEGGG) 
was removed with a PCR-purification column and the remaining 
two fragments (XhoI/EarI and EarI/SmaI) were ligated into the 
dephosphorylated XhoI/SmaI digested pP-cad-IRES2-EGFP. To 
create the P-cad point mutant (P-cadR503H), the P-cad cDNA was 
EcoRI subcloned into pBluescript and the sequence coding for a 
large part of the extracellular domain was BamHI/TaqI excised. A 
PCR product, encompassing the point mutation, was obtained, 
using the following primers: a sense primer (5’-
GGCACCCTCGACCATGAGGATGAG-3’), with the TaqI 
restriction site underlined and the point mutation in bold; and the 
antisense primer 5’-CGTGCCGTCGACCTACAGGTTCTCAAT-
3’. This product was TaqI/NdeI digested and ligated with the 
BamHI/TaqI fragment. After this, the resulting fragment was 
ligated into dephosphorylated BamHI/NdeI digested pP-cad-
Bluescript. All these constructs were EcoRI transferred to the 
LZRS-IRES-EGFP (LIE) retroviral vector, to generate the LZRS-P-
cad-IRES-EGFP vector. The LIE retroviral vector, encoding only 
EGFP, was used as a control. Direct sequencing (ABI, Perkin 
Elmer, Foster City, CA) was performed for all the constructs, in 
order to confirm their integrity. 
For the production of retroviral supernatant, the Phoenix-
Amphotropic packaging cell line (a kind gift from Dr. G.P. Nolan, 
Stanford University School of Medicine, Stanford, CA) was 
transfected with the LIE and the LZRS-P-cad-IRES-EGFP plasmids 
using calcium-phosphate precipitation (Invitrogen) to generate both 
retroviruses. The viral supernatant was spun (10 min at 350xg) and 
aliquots were stored at –70°C until use. Transduction, flow 
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cytrometrc evaluation and sorting of cell lines was performed as 
described before (Stove et al., 2003b).  
 
Cell lines, Restriction Enzymes, Antibodies and Chemical 
Reagents. Human cancer cell lines were obtained and cultured as 
described before (Stove et al., 2003a). All the restriction enzymes 
were purchased from New England BioLabs (Beverly, MA). 
Antibodies used were: monoclonal anti-P-cad (clone 56) and anti-
p120ctn (clone 98) (BD Transduction Laboratories, Lexington, 
KY), polyclonal anti-βctn (Sigma-Aldrich, Bornem, Belgium) and a 
polyclonal rabbit antiserum generated against a 15-mer peptide, 
corresponding to the C-terminus of E-cadherin, which is cross-
reactive with P-cadherin and was used for immunocytochemistry. 
  
Biotinylation, Immunoprecipitation and Immunoblotting. 
Immunoprecipitation and immunoblotting experiments were 
performed as published before, except that for preparation of cell 
lysates 0.7% Nonidet P-40 in PBS was used as lysis buffer (Stove et 
al., 2003a). For biotinylation, the cells were first incubated with 0.5 
mg/ml of biotin, during 30 min, and washed four times with PBS, 
before lysing the cells.  
 
Slow Aggregation Assays. On Semi-Solid Substratum: 2x104 cells 
in 200 µl medium were seeded on solidified agar in a 96-well-plate 
(Boterberg et al., 2001). Aggregate formation was evaluated under 
an inverted microscope at indicated time points. In Suspension: 
6x105 cells were added to 50 ml-Erlenmeyer flasks in 6 ml medium.  
The flasks were incubated on a Gyratory shaker (New Brunswick 
Scientific Co., New Brunswick, NJ) at 72 rpm, and continuously 
gassed with humidified 10% CO2 in air. The particle size 
distribution of the aggregates was measured with a Coulter Particle 
Size Counter (LS2000, Coulter Company, Miami, FL).  The 
diameter of the particles can be considered as a measure for 
aggregate formation. Statistical analysis of differences between the 
particle size distribution curves was done with the Kolmogorov-
Smirnov method. 
 
Chick Heart Invasion Assay. The chick heart invasion assay was 
used as described earlier (Bracke et al, 2001). Briefly, heart 
fragments of 9-day old chick embryo's were precultured for 4 days 
(PHF) and then confronted with tumour cells under continuous 
Gyrotory shaking. Tumour cells were applied as monolayer 
fragments. The individual confrontations were fixed in Bouin-
Hollande’s solution after 4 or 8 days of incubation. They were 
afterwards embedded in paraffin, serially sectioned and stained with 
haematoxylin-eosin. 
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ABSTRACT 
 
P-cadherin expression in breast carcinomas 
has been associated with tumors of high 
histological grade and lacking estrogen receptor-α, 
suggesting a link between these proteins. In the 
MCF-7/AZ breast cancer cell line, blocking 
estrogen receptor-α signaling with the antiestrogen 
ICI 182,780 induced an increase of P-cadherin, 
which coincided with induction of in vitro invasion. 
Retroviral transduction of MCF-7/AZ cells, as well 
as HEK 293T cells, showed the pro-invasive 
activity of P-cadherin, which requires the 
juxtamembrane domain of its cytoplasmic tail. 
This study establishes a direct link between P-
cadherin expression and the lack of estrogen 
receptor-α signaling in breast cancer cells, and 
suggests a role for P-cadherin in invasion, through 
its interaction with proteins bound to the 
juxtamembrane domain. 
 
 
INTRODUCTION 
 
Cell adhesion determines morphogenesis and 
regulates cell motility, growth, differentiation and 
survival (1). Classical cadherins are a superfamily of 
transmembrane glycoproteins responsible for 
calcium-dependent cell-cell adhesion (2), which 
mediate homophilic protein-protein interactions. 
These are modulated by their conserved cytoplasmic 
juxtamembrane domain (JMD)3 and catenin-binding 
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domain (CBD), linking them to the actin cytoskeleton. 
α-, β-, p120-, and γ-catenins are the best-documented 
interaction partners (3). β-catenin (βctn) (and perhaps 
also γ-catenin) is a signaling molecule, implicated in 
tissue patterning and maintenance of the cell 
phenotype, whose functions are regulated by binding 
to the CBD of cadherins, and by interactions with 
receptor tyrosine kinases and transcription factors of 
the lymphocyte enhancer factor/T-cell factor family 
(4). P120-catenin (p120ctn) was identified as a 
substrate for Src and several receptor tyrosine kinases 
(5), and interacts directly with the JMD of cadherins 
(6), modulating cadherin clustering and cell motility 
in a cell type and phosphorylation state-dependent 
way (7). The cadherin/catenin junctional complex is 
linked to the actin cytoskeleton via α-catenin (8), thus 
strengthening its adhesive force.  
Reduced expression of E-cadherin (E-cad) is 
associated with tumor progression in many different 
cancers, including breast cancer (9), and may result 
from mutations, loss of heterozygosity, promoter 
hypermethylation, or upregulation of transcriptional 
repressors, as SIP1, Snail, Slug or Twist (1). 
Moreover, the invasion suppressor function of 
normally expressed E-cad may be overcome by the 
aberrant expression of N-cadherin (N-cad) (10) or 
cadherin-11 (11), which have been associated with 
progression of breast carcinoma through interference 
with E-cad function (12). 
P-cadherin (P-cad), another classical cadherin, is 
expressed in ectodermal tissues, more specifically in 
the basal layers of stratified epithelia (13-15) and in 
myoepithelial cells of the breast (16-17). P-cad is 
implicated in growth and differentiation, as evidenced 
by knockout mice displaying precocious 
differentiation of the mammary gland (18), and is 
aberrantly expressed in mammary carcinomas of high 
histological grade and with a poor prognosis (19-24), 
as well as in other types of carcinomas and 
proliferative inflammatory lesions (25-29). It has been 
suggested that suppression of the P-cad gene is lost 
during carcinogenesis (14), but the nature of this 
mechanism and the biological role of the newly 
acquired P-cad remain to be investigated. 
Since aberrant expression of P-cad identified a 
subgroup of estrogen receptor-α (ERα) negative breast 
carcinomas (23), we raised the hypothesis that the 
New regulatory molecules in growth and invasion of melanoma and breast cancer: cadherins, heregulin and follistatin 
108 
expression of P-cad in mammary epithelial cells is 
hormonally regulated, as described for E-cad (30), N-
cad (31) and cadherin-11 (32). 
In mammary epithelial cells, ERα is a key 
regulator of proliferation and differentiation and a 
crucial prognostic indicator and therapeutic target in 
breast cancer (33). ERα is a ligand-dependent 
transcription factor (34) acting through direct 
transcriptional target activation (35). Estradiol acts as 
a potent mitogen for many breast cancer cell lines 
(36), and about 70% of breast carcinomas are ERα 
positive. This mitogenic effect is blocked by estrogen 
antagonists. Pure antiestrogens (like ICI 182,780 
(ICI)) and selective estrogen receptor modulators (like 
tamoxifen) (37-38) are used for the treatment of 
osteoporosis, breast cancer and other diseases (39). In 
breast cancer, a high number of patients eventually 
develop antiestrogen resistance, for unknown reasons. 
Continuous exposure of steroid-hormone responsive 
breast cancer cell lines to ICI leads to resistant sub-
lines, with signaling pathways alternative to ERα 
(40). 
Using the antiestrogen ICI, we investigated a 
putative molecular and functional link between the 
absence of ERα signaling and P-cad expression in 
breast cancer cells. In order to understand the 
relationship between P-cad and the aggressive breast 
cancer phenotype, we studied the effect of wild-type 
P-cad and several mutants on cell aggregation and 
invasion. We report that aberrant expression of P-cad 
may result from a lack of ERα signaling and may 
induce cell invasion, in a JMD-dependent manner.  
 
 
MATERIALS AND METHODS 
 
 Plasmids and cDNA Constructs. The hP-cad/pBR322-23-b 
expression vector, containing the 3.2kb cDNA encoding full-length 
human P-cad (13), was kindly provided by Prof. Keith R. Johnson 
(Department of Oral Biology, College of Dentistry and the Eppley 
Cancer Center, Nebraska Medical Center, Omaha, NE), with the 
permission from Prof. Yukata Shimoyama (Department of Surgery, 
International Catholic Hospital, Nakaochiai, Shinjuku, Tokyo, 
Japan). The cDNA encoding full-length mouse E-cad was kindly 
provided by Jolanda van Hengel (Department of Molecular 
Biology, Laboratory of Molecular Cell Biology, Ghent University 
and Flanders Interuniversity Institute of Biotechnology, Ghent, 
Belgium). Both cDNAs (PC-WT and mEC-WT) were transferred to 
the expression vector pIRES2-EGFP (Clontech, Palo Alto, CA), in 
order to facilitate the evaluation of transfection efficiencies due to 
co-expression of EGFP after transfection. To generate P-cad 
deletion mutants, P-cad was EcoRI subcloned into pBluescript 
(Promega, Madison, WI) and NdeI/SalI digested to remove the 
region coding for the C-terminal part of this protein. PCR 
fragments corresponding to different lengths of the removed tail, 
flanked by NdeI/SalI restriction enzyme digest sites at the 5’ and 3’ 
ends, respectively, were obtained using always the same sense 
primer (5’-AAGCAGGATACATATGACGTG-3’) and different 
antisense primers for the following constructs: PC-CT682: 5’-
CGTGCCGTCGACCTACTTCCGCTTCTT-3’; PC-CT702: 5’-
CGTGCCGTCGACCTAGCCATAGTAGAA-3’; PC-CT711: 5’-
CGTGCCGTCGACCTACTGGTCCTCTTC-3’; PC-CT719: 5’-
CGTGCCGTCGACCTAGTGGAGCTGGGT-3’; PC-CT727: 5’-
CGTGCCGTCGACCTACTCCGGCCTGGC-3’; and PC-CT762: 
5’-CGTGCCGTCGACCTACAGGTTCTCAAT-3’. After NdeI/SalI 
digestion, these products were ligated into dephosphorylated 
NdeI/SalI digested pP-cad-Bluescript, and the resulting construct 
was EcoRI/SalI transferred to pIRES2-EGFP. Additionally, a 
mutant with a small deletion in the p120ctn-binding sequence 
(lacking the nucleotides coding EEGGG), and retaining the intact 
CBD, was created (PC-∆703-707). Therefore, pP-cad-IRES2-EGFP 
was XhoI/SmaI digested and the removed fragment was cut with 
EarI, recognizing two nearby sites in the P-cad sequence. The small 
fragment between the two EarI restriction sites (encoding EEGGG) 
was removed with a PCR-purification column and the remaining 
two fragments (XhoI/EarI and EarI/SmaI) were ligated into the 
dephosphorylated XhoI/SmaI digested pP-cad-IRES2-EGFP. To 
create the P-cad point mutant (PC-R503H), the P-cad cDNA was 
EcoRI subcloned into pBluescript and the sequence coding for a 
large part of the extracellular domain was BamHI/TaqI excised. A 
PCR product, encompassing the point mutation, was obtained, 
using the following primers: a sense primer (5’-
GGCACCCTCGACCATGAGGATGAG-3’), with the TaqI 
restriction site underlined and the point mutation in bold; and the 
antisense primer used for generating PC-CT762. This product was 
TaqI/NdeI digested and ligated with the BamHI/TaqI fragment. 
After this, the resulting fragment was ligated into dephosphorylated 
BamHI/NdeI digested pP-cad-Bluescript and the construct was 
EcoRI transferred to pIRES2-EGFP. Direct sequencing (ABI, 
Perkin Elmer, Foster City, CA) was performed for all the 
constructs, in order to confirm their integrity. 
Restriction Enzymes, Antibodies and Chemical Reagents. 
All the restriction enzymes were purchased from New England 
BioLabs (Beverly, MA). Anti-human primary mouse monoclonal 
antibodies used were against: P-cad (clone 56) and p120ctn (clone 
98) (BD Transduction Laboratories, Lexington, KY), N-cad (CH-19 
and GC-4) and α-tubulin (B-5-1-2) (Sigma-Aldrich, Bornem, 
Belgium), E-cad (HECD-1) (Takara Biochemicals, Kyoto, Japan), 
and ERα (NCL-L-ER-6F11) (Novocastra, Newcastle, United 
Kingdom). 17β-estradiol (E2) was purchased from Sigma-Aldrich 
Química (Portugal) and ICI was kindly provided by AstraZeneca 
(Portugal). Both drugs were dissolved in 100% ethanol, and added 
to the culture media. The concentrations used were 10 nM for E2 
and 100 nM for ICI, unless mentioned otherwise. Cycloheximide 
(CHX) was obtained from Sigma, and used at 25 µg/ml. For the 
control situations, cells were treated only with 100% ethanol. 
Cells and transient transfection. Human cancer cell lines 
were obtained as follows: BT-20 from P. Coopman (Laboratory of 
Molecular Biology, Ghent University, Belgium), MCF-7/AZ 
(MCF7) from P. Briand (The Fibiger Institute, Copenhagen, 
Denmark), ZR-75.1 and T47D from American Type Culture 
Collection (Manassas, VA), and HEK 293T (HEK) cells from V. 
De Corte (Department of Biochemistry, Faculty of Medicine and 
Health Sciences, Flanders Interuniversity Institute for 
Biotechnology, Ghent University, Belgium). Cell lines were 
routinely maintained at 37ºC, 10% CO2, in the following media 
(Invitrogen, Merelbeke, Belgium): 50% DMEM/50% HamF12 
(MCF7), DMEM (BT-20, T47D, HEK) or RPMI-1640 (ZR-75.1). 
All media for routine culture contained 10% heat-inactivated FBS 
(Greiner bio-one, Wemmel, Belgium), 100 IU/ml penicillin, 100 
µg/ml streptomycin and 2.5 µg/ml amphotericin B (Invitrogen). To 
obtain transient transfectants, appropriate expression vectors (2.5 
µg) were introduced into HEK cells (2x105) with Fugene® (Roche 
Molecular Biochemicals, Mannheim, Germany) and transfection 
efficiencies were evaluated by measuring EGFP expression by flow 
cytometry. 
Retroviral Transduction. The P-cad coding sequence was 
EcoRI digested from pIRES2-EGFP, and EcoRI subcloned into the 
LZRS-IRES-EGFP (LIE) vector, to generate the LZRS-P-cad-
IRES-EGFP vector. The LIE retroviral vector, encoding only 
EGFP, was used as a control. For the production of retroviral 
supernatant, the Phoenix-Amphotropic packaging cell line (a kind 
gift from Dr. G.P. Nolan, Stanford University School of Medicine, 
Stanford, CA) was transfected with the LIE and the LZRS-P-cad-
IRES-EGFP plasmids using calcium-phosphate precipitation 
(Invitrogen) to generate both retroviruses. The viral supernatant 
was spun (10 min at 350xg) and aliquots were stored at –70°C until 
use. Transduction of cell lines was performed as described before 
(41). 
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Flow Cytometry Staining and Cell Sorting. For analysis of 
E- and N-cad surface expression, cells were detached under 
cadherin saving procedures (42) and approximately 1x105 cells 
were used for staining. Cells were washed with cold PBS 
containing BSA and incubated for 30 min with the anti-E-cad 
HECD-1 or anti-N-cad GC-4 antibodies. This was followed by two 
washes with PBS/BSA, 30 min incubation with biotinylated rabbit 
anti-mouse monoclonal antibody, two washes with PBS/BSA, 20 
min incubation with streptavidin-phycoerythrin and a final wash 
with PBS/BSA. For routine analysis of EGFP expression, cells 
were detached with trypsin/EDTA. Flow cytometric analysis and/or 
cell sorting were performed as described before (41). 
Biotinylation, Immunoprecipitation and Immunoblotting. 
Immunoprecipitation and immunoblotting experiments, and 
quantification of bands, were performed as published before (43). 
For biotinylation, the cells were first incubated with 0.5 mg/ml of 
biotin, during 30 min, and washed four times with PBS, before the 
cell lyses. To control for equal loading of total lysates, 
immunostaining with anti-α-tubulin was performed routinely (not 
always shown). Each immunoblot was done at least three times and 
the ones that were selected to show are representative experiments.  
RT-PCR. RT-PCR experiments were done as previously described 
(43). Primers specific for P-cad cDNA were: sense 5’-
ACGAAGACACAAGAGAGATTGG-3’ and antisense 5’-
CGATGATGGAGATGTTCATGG -3’, to generate a 287-bp 
product. PCRs were done in a Minicycler™ (Biozym, The 
Netherlands) with an annealing temperature of 55°C. 
Slow Aggregation Assays. On Semi-Solid Substratum: 2x104 
cells in 200 µl medium were seeded on solidified agar in a 96-well-
plate (42). Aggregate formation was evaluated under an inverted 
microscope after 24h, 48h and 72h. In Suspension: 6x105 cells were 
added to 50 ml-Erlenmeyer flasks in 6 ml medium.  The flasks were 
incubated on a Gyratory shaker (New Brunswick Scientific Co., 
New Brunswick, NJ) at 72 rpm, and continuously gassed with 
humidified 10% CO2 in air. The particle size distribution of the 
aggregates was measured with a Coulter Particle Size Counter 
(LS2000, Coulter Company, Miami, FL).  The diameter of the 
particles can be considered as a measure for aggregate formation. 
Statistical analysis of differences between the particle size 
distribution curves was done with the Kolmogorov-Smirnov 
method. 
Invasion Assays. Collagen Type I Invasion Assay (44): Six-
well plates were filled with 1.3 ml of neutralized collagen type I 
(0.09% w/v) (Upstate Biotechnology, Inc, Lake Placid, NY) and 
incubated for at least 1h at 37°C to allow gelification. 1x105 cells of 
a single-cell suspension were seeded on top of the gel and cultures 
were incubated at 37°C during 24h. Using an inverted microscope 
controlled by a computer program (45), invasive and superficial 
cells were scored blind-coded in 12 fields of 0.157 mm2. The 
invasion index expresses the percentage of cells invading into the 
gel over the total number of cells counted. Matrigel Invasion Assay: 
Transwell chambers with polycarbonate membrane filters (6.5 mm 
diameter, 8 µm pore size) (Costar, Corning, NY) were coated with 
20 µl of a Matrigel solution (Becton Dickinson). 1x105 cells were 
added to the upper compartment of the chamber. In the lower 
compartment, conditioned cell culture medium of the MRC-5 
human embryonic lung fibroblast cell line was added as a chemo-
attractant. After 24h of incubation at 37°C, the upper surface of the 
filter was cleared from non-migratory cells with a cotton swab and 
washes with serum-free DMEM. The remaining (invasive) cells at 
the lower surface of the filter were fixed with cold methanol and 
stained with DAPI (Sigma, 0.4 mg/ml). Invasive cells were scored 
by counting 50 fields/filter with a fluorescence microscope, at x250 
of magnification. Rat myofibroblast DHD-FIB cells were routinely 
included as a positive control for invasion in both assays. Each 
experiment was repeated at least three times. For collagen invasion 
assay, data are expressed as mean ± SD; for matrigel invasion 
assay, a representative experiment is shown, with the SD for the 
number of cells scored on the 50 microscopic fields. Statistical 
significance was determined by t test, and differences between 
groups were analyzed using the ANOVA; p<0.05 was considered 
significant. 
RESULTS 
 
The antiestrogen ICI 182,780 upregulates P-
cadherin in ERα positive breast cancer cell lines 
To test the hypothesis that ERα negatively 
regulates P-cad, we examined the expression of ERα 
and cadherins in breast cancer cell lines by Western 
blot (Table I). Interestingly, higher levels of P-cad 
were found in ERα negative BT-20 cells. 
A 24h treatment with the antiestrogen ICI [10-7 
M] increased P-cad protein levels in MCF7 and ZR-
75.1 cells, but not in BT-20 cells (Fig. 1). There were 
no significant changes in P-cad levels observed in 
T47D cells, bearing already higher pre-treatment 
levels of P-cad and lower levels of ERα than the 
responsive cell types. ICI-induced increase of P-cad 
was associated with a decline of ERα levels (Fig. 1).  
For further investigation, we chose the MCF7 cell 
line, because it is ERα positive, highly responsive to 
estrogen and extensively investigated as a model of 
breast cancer (46). In these cells, ICI induced, 
respectively, up- and downregulation of P-cad and 
ERα in a time- and dose-dependent way (Fig. 2A and 
2B). A decrease of ERα levels was already observed 
after 6h of treatment, whereas P-cad levels nearly 
doubled after 12h. After 24h of exposure to ICI, 
 Type E-
cada,b 
P-
cada,b 
N-
cada,b 
ERαa
,b 
Invasion in 
Collagen 
Type Ic,d 
MCF-7/AZ Breast +++ + ─ +++ ─ 
ZR-75.1 Breast +++ + + +++ ─ 
T47D Breast +++ ++ ─ ++ + 
BT-20 Breast +++ +++ ─ ─ + 
HEK 293T Kidney ─ ─ +++ ─ ─ 
 
Table I. Analysis of E-cad, P-cad, N-cad and ERα expression, and 
in vitro invasion into collagen type I, of the human cell lines used in 
this study. a, determined by Western blot analysis; b, ─, negative; +, 
low; ++, moderate; +++, strong; c, determined by Collagen Type I 
Invasion Assay; d, ─, not invasive; +, invasive 
Figure 1. Effect of ICI 182,780 on P-cadherin and Estrogen 
Receptor-α expression in breast cancer cell lines. 
Immunoblotting, using anti-P-cad and anti-ERα mAb, of cell lysates 
derived from the breast cancer cell lines MCF7, ZR-75.1, T47D (50 
µg of protein loaded) and BT-20 (30 µg), after a 24h treatment with 
ICI [10-7M]. Band quantification was done relatively to the 
expression levels in control cells. An increase of P-cad expression 
in MCF7 and ZR-75.1 cells was observed, whereas the levels in 
ERα-negative BT-20 cells were not altered. P-cad levels were not 
changed in T47D cells, although ERα levels declined in all positive 
cell lines.
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higher P-cad and lower ERα levels persisted during 
several days, with normalization 96h after ICI 
withdrawal (Fig. 2C). To examine whether or not the 
effect of ICI on P-cad expression was mediated via 
ERα, we did a competition experiment. As already 
described (47), E2 readily decreased ERα levels, 
although to a lesser extent than ICI did (Fig. 2D). 
Importantly, the ICI-induced upregulation of P-cad 
was counteracted by E2 (Fig. 2D), as it also 
accelerated normalization of P-cad in cells treated for 
24h with ICI (Fig. 2E). Together, these results suggest 
that not the decrease in ERα, but the lack of ERα 
signaling is responsible for the increase of P-cad by 
ICI. 
RT-PCR revealed an increase of P-cad mRNA 
after ICI treatment, suggesting that the higher P-cad 
protein expression is based on an upregulation of P-
cad transcripts (Fig. 3A). This was confirmed by a 
micro-array, performed on estradiol- or ICI-treated 
MCF-7 cells, in which estradiol did not alter P-cad 
mRNA levels, whereas ICI induced an eightfold 
increase. Finally, it remained to be determined 
whether induction of the P-cad gene (CDH3) was a 
direct effect of ICI or required prior induction of other 
genes. We addressed this question by blocking protein 
synthesis in cells, since the induction of primary 
target proteins (like ERα), or immediate early genes, 
should not be sensitive, whereas secondary targets 
should be blocked. The treatment of MCF7 cells with 
Figure 2. Regulation of P-cadherin expression by an ERα-dependent signaling pathway in MCF-7/AZ breast cancer cells. 
Immunoblotting, using anti-P-cad and anti-ERα mAb, of total lysates from MCF7 cells that had been treated with the indicated 
concentrations of ICI, for the indicated time points. Band quantification was done relatively to the expression levels in untreated cells. 
Immunostaining for anti-α-tubulin was done to control for equal loading. (A) ICI induces upregulation of P-cad and downregulation of 
ERα levels in a time-dependent manner, being maximal after 12h of treatment. (B) ICI induces upregulation of P-cad and downregulation 
of ERα levels in a dose-dependent way, the higher concentrations leading to a more pronounced effect. (C) MCF7 cells were grown in the 
presence of ICI for 24h. At time 0h, ICI was withdrawn and cell lysates were prepared at the indicated time points. Immunoblotting was 
performed to analyze P-cad (hatched bars) and ERα (black bars) expression. The levels of both proteins start to normalize again 96h after 
ICI withdrawal, showing the reversibility of the effect. (D) Cells were treated with ICI, E2 or a combination of both, for 24h. Although 
both ICI and E2 decreased ERα levels, the ICI-induced upregulation of P-cad was counteracted by estradiol. (E) MCF7 cells were grown 
in the presence of ICI for 24h (lanes 2, 5 and 6). After that, ICI was withdrawn and cells were treated (4 and 6) or not (3 and 5) with E2 
[10-8M] for additional 24h. E2 accelerated the reversion of P-cad expression to control levels in cells that had been treated with ICI. 
 
Figure 3. Effect of ICI 182,780 on P-cadherin mRNA levels in 
MCF-7/AZ cells and involvement of de novo protein synthesis in 
this process. (A) RT-PCR analysis of P-cad mRNA levels after ICI 
treatment of MCF7 cells for 24h. The analysis was done after the 
indicated No. of cycles of PCR amplification. P-cad mRNA 
increased in the presence of ICI (more evident at the 30 cycle point, 
in the exponential phase). Band quantification is presented in the 
graph shown below. (B) Immunoblotting, using anti-P-cad and anti-
ERα mAb, of lysates from cells treated with CHX during 24h, alone 
or in combination with ICI. Band quantification was done relatively 
to the expression levels in untreated cells. CHX blocked P-cad 
upregulation induced by ICI, suggesting the involvement of de novo 
protein synthesis. 
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CHX, a de novo protein synthesis inhibitor, largely 
blocked P-cad upregulation by ICI (Fig. 3B), which is 
consistent with a requirement for newly synthesized 
proteins, probably induced by ICI, prior to CDH3 
activation. In contrast, as expected, this drug did not 
block ERα downregulation mediated by ICI (Fig. 3B). 
 
ICI 182,780 decreases cell-cell adhesion and 
increases invasiveness of MCF-7/AZ cells 
MCF7 cells formed compact aggregates on top of 
soft agar or when incubated in Erlenmeyer flasks 
under continuous shaking (Fig. 4A(i) and 4B), as 
previously shown (48). In presence of ICI, this effect 
was counteracted (Fig. 4A(ii) and 4B). Even a 24h 
pre-treatment with ICI, followed by testing these cells 
in the absence of ICI, still revealed inhibition of 
aggregation (Fig. 4A(iii)). 
These same MCF7 cells failed to invade into 
collagen, as previously described (48-49). A 24h pre-
treatment with ICI induced invasion of MCF7 cells, 
tested in the absence of ICI, which was also shown in 
the Matrigel assay (Fig. 4C and 4D). These pro-
invasive effects of ICI were counteracted by E2 (Fig. 
4C and 4D), indicating that they are mediated by 
interference with ERα-signaling. 
Aggregation and invasion of MCF7 cells, in the 
presence of ICI, mimics the behavior of the poorly 
aggregating and invasive ERα negative and P-cad 
positive BT-20 cells (Table I), which remained 
unchanged upon treatment with ICI (Fig. 5). 
 
P-cadherin expression increases invasiveness but 
does not alter cell-cell adhesion of MCF-7/AZ cells 
Cells, retrovirally transduced to encode only 
EGFP (MCF7.LIE) or both P-cad and EGFP 
(MCF7.P-cad), were sorted to more than 90% EGFP 
positivity (Fig. 6A). P-cad levels were higher at the 
cell surface in P-cad transduced cells (Fig. 6B). The 
levels of cell-surface E-cad were the same in P-cad 
transduced cells, as in vector-transduced cells (Fig. 
6A and 6B), excluding an effect of the exogenous 
cadherin on the levels of the major endogenous 
cadherin.  
On plastic substratum, P-cad transduced MCF7 
cells, like their parental or vector-transduced cells, 
formed epithelioid islands, showing no morphotype 
differences (data not shown). Transduction with P-cad 
did not interfere with E-cad mediated cell-cell 
adhesion (Fig. 6C and 6D). However, P-cad induced 
invasion, in collagen type I and in Matrigel, as was 
observed with ICI-treated MCF7 cells, but not with 
parental or vector (LIE) controls (Fig. 6E and 6F).  
 
Figure 4. Effect of ICI on aggregation and on in vitro invasion of MCF7 cells. A: Pictures, after 72h, of the slow aggregation assay on 
semi-solid substratum. (i) Cells that were left untreated form compact aggregates, which are inhibited in cells cultured in presence of ICI (ii), 
and in cells that have been pre-treated with ICI before seeding on top of agar (iii). B: Slow aggregation assay in suspension: the cells were pre-
treated with ICI for 24h, before incubation in Erlenmeyer flasks. A particle size distribution curve was generated using a particle size counter. 
Aggregates formed by ICI-treated cells were significantly smaller (*, p=0.002) than control aggregates. The arrow indicates the measurement 
of a single cell suspension at the beginning of the experiment. C and D: Cells that had been pre-treated for 24h with the indicated 
concentrations of ICI, E2 or the combination of both, were seeded as a single cell suspension on top of collagen type I gels (C) or on matrigel-
coated filters (D). In collagen type I invasion assay, ICI-treated cells were significantly more invasive than control cells (*, p=0.0081, p=0.02 
and p=0.03 for ICI [10-7M], [10-6M] and [10-5M], respectively). In Matrigel, the differences were also statistically significant (*, p<0.001 for 
ICI [10-7M] and [10-6M]). 
 
Figure 5. Effect of ICI on aggregation and on in vitro invasion of 
BT-20 cells. A: Pictures, after 72h, of the slow aggregation assay on 
semi-solid substratum. (i) Cells that were left untreated do not form 
compact aggregates; no alterations (ii) in cells cultured in presence 
of ICI, and (iii) in cells that have been pre-treated with ICI before 
seeding on top of agar, in the absence of ICI. B: Cells that had been 
pre-treated for 24h with ICI were seeded as a single cell suspension 
on top of collagen type I gels (black bars) and on matrigel (hatched 
bars). ICI-treated cells are as invasive as control cells. 
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P-cadherin-induced invasion is not breast cancer 
cell or endogenous cadherin-specific 
P-cad retroviral transduction was also performed 
with HEK cells, expressing at their surface low and 
high levels of E- and N-cad, respectively (50) (Table I 
and Fig. 7A), and being invasive neither into collagen 
type I nor into Matrigel (51). Sorting of vector- or P-
cad-transduced cells resulted in populations having 
either moderate or high EGFP expression 
(HEK.LIE.Med, HEK.LIE.High, HEK.P-cad.Med and 
HEK.P-cad.High) (Fig. 7A and 7B). As for MCF7 
cells, no differences in morphotype or aggregation 
were observed between parental and transduced cells 
(Fig. 7C and 7D). Although there was a 
downregulation of superficial N-cad in the highest P-
cad expressing cells (Fig. 7B), this did not result in a 
significant decrease in total levels of N-cad (Fig. 7A). 
P-cad transduced cells were significantly more 
invasive into collagen type I or Matrigel than vector-
transduced cells, with higher invasiveness of the cells 
expressing more P-cad (Fig. 7E and 7F). In both 
assays, the control cells with higher LIE expression 
levels showed an increased invasion index when 
compared to the ones with moderate levels of 
expression. This may be due to the insertion of viral 
promoters into the host genome, leading to the 
aberrant activation of host genes. However, although 
this observation highlights the care that should be 
taken when using these systems, it does not influence 
the interpretation of our results as such: the values of 
the P-cad transduced cells remain significantly 
different from those of the respective vector-
transduced cells. 
 
P-cadherin mediates invasion of HEK 293T cells 
via its juxtamembrane domain 
To identify the P-cad domain(s) necessary for its 
pro-invasive effects, we used several P-cad constructs 
(Fig. 8A) for transient transfection of the HEK cell 
line. Biotinylation and immunoblotting confirmed 
expression of all constructs at the plasma membrane 
(Fig. 8B). Transient transfection with P-cad induced 
invasion into collagen type I, as observed with stably 
transduced HEK cells (Fig. 8C). 
The P-cad point mutant, PC-R503H (Fig. 8A), 
representing the missense mutation in CDH3, found 
in hypotrichosis with juvenile macular dystrophy (52), 
failed to support strong cell-cell adhesion unlike wild-
type P-cad (unpublished data). Most likely, the reason 
for this failure is the disruption of the strongly 
conserved LDRE Ca2+-binding motif in the fourth 
extracellular domain of P-cad. Nevertheless, PC-
R503H still induced invasion (Fig. 8C). 
Mutants of the P-cad cytoplasmic tail were also 
generated (Fig. 8A). Transfection into HEK cells 
showed that PC-CT762, retaining the intact P-cad 
JMD, induced invasion like wild-type P-cad (Fig. 
8C). Since this mutant is truncated just before the 
CBD, we assume that βctn, γ-catenin, or any other 
protein that binds to this region are not needed for P-
cad-mediated invasion. 
With mutants within the JMD (Fig. 8A), statistically 
significant invasion into collagen was seen only with 
the truncation mutants that still retained the intact 
JMD (PC-CT719 and PC-CT727) (Fig. 8C). The 
somewhat decreased ability of PC-CT719 to induce 
invasion (Fig. 8C) might be due to its lower 
expression levels (Fig. 8B). In line with the results 
obtained with the truncation mutants, and confirming 
that the CBD is not involved in the pro-invasive 
effects, the PC-∆703-707 mutant (lacking EEGGG in 
the p120ctn binding site), with impaired p120ctn 
binding (Fig. 8D), was not able to induce invasion of 
HEK cells into collagen type I (Fig. 8C). So, P-cad 
needs to have an intact JMD to be able to induce 
invasion of HEK cells.  
To exclude that the gain of any exogenous 
cadherin, retaining its JMD, would be sufficient for a 
 
 
Figure 6. Cell aggregation and in vitro invasion of stably transduced MCF7 cells with P-cad cDNA. A: Flow cytometric evaluation of 
EGFP expression (x-axis) and E-cad expression (y-axis) in MCF7.LIE and MCF7.P-cad cells. P-cad expression did not induce alterations in 
E-cad expression levels (right plot). The percentage of EGFP positivity is indicated for each cell line. B: Immunoblotting, using anti-E-cad 
and anti-P-cad antibodies, of lysates from biotinylated MCF7.LIE and MCF7.P-cad cells. C: In the slow aggregation assay in suspension, 
both MCF7.LIE and MCF7.P-cad cells form similar compact aggregates, after 48h. The arrow indicates the measurement of a single cell 
suspension at the beginning of the experiment. D: Pictures, after 48h, of the slow aggregation assay on semi-solid substratum. MCF7.LIE (i) 
and MCF7.P-cad (ii) cells form round and compact aggregates, with no differences observed. E: In the collagen type I invasion assay, 
MCF7.P-cad cells invade significantly more (*, p=0.0024). F: Representative experiment of Matrigel invasion assay, where MCF7.P-cad 
cells invade significantly more than empty-vector transduced cells (*, p<0.001). 
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pro-invasive effect, we demonstrated that HEK cells 
transfected with mouse wild-type E-cad cDNA (Fig. 
8A) failed to invade into collagen type I (Fig. 8C). In 
conclusion, the juxtamembrane domain of P-cad 
confers to this molecule the specific ability to induce 
invasion of HEK cells, in the presence of the 
endogenously expressed cadherin. 
 
 
DISCUSSION 
 
The antiestrogen ICI increased time- and dose-
dependently P-cad expression in ERα-positive breast 
cancer cells. This increase could be completely 
reverted by E2, categorizing CDH3 as an estrogen-
repressed gene and pointing to E2 as a key regulator 
of this cadherin. In addition to competing for ERα, 
ICI also increased its breakdown (37). As a result, ICI 
abrogates ERα signaling, and the subsequent 
regulation of E2 responsive genes (53). As the human 
P-cad promoter (GI:2950171) does not contain the 
consensus sequence 5’-GGTCAnnnTGACC-3’ of the 
estrogen-responsive elements (54), E2 is unlikely to 
have a direct inhibitory effect on transcription of the 
CDH3 gene. The increase of P-cad by ICI, some 
hours after the decrease of ERα, and its inhibition by 
CHX, pleads for the activation of a CDH3 
transcription factor, through ICI-mediated abrogation 
of ERα. Presence of this E2-regulated factor may 
account for the high P-cad levels in some breast 
cancer cell lines and for the inverse correlation 
between ERα and P-cad expression in mammary 
tumors. 
In MCF7 breast cancer cells, ICI treatment led to 
a decreased cell-cell adhesion and promotion of 
invasion in vitro. This is in line with the finding that 
E2 (55-56), and even the unliganded receptor (57), 
may decrease in vitro invasiveness and motility of 
breast cancer cells, suggesting that some estrogen-
regulated genes negatively control invasion. Since this 
control is lost in cells treated with high concentrations 
of ICI, which upregulate P-cad, the latter was further 
investigated in in vitro aggregation and invasion 
assays.  
Surprisingly, retroviral transduction of MCF7 and 
HEK cells with P-cad did not change aggregation. 
These results suggest that P-cad does not shift the 
aggregation balance established by the other cadherins 
in these systems. By contrast, such balance may well 
be changed for invasion, as demonstrated with P-cad 
transduced cells. Furthermore, the pro-invasive effect 
of P-cad was not restricted to E-cad positive MCF7 
cells, suggesting factors others than endogenous 
cadherins. A critical level of P-cad seems to be 
needed for its pro-invasive activity, as evidenced by a 
comparison between the highly invasive and highly P-
cad positive BT-20 and T47D cells, and the non-
invasive and weakly P-cad positive MCF7 and ZR-
75.1 cells (Table I). 
In contrast to its pro-invasive activity in our cells, 
transfection of other cell lines with P-cad inhibited 
 
 
Figure 7. Cell aggregation and in vitro invasion of stably transduced HEK cells with P-cad cDNA. A: Immunoblotting, using anti-N-cad 
and anti-P-cad antibodies, of lysates from biotinylated HEK, HEK.LIE.Med, HEK.P-cad.Med, HEK.LIE.High and HEK.P-cad.High cells. 
Band quantification was done relatively to the expression levels in control cells. To control for equal loading, immunostaining with anti-α-
tubulin was done. B: Flow cytometric analysis of EGFP expression (x-axis) and N-cad expression (y-axis) in the indicated cell lines. High 
levels of P-cad in the HEK.P-cad.High cell line induced downregulation of endogenous N-cad. The percentage of EGFP positivity is indicated 
for each cell line. C: In the slow aggregation assay in suspension, HEK.LIE.Med, HEK.P-cad.Med, HEK.LIE.High and HEK.P-cad.High cell 
lines form similar compact aggregates, after 48h. The arrow indicates the measurement of a single cell suspension at the beginning of the 
experiment. D: Pictures, after 48h, of the slow aggregation assay on semi-solid substratum. HEK.LIE.Med (i), HEK.LIE.High (ii), HEK.P-
cad.Med (iii), and HEK.P-cad.High (iv) cells form round and compact aggregates, with no differences observed. E: A single cell suspension 
of these cell lines was seeded on top of collagen type I gels. After 24h of incubation, HEK.P-cad.Med and HEK.P-cad.High cells invaded 
significantly more into the collagen type I matrix (*, p=0.005 and p=0.02, respectively). Although HEK.LIE.High was statistically different 
from non-transduced cells (*, p=0.003), the comparison with HEK.P-cad.High still shows the significant effect of P-cad (p=0.03). F: 
Representative experiment of Matrigel invasion assay. HEK.P-cad.Med and HEK.P-cad.High cells invaded significantly more than empty-
vector transduced cells (*, p<0.001). Also here, although HEK.LIE.High differed significantly from control, the comparison with HEK.P-
cad.High still shows the significant effect of P-cad on invasion (p<0.001). 
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invasion (58-59 and our unpublished data), suggesting 
that P-cad may act both as an invasion promoter and 
suppressor, depending on the cell type and its invasive 
status. Transgenic mice expressing high levels of P-
cad in the normal mammary epithelium (60) 
contributed little to this issue, as they did not produce 
tumors, and as neu oncogene-induced mammary 
tumors were always P-cad negative. 
In the present study, the pro-invasive action of P-
cad is unlikely to be the result of alterations in cell-
cell adhesion, since 1) the assays score invasion of 
single cells into or through a matrix, 2) the retroviral 
transduction of MCF7 and HEK cells with P-cad did 
not change aggregation, and 3) the point mutant PC-
R503H, incapable of supporting strong P-cad 
mediated adhesion, still induced invasion. We 
presume that the pro-invasive activity of P-cad is due 
to changes in signaling pathways. 
The cytoplasmic domain of classical cadherins is 
highly conserved, suggesting crucial roles for proteins 
binding to this region (3). Recently, Wong and 
Gumbiner (61) attributed the anti-invasive activity of 
wild-type E-cad to its interaction with βctn. An E-cad 
mutant, retaining the CBD, but with a point mutation 
that abolishes p120ctn binding, was still able to 
suppress invasion. By contrast, in P-cad, maintenance 
of the JMD domain is crucial for the induction of 
invasion, irrespective of the CBD. Ireton et al. (62) 
showed that restoration of p120ctn in a colon 
carcinoma cell line resulted in E-cad stabilization and 
rescue of its function, either directly or indirectly, by 
preventing other proteins of hampering E-cad. 
Although a related mechanism could account for the 
induction of invasion by P-cad, where destabilization 
of anti-invasive cadherin/catenin complexes would 
result from competition for the available p120ctn by 
the P-cad JMD, we consider this possibility less 
likely. Despite the fact that the downregulation of N-
cad in HEK cells by high levels of the several P-cad 
constructs coincided with stimulation of invasion 
(Fig. 8C and 9), moderate P-cad expression levels, 
leaving the endogenous cadherin unchanged, were 
Figure 8. In vitro invasion of HEK cells transiently transfected with P-cad constructs. A: Schematic diagram of the various constructs 
used for transient transfection of HEK cells. B: Immunoblotting, using anti-P-cad antibody, of streptavidin precipitations of biotinylated HEK 
cells, transiently transfected with P-cad constructs. C: A single cell suspension of HEK cells, transiently transfected with the indicated 
constructs, was seeded on top of collagen type I gels. After 24h, invasive cells were scored. Besides HEK.PC-WT cells, also HEK.PC-
R503H, HEK.PC-CT762, HEK.PC-CT719, and HEK.PC-CT727 invaded significantly more than empty-vector transfected cells (HEK.IRES) 
into the collagen (*, p<0.001 for HEK.PC-WT and HEK.PC-R503H, p=0.003 for HEK.PC-CT762, p=0.015 for HEK.PC-CT719, and 
p=0.023 for HEK.PC-727). D: Immunoprecipitation (I.P.), using anti-p120ctn antibody, of total lysates of HEK cells transiently transfected 
with the empty vector (IRES), with PC-WT and with PC-∆703-706 constructs. Immunostaining (I.S.) of these blots with anti-P-cad and anti-
p120ctn antibodies, showed that PC-WT strongly precipitates with p120ctn, as compared to PC-∆703-706, where there is interference with 
this binding (right two blots). The staining of total lysates with P-cad indicates a similar expression of the transfected P-cad constructs (left 
blot). 
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sufficient to induce invasion. Further, transfection of 
HEK cells with E-cad did not induce invasion (Fig. 
8C), despite decreased endogenous cadherin in highly 
expressing cells (Fig. 9), and expected competition for 
cadherin-binding proteins. Alternatively, P-cad may 
generate a specific pro-invasive signal via its JMD. In 
this hypothesis, JMD binding of p120ctn, or other 
proteins, to P-cad has to differ from the binding to E- 
or N-cad, either by strength, conformation or 
recruitment of other members of the complex. This, in 
turn, may result in the activation of pathways that 
overcome the suppressive signals mediated by the 
endogenous cadherins.  
Although the JMD of cadherins is highly 
conserved, its function is very context-dependent. It 
may both positively and negatively regulate cadherin 
activity. Cells expressing mutated E-cad JMD are 
weakly adherent (63-64), more motile (65), but still 
epithelioid. Upon formation of adhesive contacts, the 
JMD recruits and activates Rac, regulating the actin 
cytoskeleton (66-68). In another context, the JMD 
inhibits aggregation mediated by classical cadherins 
and induces cell motility (69-71).  The JMD of VE-
cadherin, for example, excludes endogenous N-cad 
from junctions, and regulates cell proliferation (72). 
Except from the presently demonstrated induction of 
invasion, no regulatory functions have been described 
for the P-cad JMD.  
Although binding of proteins to the JMD of P-cad 
has just been documented for p120ctn (6), we cannot 
exclude the possibility that its disruption introduces 
conformational changes and/or uncouples the 
interaction of other proteins, which could be 
responsible for the observed effects. Striking 
examples of this were shown for E-cad, where 
functional differences have been noted between larger 
and minimal deletions of the JMD, with even the 
minimal changes disrupting binding of multiple 
molecules (71, 73).  
Data about the role of p120ctn in normal and 
cancer cells are conflicting. Positive and negative 
regulation of cell-cell adhesion and motility possibly 
reflect differences in cell type, cadherins, p120ctn 
isoforms and shuttling between cadherin-bound and 
cytoplasmic pools (74). When overexpressed in the 
cytoplasm, p120ctn may regulate the actin 
cytoskeleton and cell motility, through Rho GTPases 
(75-77). E-cad would also bind p120ctn more tightly 
than N-cad, which is found in motile cells such as 
fibroblasts (78). Similarly, in our experiments, 
differences in binding strength between E-, N- and P-
cad-bound p120ctn may influence its effect on the 
activity of the Rho GTPases, possibly making the 
cells more prone to invade. Alternatively, the panel of 
molecules recruited by p120ctn may differ depending 
on the cadherin it is bound to.  
In addition, other molecules, like Hakai and 
presenilin-1 (PS-1) have been reported to bind to the 
JMD of classical cadherins, to a sequence adjacent to 
or overlapping the p120ctn-binding domain, thereby 
competing with p120ctn for binding (73, 79). 
However, the significance of these interactions is not 
well known, and the interaction of these proteins with 
P-cad still has to be confirmed.  
In conclusion, our study establishes an as yet 
unknown role for P-cad in cancer: 1) P-cad expression 
is regulated through ERα-signaling, suggesting that 
the inverse in vivo correlation between these 
molecules stems from a causal relationship. 2) P-cad 
induces invasion, in the context of endogenous E- or 
N-cad expression; since P-cad expression in breast 
cancer is far more frequent than aberrant expression 
of N-cad, its physiological relevance is more likely to 
be higher (22, 24). 3) Invasion mediated by P-cad 
required its intact JMD. This establishes a novel role 
for this domain and distinguishes P-cad mediated 
invasion from invasion induced by N-cad, which  
depends on a physical interaction of its extracellular 
domain with the fibroblast growth factor receptor  
(80). Moreover, although the P-cad JMD differs in 
only few amino acids from the corresponding E-cad 
domain, yet it exerts an opposite function: whereas 
 
 
Figure 9. N-cadherin expression of HEK cells transiently transfected with P-cad constructs. Flow cytometric analysis of EGFP 
expression (x-axis) and N-cad expression (y-axis) in the indicated cell lines. High levels of the P-cad constructs, which maintain an intact 
JMD, induced downregulation of endogenous N-cad. The percentage of N-cad downregulation is indicated for each cell line, compared to 
HEK.IRES cell line (0%). 
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the E-cad JMD suppresses motility (81), the P-cad 
JMD is necessary for induction of invasion. In order 
to understand why such related domains can have 
opposite functions, it will be crucial to identify new 
interaction partners and/or to study if the interaction 
of known partner molecules differs between 
cadherins. 
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II.6. E-cadherin is a substrate for multiple proteases 
 
One of the multiple mechanisms of 
functional downregulation of E-cadherin that have 
been described, is its post-translational inactivation 
via proteolytical cleavage. This processing may occur 
by various enzymes at distinct sites of the 120kD E-
cadherin protein (see inset).  
Calpain cleaves the cytosolic E-cadherin 
domain upstream of the β-catenin binding motif, 
generating a 100-kD transmembrane fragment that 
cannot bind β-, γ- or p120 catenin anymore. 
Consistent with the frequent overexpression of calpain 
in prostate cancer, the 100kD fragment was found to 
accumulate in prostate tumors (Rios-Doria et al., 
2003). 
When epithelial cells go into apoptosis, a 
97kD membrane-bound E-cadherin fragment is 
detected in the cells. This fragment derives from an 
intracellular proteolytic event, releasing part of its 
cytoplasmic tail, including the β-catenin binding 
domain (Vallorosi et al., 2000). A subsequent study 
showed that this cleavage was mediated by caspase-3, 
a cysteine protease involved in apoptosis that cleaves 
its substrates after aspartate residues (Steinhusen et 
al., 2001). In addition to this caspase-3 mediated 
cleavage, a second proteolytic event leads to release 
of the E-cadherin ectodomain (see further). 
Accumulation of the truncated 97kD fragment has 
been observed in prostate carcinomas, as compared to 
matched normal prostate tissue (Rashid et al., 2001). 
Presenilin-1 (PS1) is a polytopic 
transmembrane protein involved in most cases of 
early-onset familial Alzheimer’s disease. It is part of a 
multi-protein complex, which is involved in the γ-
secretase cleavage of multiple proteins (Selkoe, 
2001). PS1 binds to the juxtamembrane intracellular 
domain of E-cadherin, to the same domain that is 
responsible for p120 catenin binding, and competes 
with p120 catenin for binding. PS1 binding to E-
cadherin stimulates association of E-cadherin with β- 
and γ-catenin, promotes cytoskeletal association of the 
cadherin/catenin complex and increases Ca2+-
dependent aggregation (Baki et al., 2001). However, 
PS1 has also been implicated in E-cadherin 
proteolysis. PS1-mediated cleavage of both full-length 
and truncated (after ectodomain shedding) E-cadherin 
at the membrane-cytoplasm interface has been shown 
to release the E-cadherin cytoplasmic tail into the 
cytosol, promoting disassembly of adherens junctions 
(Marambaud et al., 2002). What role for PS1 prevails 
in a particular system may be dependent on the 
conditions. Under conditions promoting cell-cell 
adhesion, incorporation of PS1 into the E-
cadherin/catenin complex may have a stabilizing 
effect. However, in conditions of stress, cell-cell 
dissociation or apoptosis, PS1 may facilitate cell 
separation by promoting disassembly of the adherens 
junctions. These two contrasting effects combined 
into one polypeptide may represent a quick and 
efficient way for the modulation of cell-cell contacts. 
Recently, PS1-mediated cleavage of N-cadherin was 
shown to release a cytoplasmic fragment that was 
capable of modulating signaling via binding to the 
transcription factor CBP (CREB binding protein; 
CREB, cyclic AMP response element binding protein) 
(Marambaud et al., 2003). Association of the 
cytoplasmic N-cadherin fragment with CBP promoted 
degradation of the latter, resulting in suppression of 
CREB-mediated transcription. Whether the E-
cadherin intracellular tail may have a similar function, 
remains to be determined. 
Cleavage in the extracellular juxtamembrane 
domain of the 120kD E-cadherin gives rise to a 
released 80kD ectodomain, coined soluble E-cadherin 
(sE-CAD). E-cadherin ectodomain shedding was first 
suspected from the detection of a soluble 80kD 
fragment in medium conditioned by MCF-7 breast 
cancer cells (Wheelock et al., 1987). E-cadherin 
cleavage and release of the 80kD sE-CAD is not 
necessarily a pathological process, as it also occurs 
during the preparation phase for uterine invasion in 
pregnant mice, where it is promoted by estradiol 
(Potter et al., 1996). Distinct sE-CAD fragments may 
be formed, depending on the protease involved. E-
cadherin ectodomain shedding following treatment 
with trypsin, in the presence of Ca2+, results in a 
fragment that is somewhat smaller than that seen upon 
cleavage by metalloproteases (MMPs). The latter has 
been studied most extensively, with characterization 
of the cleavage site (Steinhusen et al., 2001; 
Marambaud et al., 2002). Several MMPs, including 
stromelysin-1 (MMP-3) and matrilysin (MMP-7), 
have been involved in the production of sE-CAD in 
cancer (Noë et al., 2001; Davies et al., 2001), as well 
as in injured epithelia (McGuire et al., 2003). 
Interestingly, stromelysin-1 has been shown to induce 
EMT and acquisition of a premalignant phenotype, 
concomitant with cleavage of E-cadherin and release 
of sE-CAD by mammary epithelial cells (Lochter et 
 
..VCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLS… 
                    ↑                                                                       ↑                                               ↑                                                      ↑ 
                 MMP                                                             γ-secretase                                caspase-3                                      calpain 
 
Amino acid sequence of the human E-cadherin juxtamembrane extracellular (left), transmembrane (shaded) and 
juxtamembrane intracellular domain (right), indicating the cleavage sites of proteases (based upon Steinhusen et al.,2001; 
Marambaud et al., 2002, Rios-Doria et al., 2003) . 
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al., 1997). In the study presented here, we show that 
exposure of E-cadherin expressing cells to the serine 
protease plasmin may result in the generation of sE-
CAD. 
Several studies comparing the circulating sE-CAD 
levels in biological fluids of patients suffering from 
various types of cancer with the levels found in 
healthy persons revealed higher sE-CAD levels in the 
cancer patients. This was shown for liver cancer 
(Katayama et al., 1994), gastric cancer (Katayama et 
al., 1994; Gofuku et al., 1998; Chan et al., 2001), 
colon cancer (Velikova et al., 1998), bladder cancer 
(Banks et al., 1995; Grifiths et al., 1996, Protheroe et 
al., 1999), lung cancer (Cioffi et al., 1999), prostate 
cancer (Kuefer et al., 2003), skin cancer (Shirahama 
et al., 1996) and other cutaneous diseases 
(Matsuyoshi et al., 1995) and ovarian cancer 
(Sundfeldt et al., 2001), although controversy exists 
about the latter, since others did not find increased 
levels of sE-CAD in the cyst fluid from malignant 
ovarian tumors, as compared with benign cysts (Darai 
et al., 1998a, b). 
The release of an sE-CAD fragment may have several 
effects. First, the proteolytic release of the E-cadherin 
ectodomain may represent a mechanism that leads to a 
decrease of E-cadherin on the tumor cells, facilitating 
their release from the primary tumor, thus enhancing 
invasion and metastases. Second, the remaining 
transmembrane-intracellular fragment may compete 
with full-length cadherin for catenin binding 
(Hermiston and Gordon, 1995) or, alternatively, have 
a signaling function. Third, the released ectodomain 
may fulfill a biological role. sE-CAD has been shown 
to induce scattering of epithelial islands, which could 
be neutralized by adding an antibody against E-
cadherin (Wheelock et al., 1987). In contrast, neither 
a 84kD glycoprotein (gp84), trypsinized from murine 
embryonal carcinoma PCC4 cells (Hyafil et al., 
1980), nor a recombinant 80kD fragment 
(Herrenknecht and Kemler, 1993) had decompacting 
activity. Synthetic E-cadherin peptides containing the 
histidine-alanine-valine (HAV) sequence present in 
the first extracellular domain of E-cadherin, could 
interfere with E-cadherin function, as indicated by 
inhibition of aggregation, disturbance of epithelial 
morphology and induction of invasion (Mbalaviele et 
al., 1995; Willems et al., 1995; Noë et al., 1999, 
Makagiansar et al., 2001). Moreover, sE-CAD, 
released following cleavage by MMP’s, has been 
shown to inhibit aggregation and induce invasion of 
invasion-competent cells (Noë et al., 2001). In the 
article presented here we show that a plasmin-derived 
E-cadherin ectodomain is capable of disrupting cell 
aggregation and induction of invasion into collagen 
type I. 
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Plasmin Produces an E-Cadherin Fragment That
Stimulates Cancer Cell Invasion
1998; Wang, 2001). During invasion, the urokinase-type
plasminogen activator (uPA) is released as an inactive
proenzyme, pro-uPA, that binds to its cell surface recep-
tor uPAR. Coincident binding of pro-uPA and plasmino-
gen to uPAR enhances plasminogen activation, a phe-
nomenon that is also controlled by two inhibitors, PAI-1
and PAI-2 (Mignatti and Rifkin, 1996). The widely accept-
ed promotion of invasiveness by proteases is due to the
breakdown of the extracellular matrix (ECM), facilitating
the passage of cancer cells through the basement mem-
brane and through the stroma. Plasmin, the end product
of the plasminogen activation system, can degrade di-
rectly most extracellular matrix proteins and, moreover,
promotes matrix degradation through activation of some
pro-MMPs (pro-matrix metalloproteases). We recently
described another mode of action: some MMPs cleave
sE-CADs (soluble E-cadherin fragment), and such frag-
ments stimulate invasion (Noë et al., 2001).
E-cadherin is a calcium-dependent cell-cell adhesion
and signaling molecule that is often inactivated during
carcinoma progression. E-cadherin forms together with
its intracellular associated proteins, termed catenins, a
powerful invasion-suppressor complex that is regulated
at different levels (Van Aken et al., 2001). Proteolytic
cleavage, resulting in ectodomain shedding, has been
observed for cell surface molecules such as growth fac-
tor receptors and their ligands and adhesion molecules
including E-cadherin, N-cadherin and VE-cadherin (Pyke
et al., 1991, 1993; Paradies et al., 1993; Rabbani et al.,
1995; Lochter et al., 1997; Werb et al., 1997; Herren et al.,
1998). E-cadherin ectodomain shedding was first sug-
gested by the detection of a soluble 80 kDa fragment in
the medium of the human breast cancer cell line MCF-7.
This E-cadherin fragment caused scattering of epithelial
cells in culture, an effect that could be neutralized by an-
tibodies against E-cadherin (Wheelock et al., 1987). E-
cadherin cleavage and release of the 80 kDa sE-CAD also
occurs during uterine invasion in pregnant mice and can
be induced by treatment with oestradiol (Mbalaviele
et al., 1995). sE-CAD activity was mimicked by synthetic
E-cadherin peptides containing the histidine-alanine-va-
line amino acid sequence (Noë et al., 1999). This se-
quence is conserved in the family of classical cadherins
and is crucial for homophilic interactions.
Since plasmin is also involved in ectodomain shedding
of the cell adhesion molecules L1, N-CAM and of the cy-
tokine TNF-α (Murdoch et al., 1999; Nayeem et al., 1999),
we wanted to examine whether or not plasmin cleaves
the E-cadherin ectodomain and, if so, whether the plas-
min-generated sE-CAD stimulates invasion of cancer
cells into collagen type I.
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Matrix metalloproteases from the cell surface cleave
an 80 kDa E-cadherin fragment (sE-CAD) that induces
invasion of cancer cells into collagen type I and in-
hibits cellular aggregation. Conditioned media from
MDCKts.srcCl2 cells at 40 °C and 35 °C, PCm.src5
and COLO-16 cells at 37 °C contained spontaneously
released sE-CAD; these 48 h old conditioned media
were capable of inhibiting E-cadherin functions in a
paracrine way. Here we show direct cleavage of the
extracellular domain of E-cadherin by the serine pro-
tease plasmin. sE-CAD released by plasmin inhibits
E-cadherin functions as evidenced by induction of in-
vasion into collagen type I and inhibition of cellular
aggregation. This functional inhibition by sE-CAD
was reversed by aprotinin or by immunoadsorption
on protein Sepharose 4 fast flow beads with antibod-
ies against the extracellular part of E-cadherin. Our
results demonstrate that plasmin produces extracel-
lular E-cadherin fragments which regulate E-cad-
herin function in cells containing an intact E-cad-
herin/catenin complex.
Key words: E-cadherin /Ectodomain shedding /
Invasion /Plasmin /Proteolysis.
Introduction
Proteolytic degradation of the extracellular matrix is cru-
cial for cancer invasion. One of the proteolytic systems
implicated in cancer invasion is the plasminogen activa-
tion system generating the serine protease plasmin (An-
dreasen et al., 1997; Bugge et al., 1998; Reuning et al.,
a These authors contributed equally to this work.
Here we show that plasmin can directly cleave E-cad-
herin and that the resulting ectodomain fragments are ca-
pable of inhibiting E-cadherin functions in canine kidney
MDCKts.srcCl2 cells as tested by the fast aggregation
and collagen type I invasion assays. This observation
provides a novel mechanism by which plasmin may in-
duce tumor cell invasion.
Results
Plasmin Cleavage of E-Cadherin on Cells
Treatment of MDCKts.srcCl2 at 40 °C and 35 °C,
PCm.src5 and COLO-16 cells at 37 °C with 1 µg/ml plas-
min for 2 h resulted in the release of an 80 kDa E-cadherin
fragment (Figure 1, lane 2) as detected by immunopre-
cipitation with DECMA-1 or HECD-1 and immunostaining
of Western blots with HECD-1 or SEC-11 antibody and
compared with untreated cells (lane 1). This activity of
plasmin was blocked by the serine protease inhibitor
aprotinin at 10 µg/ml (lane 3). The cells also sponta-
neously released sE-CAD, as is evident from the analysis
of 48 h old conditioned medium (lane 5). sE-CAD could
be removed from the conditioned medium by repeated
immunoadsorption (lane 4).
Plasmin Cleavage of E-Cadherin Immunoadsorbed
on Sepharose Beads
sE-CAD production by plasmin treatment could be due to
direct cleavage of E-cadherin or to the activation of a
common enzymatic cascade, since plasmin may activate
other proteases some of which cleave E-cadherin (Noë et
al., 1999). To distinguish between these two possibilities,
we purified canine E-cadherin from MDCKts.srcCl2 cells
by immunoprecipitation on protein A Sepharose 4 fast
flow beads with an antibody against the cytoplasmic do-
main of cadherins. Immobilized E-cadherin was treated
with different concentrations of plasmin or with trypsin in
the presence of Ca2+. Cleavage of E-cadherin was appar-
ent by decreasing amounts of full length E-cadherin re-
tained on the beads (Figure 2A) and by the appearance of
lower molecular weight bands in the supernatant (Figure
2B). Plasmin treatment of immobilized canine E-cadherin
results in the release of different E-cadherin fragments in
the supernatant, depending upon the plasmin concentra-
tion. Treatment with 0.01 µg/ml plasmin results in an E-
cadherin fragment of about 99 kDa (lane 3). This fragment
gradually disappears when higher doses of plasmin are
added, probably due to further proteolytic degradation.
Finally, two E-cadherin fragments of 80 kDa and 60 kDa
are detected when human E-cadherin is treated with
plasmin or trypsin (lane 5 and 6).
Stimulation of MDCKts.srcCl2 Invasion into Collagen
Type I by Plasmin-Released sE-CAD
Control MDCKts.srcCl2 cells do not invade into collagen
type I at 40 °C. Conditioned medium from MDCKts.src-
Cl2 cells at 40 °C and 35 °C, PCm.src5 and COLO-16
cells at 37 °C treated with plasmin for 2 h induced colla-
gen type I invasion in a paracrine way, whereas culture
medium incubated for 2 h with untreated cells or with
aprotinin in the presence of plasmin for 2 h had no effect
(Figure 3). The invasion index observed with conditioned
medium from 2 h plasmin treated cells was similar to the
invasion index seen with the 48 h conditioned medium
containing constitutively shed sE-CAD, illustrating the
strong effect of protease activity. To ensure that the in-
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Fig. 1 Effect of Plasmin on the Release of Soluble E-Cadherin
Fragments (sE-CAD) from Cells Cultured on Solid Substrate.
Conditioned media were harvested from cells that were left un-
treated for 2 h (1) or 48 h (5) or were treated for 2 h with 1 µg/ml
plasmin without (2) or with 10 µg/ml aprotinin (3). Precipitated
proteins were separated by SDS-PAGE, blotted, immunostained
with SEC-11 (for canine cells) or HECD-1 antibodies (for human
cells), and detected with the ECL reagent. Lane 4 shows medium
prepared with 1 µg/ml plasmin and sE-CAD immunodepletion.
Fig. 2 Direct Cleavage of Canine E-Cadherin by Plasmin.
E-cadherin was immunoprecipitated from lysates of MDCKts.sr-
cCl2 cells with a polyclonal pan-cadherin antibody on
Sepharose beads. The beads were incubated at 37 °C in 50 µl
PBS only (l), with 1 ng (2), 10 ng (3), 100 ng (4) or 1 µg (5) plasmin
or with 0.025% trypsin (6) in the presence of 0.04 mM Ca2+.
Beads (panel A) and supernatant (panel B) were separated, pro-
teins were resolved by SDS-PAGE, blotted and immunostained
with the anti-E-cadherin antibody recognizing the cytoplasmic
tail (panel A), or DECMA-1 recognizing the extracellular part of E-
cadherin (panel B).
creased invasion was due to the presence of sE-CAD and
not a direct result of the added protease acting on the
collagen gel, sE-CAD was selectively removed. Immun-
odepletion of sE-CAD from the conditioned media com-
pletely abrogated the invasion-inducing activity of the
media, thus indicating that this phenomenon was not due
to the presence of the added plasmin. Moreover, addition
of plasmin to unconditioned medium did not induce inva-
sion (data not shown).
Inhibition of MDCKts.srcCl2 Aggregation by
Plasmin-Released sE-CAD
Because the E-cadherin/catenin complex is responsible
for epithelial cell-cell adhesion, we tested the effect of the
sE-CAD released by plasmin on this function. Aggrega-
tion of MDCKts.srcCl2 cells at 40 °C was abundant for
cells left untreated (arrows indicate peak values at N0’
and N30’), or treated with 2 h conditioned medium or with
2 h conditioned medium produced with plasmin in the
presence of aprotinin. The 48 h conditioned medium from
donor cells or 2 h conditioned medium from cells treated
with plasmin significantly inhibited aggregation. When
sE-CAD was immunodepleted from the conditioned
medium inhibition of aggregation did no longer occur
(Figure 4). We could also demonstrate that donor MDCK-
ts.srcCl2 cells after treatment with plasmin or trypsin be-
come non-aggregating (data not shown).
Discussion
Plasmin is an invasion promoter as evidenced by in vitro
experiments and by observations of animal and human
tumors in vivo; it acts through breakdown of the extracel-
lular membrane, providing space for invading cancer
cells and through stimulation of migration (Andreasen
et al., 1997). Our present experiments suggest one more
mechanism, namely enzymatic release of invasion-stim-
ulating fragments from the extracellular part of E-cad-
herin, called sE-CAD, on the surface of cancer cells.
Our test tube experiments with immunoadsorbed E-
cadherin demonstrate that plasmin may produce sE-
CAD through direct enzymatic digestion of the protein. In
cell culture or in vivo, however, plasmin might also cause
cleavage of sE-CAD in a proteolytic cascade, e. g.
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Fig. 3 Induction of Invasion of MDCKts.srcCl2 Cells into Colla-
gen Type I by Plasmin-Released sE-CAD.
Cells were seeded on top of a collagen gel and incubated at 40 °C
for 24 h with or without conditioned medium that was obtained
from the indicated donor cell lines. Donor cells were incubated for
2 h either without or with 1 µg/ml plasmin or with 1 µg/ml plasmin
plus 10 µg/ml aprotinin. As a control for the sE-CAD-specificity of
stimulation of invasion, sE-CAD was immunodepleted from the
conditioned media treated with 1 µg/ml plasmin for 2 h by im-
munoprecipitating three times with an antibody against the extra-
cellular part of E-cadherin (3 × I.P.). As a positive control for spon-
taneously released sE-CAD, we used conditioned media of 48 h
untreated donor cells. A mouse IgG1 antibody (3 × I.P.°) was used
as a control for HECD-1 specificity. *Invasion of treated cells that
are significantly different (Student’s t-test) from untreated cells.
Fig. 4 Inhibition of Cellular Aggregation by sE-CAD Released
by Plasmin.
Cells were detached under E-cadherin saving conditions. Con-
trol MDCKts.srcCl2 cells were incubated in aggregation buffer
and allowed to aggregate for 30 minutes. Arrows indicate peaks
of MDCKts.srcCl2 cells at 40 °C, as mearured by a particle size
counter either after 0 (N0) or 30 (N30) minutes. Aggregation was
inhibited by sE-CAD containing conditioned medium after 2 h
plasmin treatment (- - -) and 48 h conditioned medium (-- --); ag-
gregation was not inhibited by 2 h conditioned medium (––––), by
2 h conditioned medium treated with plasmin + aprotinin (–– · ––)
and by immunodepletion of sE-CAD in plasmin-derived 2 h con-
ditioned medium (········).
through activation of pro-MMPs (pro matrix metallopro-
teases), such as pro-MMP-3 or pro-MMP-9 (Werb et al.,
1997; Ramos-DeSimone et al., 1999). We know from pre-
vious experiments that MMP-3 (stromelysin-1) as well as
MMP-7 (matrilysin) release invasion-stimulating sE-CAD
from epithelial cancer cells in culture (Noë et al., 2001). In
the present experiments, we demonstrated the invasion-
stimulating capacity of plasmin-generated sE-CAD in a
paracrine system: the MDCKts.srcCl2 acceptor cells
stimulated to invade by sE-CAD had an intact E-cad-
herin/catenin complex or restored it during the assay.
They were exposed to conditioned medium not only from
the same type of cultures but also from cultures of cells of
different types and different species. Since the E-cad-
herin/catenin complex is a powerful invasion-suppressor
(Bracke et al., 1996) whose downregulation leads to inva-
sion in multiple in vitro and in vivo situations, one might
expect that plasmin would also induce invasion of the
cells from which the extracellular part of E-cadherin has
been removed. We were, however, unable to demon-
strate a direct effect of plasmin on invasion. Neither did
the spontaneously released sE-CAD from 1- and 2-day
old collagen type I invasion cultures stimulate invasion in
an autocrine manner. One possible explanation might be
that the minimum concentration of sE-CAD necessary to
stimulate invasion is not reached by the release during
the invasion assay because of dilution in the culture
medium. The concentration of sE-CAD is 50 times lower
in an experiment without conditioned medium than with
conditioned medium as measured by ELISA. In condi-
tioned medium of PCm.src5, the minimum concentration
of sE-CAD that stimulated invasion of MDCKts.srcCl2 at
40 °C was between 600 and 300ng/ml (our unpublished
results). Release of the 80 kDa sE-CAD can be inhibited
by overexpression of the tissue inhibitor of MMP-2 and
stimulated by phorbol-12-myristate-13-acetate (Noë
et al., 1999). Interestingly, ectodomain shedding of E-
cadherin results in a loss of function in the fast aggrega-
tion assay. In long-term experiments, such as the slow
aggregation assay and the collagen type I invasion assay,
we find recovery of E-cadherin and results that are diffi-
cult to interprete (our unpublished results).
Since sE-CAD is also found in human cancers, our
present in vitro experiments may also be relevant for in-
vasion in vivo (Katayama et al., 1994; Banks et al., 1995;
Griffiths et al., 1996; Gofuku et al., 1998). Here, tumor mi-
croecosystems may generate higher amounts of sE-CAD
through proteases from host cells (De Wever and Mareel,
2002). Furthermore, there may be contributions from
cells undergoing apoptosis and producing MMPs in con-
cert with caspases acting on β-catenin and plakoglobin
(Herren et al., 1998; Steinhusen et al., 2001).
Although our data reveal the invasion-promoting effect
of the released sE-CAD, it is possible that the remnant
transmembrane fragment may have a similar function.
There is evidence in the literature for a function of such a
fragment of receptor tyrosine kinases, where removal of
the ectodomain results in constitutive activation of the ki-
nase activity present in the remaining fragment (Ro-
drigues and Park, 1994; Cabrera et al., 1996). It has been
reported that trypsin-mediated removal of the E-cadherin
ectodomain induces tyrosine phosphorylation of ß-
catenin (Takahashi et al., 1997), a protein that associates
with the E-cadherin cytoplasmic tail, forming part of the
adherens complex. Mutant cadherins containing the
transmembrane domain and the cytoplasmic tail, thus
mimicking the 40 kDa remnant fragment, exert dominant-
negative effects when expressed in Xenopus embryos
(Kintner, 1992), in cultured epithelial cells (Fujimori et al.,
1993), and in mouse intestinal epithelia (Hermiston and
Gordon, 1995a, b). Such fragments have also been
shown to directly block ß-catenin signaling (Crawford
et al., 1999; Orsulic et al., 1999). E-cadherin cleavage
may therefore promote invasion through both an sE-CAD
fragment acting in a paracrine manner and a 40 kDa rem-
nant fragment that acts in an autocrine manner.
How sE-CAD stimulates invasion is not yet clear
(Willems et al., 1995; Noë et al., 2001). The present ag-
gregation assay suggests that sE-CAD inhibits the
homophilic cell-cell adhesion function of the E-cad-
herin/catenin complex, which is in line with stimulation of
invasion. Both aggregation and lack of invasion require
an intact E-cadherin/catenin complex as evidenced by
neutralizing antibodies against E-cadherin (Boterberg et
al., 2000; Bracke et al., 2000). The E-cadherin-specificity
of the loss of function caused by sE-CAD is suggested by
increased tyrosine phosphorylation of ß-catenin. Experi-
ments with dominant negative mutants and with pharma-
cological inhibitors point to invasion-promoter or inva-
sion-suppressor pathways implicating Rho GTPases, PI3
kinase and trimeric G proteins (our unpublished results in
collaboration with C. Gespach, Paris, France).
The immunodepletion of sE-CAD from conditioned me-
dia, associated with loss of activity, proves that sE-CAD is
responsible for inhibition of aggregation and stimulation of
invasion by these conditioned media. Here, sE-CAD might
mimic an intact E-cadherin molecule anchored to the cell
surface and thus disturb homophilic interactions responsi-
ble for cell-cell adhesion. The presence of multiple molec-
ular networks around cell surface receptors (Mareel et al.,
1997) does, however, suggest that this simple physical
disruption of cell-cell contacts is not solely responsible
and that other signal transduction pathways, either stimu-
lated directly by sE-CAD interactions with E-cadherin or
indirectly by the disruption of cell-cell contacts, contribute
to the stimulation of invasion.
Materials and Methods
Cell Culture
Cells expressing E-cadherin were used as donor cells to monitor
the release of sE-CAD into their conditioned medium and to test
its influence on E-cadherin functions in acceptor cells. MDCK-
ts.srcCl2 (Behrens et al., 1993) are Madin-Darby canine kidney
(MDCK) cells transformed with a temperature sensitive src onco-
gene. They were used as donor cells at the non-permissive tem-
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perature for p60v-src activity (40 °C), when their E-cad-
herin/catenin complex is functional and at the src permissive
temperature (35 °C), when the E-cadherin/catenin complex is
deficient as evidenced by loss of aggregation and gain of inva-
sion. The following cells were also used as donor cells. Parental
PC/AA/C1 cells are derived from a colonic adenoma in a patient
with familial adenomatous polyposis (FAP); they are non-tumori-
genic in nude mice. PCm.src5 cells are PC/AA/C1 cells trans-
fected with an activated c-src oncogene, which becomes sus-
ceptible to invasiveness upon addition of HGF (Empereur et al.,
1997). MDCKts.srcCl2 and PCm.src5 cells are maintained in
Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies,
Ghent, Belgium), supplemented with 10% (w/v) fetal bovine
serum (FBS, Life Technologies) and 0.05% (v/v) L-glutamine.
COLO-16 cells are derived from a human skin squamous carci-
noma; they are cultured in RPMI-1640 supplemented with 10%
(v/v) FBS and 0.05% (w/v) L-glutamine (Moore et al., 1975). The
MDCKts.srcCl2 cells were used as acceptor cells at the non-
permissive temperature for p60v-src activity (40 °C).
Antibodies and Chemicals
DECMA-1 is a rat monoclonal antibody, raised against the
murine embryonal cell line PCC7 Aza RI, recognizing the extra-
cellular domain of murine and canine E-cadherin (Sigma, St.
Louis, USA). HECD-1 is a murine monoclonal antibody recogniz-
ing the extracellular domain of human E-cadherin (Takara, San
Diego, USA). A rabbit polyclonal pan-cadherin antibody was
raised against a synthetic peptide corresponding to a conserved
sequence in the cytoplasmic tail of classical cadherins. The im-
mune serum recognizes bands corresponding with E-cadherin,
N-cadherin and P-cadherin on Western blots. We also used the
mouse monoclonal anti-E-cadherin, recognizing the cytoplas-
mic tail of E-cadherin (Transduction Laboratories, Lexington,
USA). The monoclonal antibody SEC-11 was raised against a
synthetic peptide corresponding to amino acids 9 – 21
(CPENEKGPFPKNL) of mature human E-cadherin, a sequence
shared with only dog E-cadherin and implied in calcium binding.
Briefly, female BALB/c mice were immunized with one subcuta-
neous and two intraperitoneal booster injections of the peptide
conjugated to keyhole limpet hemocyanin. Spleen cells were
harvested after 7 weeks and fused with NS0 mouse myeloma
cells according to the protocol of Brown and Ling (1988). Hy-
bridomas were screened using ELISA for specific recognition of
the synthetic peptide. After testing positive hybridomas for
recognition of E-cadherin by Western blotting, limiting dilution
was performed to obtain stable clones. SEC-11 (IgG1) was
found to recognize human and dog, but not mouse or rat 120
kDa E-cadherin and its 80 kDa extracellular part (sE-CAD) by
Western blotting.
For incubation with cells, 1 µg/ml plasmin or 0.025% trypsin
were dissolved in serum-free medium. To test the effect on puri-
fied E-cadherin, 1 ng, 10 ng, 100 ng or 1 µg plasmin were dis-
solved in 50 µl PBS and 0.025% trypsin was diluted in PBS con-
taining 0.04 mM CaCl2. The serine protease inhibitor aprotinin
(ICN, Costa Mesa, USA) was used at a concentration of 10
µg/ml. Immunodetection was achieved with HECD-1 for the hu-
man cell-lines and with SEC-11 for the canine cells.
Immunoprecipitation and Western Blotting
Cells were lysed with PBS containing 1% NP-40, 1% Triton-X
100 and the following protease inhibitors (all from ICN): phenyl-
methylsulfonyl fluoride (1.72 mM), leupeptin (21 mM), aprotinin
(10 µg/ml). Equal amounts of protein (1 mg) or conditioned me-
dia from equal amounts of cells were incubated with an antibody
for 3 h at 4 °C followed by protein A Sepharose 4 fast flow beads
or protein G Sepharose 4 fast flow beads (Pharmacia LKB, Upp-
sala, Sweden) for 1 h. Precipitated proteins were dissolved in
sample buffer, boiled in the presence of 5% 2-mercaptoethanol,
separated by SDS-PAGE and transferred onto Immobilon-P
membranes (Millipore Corp., Bedford, USA). For immunostain-
ing, blots were quenched with 5% non-fat dry milk in PBS con-
taining 0.5% Tween 20, the membranes were incubated with pri-
mary antibody, followed by 3 times washing for 5 minutes and
incubation with horseradish peroxidase conjugated secondary
antibodies. Proteins were stained using ECL reagent (Amersham
Life Science, Buckinghamshire, UK) as substrate.
Conditioned Medium
Conditioned medium of donor cells was obtained as follows.
Seventy-five cm2 monolayers of 75% confluency of MDCKts.sr-
cCl2 at 40 °C or 35 °C, PCm.src5 or COLO-16 donor cells at 37
°C were washed 3 times with serum-free DMEM (Life Technolo-
gies) and incubated for 2 h at 37 °C with serum-free DMEM to
which 1 µg/ml plasmin was added or not. The medium was har-
vested, centrifuged at 2000 g for 15 min, 5-fold concentrated in
centriprep tubes YM-30 (Amicon, Millipore Corp., Bedford, USA)
and filtered through a 0.22 µm filter. To remove sE-CAD, 1 ml of
conditioned medium was incubated at 4 °C for 3 h with 2 µg
DECMA-1 for canine kidney cells and 10 µg HECD-1 for human
cells, followed by protein A Sepharose 4 fast flow beads or pro-
tein G Sepharose 4 fast flow beads for 1 h. This procedure was
repeated a second and a third time to remove all sE-CAD. As a
control for specificity of the HECD-1 precipitation, we used an
isotype mouse IgG1 antibody. Finally the conditioned media
were filtered through a 0.22 µm filter and diluted 1:2 before use
in the collagen type I assay.
Proteolytic Cleavage of E-Cadherin
Direct cleavage of E-cadherin was examined by the treatment of
pan-cadherin immunoprecipitated E-cadherin on beads. After 3
washes with PBS, the beads carrying E-cadherin were incubat-
ed for 30 min at 37 °C in 50 µl PBS containing plasmin or trypsin.
Supernatant and beads were separately dissolved in sample
buffer, boiled in the presence of 5% 2-mercaptoethanol, sepa-
rated by 7.5% SDS-PAGE, transferred onto Immobilon-P mem-
branes (Millipore Corp.) and immunostained.
Collagen Invasion Assay
Type I collagen (Upstate Biotechnology, Lake Placid, USA) was
dissolved in DMEM containing bicarbonate buffer and neutral-
ized with 1 M NaOH. 1.25 ml aliquots were poured into a 6 well-
plate and incubated for at least two hours at 37 °C for gelation.
2 × 105 cells were seeded on top of the collagen gel with or with-
out conditioned medium. After 24 h of incubation, the number of
cells invading into the gel was counted (Bracke et al., 2000). The
invasion index was calculated as the number of cells inside the
gel over the total number of cells.
Aggregation Assay
Cell-cell adhesion was quantified in an aggregation assay as de-
scribed earlier (Boterberg et al., 2000). Briefly, incubation with
collagenase A in presence of 0.04 mM Ca2+ (Boehringer
Mannheim, Mannheim, Germany), followed by trypsin in pres-
ence of 0.04 mM Ca2+ (Sigma, St-Louis, MS) and neutralization
with soy bean trypsin inhibitor released cells from the substrate
with preservation of E-cadherin. The cells were allowed to ag-
gregate on a Gyrotory shaker (New Brunswick Scientific, New
Brunswick, USA) at 80 rpm for 30 min in an aggregation buffer
containing 1.25 mM Ca2+, 0.1 mg DNase/ml, 10 mM Hepes and
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0.1% (w/v) BSA and equilibrated at physiological pH and osmo-
larity. Cell aggregation was measured with a LS particle size
analyser (LS 200, Coulter Electronics, Miami, USA) after 0 min
and 30 min of aggregation. The relative volume in function of the
particle size was used as an index of aggregation.
Statistics
All experiments were performed at least twice. Student’s t-test
was used for statistical analysis of the collagen invasion assay
and Kolmogorov-Smirnov statistics to analyze the differences
between the cumulative distribution curves obtained in the fast
aggregation assay.
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Discussion and Perspectives 
 
The experiments discussed in this thesis 
provide novel insights into several systems that may 
play a role in carcinogenesis. Tumorigenesis mostly 
results from the accumulation of genetic events, in a 
first phase leading to the establishment of a primary 
tumor whose growth has to be sustained. Activation 
of particular pro-survival cellular pathways is likely to 
be crucial in this phase. In a second phase, the tumor 
cells may leave the primary site and invade the 
surrounding tissue, which may eventually result in 
metastasis. Impaired function of cell adhesion 
molecules may facilitate this process. Although many 
cancer types go through this multi-step process of 
progression, recently more attention is being given to 
the so-called ‘metastatic signature’ of cancer cells, a 
profile which may distinguish in an early stage tumors 
that are likely to progress aggressively from more 
benign tumors. 
 
Our identification of two new growth factor 
systems, the heregulin (HRG)-human epidermal 
growth factor receptor (HER) system (Section I.3) 
and the follistatin-activin-activin receptor system 
(Section I.4), in human melanoma cell lines has 
added these systems to the ever expanding list of 
growth factors that may play a role in carcinogenesis, 
more particularly melanomagenesis. Both systems 
may contribute to the tight balance that regulates 
senescence and proliferation of melanocytes in vivo. 
Disruption of this balance, either towards increased 
proliferation or towards decreased inhibition, may 
represent a first step towards melanoma. Considering 
the tight interplay that exists between tumors and the 
surrounding micro-environment, examination of these 
systems in experimental models ex vivo or in vivo 
may provide additional valuable information 
regarding this mutual interaction. The use of retro- or 
lentivirally transduced cell lines, either leading to 
overexpression or gene silencing, may be very helpful 
in this approach. Furthermore, these experimental 
systems also allow the evaluation of invasion and 
metastasis in a physiologically relevant model. Since 
neither of both growth factor systems has been 
described in melanoma before, it will be essential to 
examine whether they occur in melanoma patients as 
well. If so, they may represent interesting targets for 
directed therapies. This is particularly true for the 
heregulin-HER system, for which several therapies 
exist, including the use of receptor-blocking 
antibodies and small tyrosine kinase inhibitors. 
 
For many years, the E-cadherin/catenin 
system is known to function as a gatekeeper in cancer. 
The studies described here have extended the 
knowledge about the mechanisms on how the anti-
invasive function of E-cadherin can be modulated. 
Our finding that the anti-invasive activity of a 
melanoma conditioned medium can be attributed, at 
least in part, to the stimulation of the E-
cadherin/catenin complex by HRG present in this 
medium (Section II.2), extends the wide array of 
functions attributed to this growth factor. Although 
HRG has been implicated in the malignant behavior 
of cells in many studies, it has a well-known 
differentiating function as well (Section I.2). This is 
reflected in its role in the mammary gland in vivo, 
which exists of a combination of maintenance of 
proliferation and, at the same time, inducing 
differentiation. In future studies, it may be interesting 
to determine what signaling pathways underlie the 
pro-aggregating and anti-invasive effects of HRG we 
observed. 
Tumor cells have developed a wide array of 
mechanisms by which they can interfere with E-
cadherin functionality. These include genomic, 
transcriptional and post-transcriptional events. The 
latter include the proteolytic cleavage of E-cadherin, 
releasing the E-cadherin ectodomain (sE-CAD). In 
our study we focused on the effects of sE-CAD, 
generated following the exposure of E-cadherin 
positive cells to the serine protease plasmin (Section 
II.7.). We found that sE-CAD can interfere with 
aggregation and induced invasion of E-cadherin 
positive cells in vitro. However, the way by which the 
sE-CAD signal is received by the cell, how it is 
transduced and what underlies the altered phenotype 
of the cells, remains elusive. As an alternative 
approach, it may be worthwhile to look at the cells 
that have produced the sE-CAD fragment. In these 
cells, the remaining transmembrane-intracellular part 
may be subjected to further processing, releasing the 
intracellular tail, and possibly influencing signaling 
pathways as has been described for the corresponding 
N-cadherin cytoplasmic tail. 
In contrast to the wealth of publications on E-
cadherin, relatively little is known about the role P-
cadherin may play in cancer. The two manuscripts on 
P-cadherin in this thesis describe new, opposite roles 
for this protein in melanoma and breast cancer. Loss 
of P-cadherin frequently occurs during melanoma 
progression. We found that de novo expression of P-
cadherin in melanoma cell lines leads to a more 
epithelioid morphology, coinciding with a reduction 
of invasion and promotion of cell-cell adhesion 
(Section II.4). Analysis of P-cadherin mutants 
suggested that these effects were dependent on the 
‘classical’ function of this cadherin, the support of 
cell-cell adhesion. Another scenario accounts for 
breast cancer, where a correlation exists between P-
cadherin expression, estrogen receptor negativity, and 
poor survival. In our study, we could provide a direct 
link between a lack of estrogen receptor signaling and 
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P-cadherin expression. Moreover, in contrast to 
melanoma, where P-cadherin has essentially an 
inhibitory effect on invasion, invasion of breast cancer 
cells is promoted by P-cadherin (Section II.5.). 
Further investigation revealed that the juxtamembrane 
domain was required for this effect, suggesting that 
this particular domain, although only differing in 
some amino acids from the corresponding domain in 
E-cadherin, actively provides the cells with a pro-
invasive signal. The mechanisms by which P-cadherin 
drives cells towards invasion remain to be elucidated. 
Possible mechanisms include differences in binding 
partners or binding characteristics of these partners. 
Domain-swapping experiments, in which the 
corresponding domains of E- and P-cadherin are 
exchanged, approaches destined to map interaction 
partners (yeast-two-hybrid, mass spectrometry), as 
well as experiments using dominant negative and 
constitutively active constructs of signal transduction 
molecules or pharmacological inhibitors may provide 
an answer to this question. In addition, although P-
cadherin transgenic mice, in which P-cadherin 
expression is driven by a murine mammary tumor 
virus (MMTV) promoter, do not spontaneously form 
tumors (Radice et al., 2002), crossing these mice with 
other transgenic mice may provide a valuable in vivo 
model to evaluate our findings. As evidenced by the 
lack of P-cadherin positive tumors upon crossing 
these mice with mice expressing the neu oncogene 
under the same promoter, the choice of the partner 
transgene may be crucial to identify tumors in which 
P-cadherin expression is present. Having in mind that 
in healthy breast tissue, P-cadherin expression is 
confined to the myoepithelial cells, good candidates 
may be transgenic mice in which components of the 
β-catenin pathway are expressed under the MMTV 
promoter, since, unlike neu transgenic mice, the 
tumors of these mice display both epithelial and 
myoepithelial characteristics (Li et al., 2003). 
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